NZ614712B2 - Oligonucleotide modulators of the toll-like receptor pathway - Google Patents
Oligonucleotide modulators of the toll-like receptor pathway Download PDFInfo
- Publication number
- NZ614712B2 NZ614712B2 NZ614712A NZ61471212A NZ614712B2 NZ 614712 B2 NZ614712 B2 NZ 614712B2 NZ 614712 A NZ614712 A NZ 614712A NZ 61471212 A NZ61471212 A NZ 61471212A NZ 614712 B2 NZ614712 B2 NZ 614712B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- nos
- nucleotide
- moiety
- nucleic acid
- Prior art date
Links
- 229920000272 Oligonucleotide Polymers 0.000 title claims abstract description 132
- 230000000051 modifying Effects 0.000 title description 6
- 102000002689 toll-like receptors Human genes 0.000 title description 6
- 108020000411 toll-like receptors Proteins 0.000 title description 6
- 230000037361 pathway Effects 0.000 title description 5
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 234
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 227
- 230000000692 anti-sense Effects 0.000 claims abstract description 197
- 229920000972 Sense strand Polymers 0.000 claims abstract description 118
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 542
- 239000002773 nucleotide Substances 0.000 claims description 498
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 245
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 183
- 235000000346 sugar Nutrition 0.000 claims description 127
- 206010049460 Abasia Diseases 0.000 claims description 101
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 92
- 108020004999 Messenger RNA Proteins 0.000 claims description 87
- 229920002106 messenger RNA Polymers 0.000 claims description 87
- 239000000203 mixture Substances 0.000 claims description 84
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 61
- 210000004072 Lung Anatomy 0.000 claims description 59
- 230000014509 gene expression Effects 0.000 claims description 57
- 238000002054 transplantation Methods 0.000 claims description 54
- 208000002193 Pain Diseases 0.000 claims description 52
- 229920003028 Threose nucleic acid Polymers 0.000 claims description 49
- 230000000295 complement Effects 0.000 claims description 46
- -1 ibouridine (dU) Chemical compound 0.000 claims description 45
- 206010022114 Injury Diseases 0.000 claims description 43
- 206010059677 Graft dysfunction Diseases 0.000 claims description 39
- 208000004530 Primary Graft Dysfunction Diseases 0.000 claims description 38
- 239000010452 phosphate Substances 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 35
- 206010063837 Reperfusion injury Diseases 0.000 claims description 29
- ASJSAQIRZKANQN-CRCLSJGQSA-N Deoxyribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 27
- 229960005305 adenosine Drugs 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 26
- 208000004296 Neuralgia Diseases 0.000 claims description 25
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 24
- 206010061218 Inflammation Diseases 0.000 claims description 24
- 230000004054 inflammatory process Effects 0.000 claims description 24
- 210000000056 organs Anatomy 0.000 claims description 23
- 230000002685 pulmonary Effects 0.000 claims description 22
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 claims description 21
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 21
- 206010030113 Oedema Diseases 0.000 claims description 21
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 20
- 230000004044 response Effects 0.000 claims description 19
- 206010060872 Transplant failure Diseases 0.000 claims description 18
- 230000001154 acute Effects 0.000 claims description 18
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 claims description 17
- 229940045145 Uridine Drugs 0.000 claims description 17
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 17
- 230000001684 chronic Effects 0.000 claims description 16
- 230000004064 dysfunction Effects 0.000 claims description 15
- 229920000023 polynucleotide Polymers 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- DWRXFEITVBNRMK-JXOAFFINSA-N 5-Methyluridine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims description 14
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 11
- PTJWIQPHWPFNBW-GBNDHIKLSA-N Pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229920002676 Complementary DNA Polymers 0.000 claims description 3
- 108020004635 Complementary DNA Proteins 0.000 claims description 3
- 238000010804 cDNA synthesis Methods 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 claims 2
- 102100012096 TLR2 Human genes 0.000 claims 2
- 101700064022 TLR2 Proteins 0.000 claims 2
- 108020004461 Double-Stranded RNA Proteins 0.000 description 155
- 150000001875 compounds Chemical class 0.000 description 131
- 229920001914 Ribonucleotide Polymers 0.000 description 103
- 239000002336 ribonucleotide Substances 0.000 description 103
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 91
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 91
- 102100010074 MYD88 Human genes 0.000 description 86
- 101700079836 MYD88 Proteins 0.000 description 86
- 102100012038 TIRAP Human genes 0.000 description 80
- 101700043462 TIRAP Proteins 0.000 description 80
- 230000004048 modification Effects 0.000 description 80
- 238000006011 modification reaction Methods 0.000 description 80
- 229920001985 Small interfering RNA Polymers 0.000 description 75
- 239000004055 small Interfering RNA Substances 0.000 description 75
- 230000002401 inhibitory effect Effects 0.000 description 55
- 239000002213 purine nucleotide Substances 0.000 description 41
- 125000000217 alkyl group Chemical group 0.000 description 39
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 37
- 239000005547 deoxyribonucleotide Substances 0.000 description 35
- 230000000694 effects Effects 0.000 description 35
- 210000004027 cells Anatomy 0.000 description 31
- 150000003212 purines Chemical class 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 28
- 208000008513 Spinal Cord Injury Diseases 0.000 description 27
- 230000002194 synthesizing Effects 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 22
- MXHRCPNRJAMMIM-SHYZEUOFSA-N Deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 21
- 150000003230 pyrimidines Chemical class 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- 229940035295 Ting Drugs 0.000 description 20
- 150000002430 hydrocarbons Chemical group 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 16
- 230000025458 RNA interference Effects 0.000 description 16
- 108020004459 Small Interfering RNA Proteins 0.000 description 16
- 239000000074 antisense oligonucleotide Substances 0.000 description 16
- 239000002719 pyrimidine nucleotide Substances 0.000 description 16
- 230000002987 rna-interference Effects 0.000 description 16
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 15
- 230000001225 therapeutic Effects 0.000 description 14
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 13
- 230000000875 corresponding Effects 0.000 description 12
- 230000002829 reduced Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- 229920001850 Nucleic acid sequence Polymers 0.000 description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
- XUYJLQHKOGNDPB-UHFFFAOYSA-M 2-phosphonoacetate Chemical compound OP(O)(=O)CC([O-])=O XUYJLQHKOGNDPB-UHFFFAOYSA-M 0.000 description 9
- 240000007427 Erythrina variegata Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 230000003828 downregulation Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 229920001239 microRNA Polymers 0.000 description 8
- 239000002777 nucleoside Substances 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 8
- 206010053552 Allodynia Diseases 0.000 description 7
- 206010061255 Ischaemia Diseases 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002679 microRNA Substances 0.000 description 7
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-Propanediol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- 206010069351 Acute lung injury Diseases 0.000 description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
- 229960000643 Adenine Drugs 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102100001547 OLIG3 Human genes 0.000 description 6
- 101700067952 OLIG3 Proteins 0.000 description 6
- 210000002966 Serum Anatomy 0.000 description 6
- 210000000278 Spinal Cord Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 125000003835 nucleoside group Chemical group 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- 229940104302 Cytosine Drugs 0.000 description 5
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 5
- 241000083551 Ena Species 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
- 206010042928 Syringomyelia Diseases 0.000 description 5
- 102100002498 TICAM1 Human genes 0.000 description 5
- 101710029702 TICAM1 Proteins 0.000 description 5
- 241001367079 Una Species 0.000 description 5
- 229940035893 Uracil Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 230000002452 interceptive Effects 0.000 description 5
- 239000012160 loading buffer Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229920002395 Aptamer Polymers 0.000 description 4
- 101700080605 NUC1 Proteins 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 108010001267 Protein Subunits Proteins 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 210000000515 Tooth Anatomy 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000996 additive Effects 0.000 description 4
- 230000003872 anastomosis Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000001086 cytosolic Effects 0.000 description 4
- 201000009910 diseases by infectious agent Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000007913 intrathecal administration Methods 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101700006494 nucA Proteins 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 230000000241 respiratory Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000002195 synergetic Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- FBPFZTCFMRRESA-KAZBKCHUSA-N (2R,3S,4R,5R)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- 229940035437 1,3-propanediol Drugs 0.000 description 3
- JFXCZJCIOSIFBM-UHFFFAOYSA-N 2-ethyl-7H-purine Chemical class N1C(CC)=NC=C2N=CN=C21 JFXCZJCIOSIFBM-UHFFFAOYSA-N 0.000 description 3
- 229920001383 5S-rRNA precursor Polymers 0.000 description 3
- 210000000988 Bone and Bones Anatomy 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 210000002683 Foot Anatomy 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000007999 Hyperesthesia Diseases 0.000 description 3
- 241000229754 Iva xanthiifolia Species 0.000 description 3
- 208000004852 Lung Injury Diseases 0.000 description 3
- 210000003205 Muscles Anatomy 0.000 description 3
- 206010028391 Musculoskeletal pain Diseases 0.000 description 3
- 229920002224 Peptide nucleic acid Polymers 0.000 description 3
- 208000005333 Pulmonary Edema Diseases 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- 229940104230 Thymidine Drugs 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000002222 downregulating Effects 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001506 immunosuppresive Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 230000003902 lesions Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000001743 silencing Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005451 thionucleotide Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000003612 virological Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 208000006569 Central Cord Syndrome Diseases 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-XVFCMESISA-N Cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 210000004195 Gingiva Anatomy 0.000 description 2
- 229920002277 Glycol nucleic acid Polymers 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 2
- 210000003041 Ligaments Anatomy 0.000 description 2
- 208000009856 Lung Disease Diseases 0.000 description 2
- 210000000214 Mouth Anatomy 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Natural products CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- WTWWXOGTJWMJHI-UHFFFAOYSA-N Perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 2
- 210000000578 Peripheral Nerves Anatomy 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 210000001032 Spinal Nerves Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940113082 Thymine Drugs 0.000 description 2
- 108020004417 Untranslated RNA Proteins 0.000 description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 108091005736 adaptor proteins Proteins 0.000 description 2
- 102000035425 adaptor proteins Human genes 0.000 description 2
- 150000003838 adenosines Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000000735 allogeneic Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 125000000477 aza group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-M carboxy(hydroxy)phosphinate Chemical compound OC(=O)P(O)([O-])=O ZJAOAACCNHFJAH-UHFFFAOYSA-M 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000000534 elicitor Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001861 immunosuppresant Effects 0.000 description 2
- 230000001771 impaired Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000302 ischemic Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- 239000005445 natural product Substances 0.000 description 2
- 229920001894 non-coding RNA Polymers 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 229960001217 perflubron Drugs 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- MEUIIHOXOWVKNP-UHFFFAOYSA-M phosphanylformate Chemical class [O-]C(P)=O MEUIIHOXOWVKNP-UHFFFAOYSA-M 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002980 postoperative Effects 0.000 description 2
- 230000001124 posttranscriptional Effects 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 201000003176 severe acute respiratory syndrome Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- YROJWWHYHBKDPB-VEGRVEBRSA-N (2R,3R,4R)-2,3,4,5-tetrahydroxypentanal;trihydroxy(sulfanylidene)-$l^{5}-phosphane Chemical group OP(O)(O)=S.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O YROJWWHYHBKDPB-VEGRVEBRSA-N 0.000 description 1
- FPHJJCBLRAPJQJ-CRKDRTNXSA-N (2S,3R,4S,5R)-2-amino-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(N)O[C@H](CO)[C@@H](O)[C@H]1O FPHJJCBLRAPJQJ-CRKDRTNXSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 2,6-Diaminopurine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- WYDKPTZGVLTYPG-UHFFFAOYSA-N 2,8-diamino-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(N)N2 WYDKPTZGVLTYPG-UHFFFAOYSA-N 0.000 description 1
- YKJZFNRWSLHRAG-UHFFFAOYSA-M 2-phosphanylacetate Chemical class [O-]C(=O)CP YKJZFNRWSLHRAG-UHFFFAOYSA-M 0.000 description 1
- LNQVTSROQXJCDD-KQYNXXCUSA-N 3'-AMP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O LNQVTSROQXJCDD-KQYNXXCUSA-N 0.000 description 1
- YHPMRWZVIQTSFZ-UHFFFAOYSA-N 3,5-difluoro-2-(2-fluorophenyl)pyridine Chemical compound FC1=CC(F)=CN=C1C1=CC=CC=C1F YHPMRWZVIQTSFZ-UHFFFAOYSA-N 0.000 description 1
- KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 description 1
- HYCSHFLKPSMPGO-UHFFFAOYSA-L 3-hydroxypropyl phosphate Chemical compound OCCCOP([O-])([O-])=O HYCSHFLKPSMPGO-UHFFFAOYSA-L 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1H-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1H-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-Methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- SVXNJCYYMRMXNM-UHFFFAOYSA-N 5-amino-2H-1,2,4-triazin-3-one Chemical compound NC=1C=NNC(=O)N=1 SVXNJCYYMRMXNM-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1H-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- XYVLZAYJHCECPN-UHFFFAOYSA-L 6-aminohexyl phosphate Chemical compound NCCCCCCOP([O-])([O-])=O XYVLZAYJHCECPN-UHFFFAOYSA-L 0.000 description 1
- PFUVOLUPRFCPMN-UHFFFAOYSA-N 7H-purine-6,8-diamine Chemical compound C1=NC(N)=C2NC(N)=NC2=N1 PFUVOLUPRFCPMN-UHFFFAOYSA-N 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical class C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- ZEXSWWSPNTYEJC-UHFFFAOYSA-L CCCOP([O-])([O-])=S Chemical compound CCCOP([O-])([O-])=S ZEXSWWSPNTYEJC-UHFFFAOYSA-L 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-L CHEBI:8154 Chemical group [O-]P([O-])=O ABLZXFCXXLZCGV-UHFFFAOYSA-L 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 206010053983 Corona virus infection Diseases 0.000 description 1
- 208000004981 Coronary Disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940109526 Ery Drugs 0.000 description 1
- 102000013165 Exonucleases Human genes 0.000 description 1
- 108060002716 Exonucleases Proteins 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- 102100012864 GADD45B Human genes 0.000 description 1
- 101710037036 GADD45B Proteins 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 Ganciclovir Drugs 0.000 description 1
- 210000003594 Ganglia, Spinal Anatomy 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 description 1
- 229940029575 Guanosine Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 208000007514 Herpes Zoster Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000019223 Interleukin-1 receptor family Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor family Proteins 0.000 description 1
- DRAVOWXCEBXPTN-UHFFFAOYSA-N Isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 206010024855 Loss of consciousness Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 208000008433 Motor Disorders Diseases 0.000 description 1
- 210000002161 Motor Neurons Anatomy 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028334 Muscle spasms Diseases 0.000 description 1
- 210000000282 Nails Anatomy 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108009000578 Oxidative Stress Proteins 0.000 description 1
- 108060006601 PRM1 Proteins 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036376 Post herpetic neuralgia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 description 1
- 210000003492 Pulmonary Veins Anatomy 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 230000036141 SERUM STABILITY Effects 0.000 description 1
- 208000008742 Seborrheic Dermatitis Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 210000002832 Shoulder Anatomy 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920001385 Spiegelmer Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N Threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- 229960003487 Xylose Drugs 0.000 description 1
- ASCUXPQGEXGEMJ-GPLGTHOPSA-N [(2R,3S,4S,5R,6S)-3,4,5-triacetyloxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(4-methylanilino)oxan-2-yl]methoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]1OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](NC=2C=CC(C)=CC=2)O1 ASCUXPQGEXGEMJ-GPLGTHOPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N aldehydo-D-arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 125000004416 alkarylalkyl group Chemical group 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 230000002146 bilateral Effects 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920002092 cellular RNA Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000009541 complex regional pain syndrome Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- KLYCPFXDDDMZNQ-UHFFFAOYSA-N dehydrobenzene Chemical compound C1=CC#CC=C1 KLYCPFXDDDMZNQ-UHFFFAOYSA-N 0.000 description 1
- 230000000368 destabilizing Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 230000000763 evoked Effects 0.000 description 1
- 230000002964 excitative Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 230000003492 excitotoxic Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- ZDPUTNZENXVHJC-UUOKFMHZSA-N guanosine 3'-monophosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O ZDPUTNZENXVHJC-UUOKFMHZSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 101700082223 how Proteins 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001722 neurochemical Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000001473 noxious Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- MHZDONKZSXBOGL-UHFFFAOYSA-L propyl phosphate Chemical compound CCCOP([O-])([O-])=O MHZDONKZSXBOGL-UHFFFAOYSA-L 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003238 somatosensory Effects 0.000 description 1
- 230000001148 spastic Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000000946 synaptic Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 200000000020 tissue injury Diseases 0.000 description 1
- 230000001256 tonic Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000000472 traumatic Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Abstract
Disclosed is a double stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the strands are selected from the oligonucleotides described as TLR2_25 as set forth in SEQ ID NOS:20607 and 20614, TLR2_28 as set forth in SEQ ID NOS:20608 and 20615, TLR2_42 as set forth in SEQ ID NOS:20609 and 20616, TLR2_43 as set forth in SEQ ID NOS:20610 and 20617, TLR2_47 as set forth in SEQ ID NOS:20611 and 20618, TLR2_31 as set forth in SEQ ID NOS:20612 and 20619, and TLR2_34 as set forth in SEQ ID NOS:20613 and 20620; wherein the sequences are as defined in the specification. Also disclosed is its use in therapy. in SEQ ID NOS:20609 and 20616, TLR2_43 as set forth in SEQ ID NOS:20610 and 20617, TLR2_47 as set forth in SEQ ID NOS:20611 and 20618, TLR2_31 as set forth in SEQ ID NOS:20612 and 20619, and TLR2_34 as set forth in SEQ ID NOS:20613 and 20620; wherein the sequences are as defined in the specification. Also disclosed is its use in therapy.
Description
OLIGONUCLEOTIDE MODULATORS OF THE
TOLL-LIKE RECEPTOR PATHWAY
RELATED APPLICATIONS
This application claims the benefit of US. Provisional ation Serial No.
61/448,707 filed March 3, 2011 entitled “TLR2, TLR4, MYD88, TICAMl and TIRAP
NUCLEOTIDE INHIBITORS AND METHODS OF USE THEREOF”, which is
incorporated herein by reference in its entirety and for all purposes.
SE UENCE LISTING
The instant application contains a Sequence Listing, which is entitled 233-
PCT1_ST25.txt, created on February 28, 2012 and 3,908 kb in size, and is hereby
orated by reference in its entirety.
FIELD OF THE ION
Provided herein are nucleic acid molecules, pharmaceutical compositions comprising
same and methods of use thereof for the inhibition of mammalian target genes TLR2, TLR4,
MYD88, TICAMl and TIRAP in the Toll-like receptor (TLR) pathway. Specific
compounds include unmodified and chemically modified dsRNA and siRNA
oligonucleotides and compositions comprising same.
BACKGROUND OF THE INVENTION
Oligonucleotide sequences and nucleotide modifications useful in generating dsRNA
have been bed by the applicants of the t disclosure in, inter alia, US Patent
ation Nos. US 20080293655, US 20090162365, US 20100292301 and US
20110112168 and PCT Patent Publication Nos. WO 66475, and
WO 201 1/085056, hereby incorporated by reference in their ty.
There remains a need for active and effective dsRNA therapeutic agents which
exhibit enhanced knock down activity, increased stability and/ or reduced off target effects
useful in modulating the Toll-like receptor pathway.
_ 1 _
SUMMARY OF THE INVENTION
Provided herein are compositions, methods and kits useful for modulating expression
of target genes in the Toll-like receptor pathway. In various aspects ed are c acid
molecule inhibitors of a mammalian gene selected from the group consisting of TLR2,
TLR4, MYD88, TICAMl and TIRAP, having mRNA polynucleotide sequences set forth in
SEQ ID NOS: l-l2 which include SEQ ID NO:l (TLR2 mRNA); SEQ ID NO:2-4 (TLR4
mRNA), SEQ ID NO:5-9 (MYD88 mRNA), SEQ ID NO:10 (TICAMl mRNA) or SEQ ID
NO:ll-12 (TIRAP mRNA).
In particular embodiments provided herein are novel double ed nucleic acid
molecules, in particular double-stranded RNA ), that inhibit, down-regulate or
reduce expression of a gene selected from the group consisting of TLR2, TLR4, MYD88,
TICAMl and TIRAP, and pharmaceutical compositions comprising one or more such
oligonucleotides or a vector capable of expressing the oligonucleotide. Further provided
herein are methods for treating inflammation and inflammatory diseases and graft rejection
associated with organ transplantation, such as lung transplantation, in which expression of
one or more of the TLR2, TLR4, MYD88, TICAMl and TIRAP genes is associated with the
etiology or progression of inflammation and graft rejection associated with organ
lantation.
In some aspects and embodiments the double stranded oligonucleotides are
chemically modified dsRNA compounds. In some ments the dsRNA sense and
antisense oligonucleotides are selected from sense oligonucleotides and corresponding
nse oligonucleotides set forth in SEQ ID NOS:l3-5846 (targeting TLR2), SEQ ID
NOS:5847-l2l44 ting TLR4), SEQ ID NOS:l2l45-l6332 (targeting MYD88), SEQ
ID NOS:l6333-18242 (targeting TICAMl) and SEQ ID NOS:18243-20606 (targeting
Accordingly, in one aspect provided herein is a nucleic acid molecule having the
following -stranded Structure:
(Al) 5’ (N)x — Z 3’ (antisense strand)
3’ Z’-(N’)y —z” 5’(sense strand)
WO 18911 2012/027174
wherein each N and N’ is a nucleotide which may be unmodified or modified, or an
unconventional moiety;
wherein each of (N)x and (N ’)y is an oligonucleotide in which each consecutive N or N’ is
joined to the next N or N’ by a covalent bond;
n each of Z and Z’ is independently present or absent, but if present ndently
comprises 1-5 consecutive nucleotides or cleotide moieties or a combination thereof
covalently attached at the 3 ’ terminus of the strand in which it is present;
wherein z” may be present or absent, but if present is a capping moiety covalently attached
at the 5’ terminus of (N’)y;
wherein each of x and y is independently an integer between 18 and 25;
wherein the sequence of (N ’)y is complementary to the sequence of (N)X and (N)x
includes an antisense sequence to a target RNA set forth in any one of SEQ ID NOS: 1-12.
In some embodiments the covalent bond joining each utive N or N’ is a
phosphodiester bond.
In some embodiments x = y and each of x and y is independently 19, 20, 21, 22 or
23. In various embodiments X = y =19.
In some embodiments the sense strand oligonucleotide and the antisense strand
oligonucleotide are ed from the oligonucleotide pairs set forth in SEQ ID NOS:13-
3060 to target TLR2; SEQ ID NOS:5847-8612 to target TLR4; SEQ ID NOS:12145-13924
to target MYD88; SEQ ID NOS:16333-16882 to target TICAMl; or SEQ ID NOS:18243-
19046 to target TIRAP.
In certain red embodiments, the sense strand and the antisense strand of a
double-stranded nucleic acid molecule (e.g., a siNA molecule) as disclosed herein include
ces corresponding to any one of the sense sequences and antisense sequences set forth
in SEQ ID NOS:13-1448 or 1449-3060 (targeting TLR2); or SEQ ID NOS:5847-8320 or
8321-8612 (targeting TLR4); or SEQ ID NOS:12145-13108 or 13109-13924 (targeting
MYD88); or SEQ ID NOS:16333-16866 or 16867-16882 ting TICAMl); or SEQ ID
NOS:18243-19010 or 19011-19046 (targeting TIRAP).
In some embodiments the sense strand and the antisense strand of a double-stranded
2012/027174
nucleic acid molecule are selected from the sequence pairs set forth in 5, TLR2_28,
TLR2_42, TLR2_43 and TLR2_47. In some embodiments the sense strand and the antisense
strand are selected from the sequence pairs set forth in TLR2_25 (SEQ ID NOS:20607 and
20614), TLR2_28 (SEQ ID NOS:20608 and 20615), TLR2_42 (SEQ ID NOS:20609 and
20616), TLR2_43 (SEQ ID NOS:20610 and 20617) and TLR2_47 (SEQ ID 611 and
20618).
In some embodiments the nucleic acid molecule (e.g., a siNA molecule) as disclosed
herein include the ce pair set forth in TLR2_25 (SEQ ID NOS:20607 and . In
some embodiments the nucleic acid molecule (e.g., a siNA molecule) as disclosed herein
include the sense and antisense strands of the sequence pair set forth in TLR2_28 (SEQ ID
NOS:20608 and 20615). In some embodiments the nucleic acid molecule (e.g., a siNA
molecule) as disclosed herein includes the sequence pair set forth in TLR2_42 (SEQ ID
NOS:20609 and . In some embodiments the c acid molecule (e.g., a siNA
molecule) as sed herein includes the sense and the antisense strands of the sequence
pair set forth in TLR2_43 (SEQ ID NOS:20610 and 20617). In some embodiments the
nucleic acid molecule (e.g., a siNA molecule) as sed herein includes the sense and the
antisense strands of the sequence pair set forth in TLR2_47 (SEQ ID NOS:20611 and
20618).
In some embodiments the sense strand and the antisense strand of a double-stranded
nucleic acid molecule are ed from the sequence pairs set forth in TLR4_08, TLR4_10,
TLR4_11, TLR4_14, TLR4_15, TLR4_28, TLR4_29, TLR4_31 and TLR4_33. In some
embodiments the sense strand and the antisense strand are selected from the sequence pairs
set forth in TLR4_08 (SEQ ID 621 and 20630), TLR4_10 (SEQ ID NOS:20622 and
20631), TLR4_11 (SEQ ID NOS:20623 and 20632), TLR4_14 (SEQ ID NOS:20624 and
20633), TLR4_15 (SEQ ID NOS:20625 and 20634), TLR4_28 (SEQ ID NOS:20626 and
, TLR4_29 (SEQ ID NOS:20627 and 20636), TLR4_31 (SEQ ID NOS:20628 and
20637) and TLR4_33 (SEQ ID NOS:20629 and 20638).
In some embodiments the nucleic acid molecule (e.g., a siNA le) as disclosed
herein includes the sequence pair set forth in TLR4_08 (SEQ ID NOS:20621 and 20630).
In some ments the nucleic acid molecule (e.g., a siNA molecule) as disclosed herein
includes the sense and the antisense strands of the sequence pair set forth in TLR4_10 (SEQ
WO 18911
ID NOS:20622 and 20631). In some embodiments the nucleic acid molecule (e.g., a siNA
molecule) as disclosed herein includes the sequence pair set forth in TLR4_ll (SEQ ID
NOS:20623 and 20632). In some embodiments the c acid molecule (e.g., a siNA
molecule) as sed herein includes the sense and the antisense s of the sequence
pair set forth in TLR4_l4 (SEQ ID NOS:20624 and 20633). In some embodiments the
nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes the sense and the
antisense strands of the sequence pair set forth in TLR4_lS (SEQ ID NOS:20625 and
20634). In some embodiments the nucleic acid molecule (e.g., a siNA molecule) as disclosed
herein includes the ce pair set forth in 8 (SEQ ID NOS:20626 and 20635).
In some embodiments the nucleic acid molecule (e.g., a siNA molecule) as disclosed herein
includes the sense and the antisense strands of the sequence pair set forth in 9 (SEQ
ID NOS:20627 and 20636). In some embodiments the nucleic acid molecule (e.g., a siNA
molecule) as disclosed herein includes the sequence pair set forth in TLR4_3l (SEQ ID
628 and 20637). In some embodiments the nucleic acid molecule (e.g., a siNA
molecule) as disclosed herein include the sense and the antisense strands of the sequence
pair set forth in TLR4_33 (SEQ ID 629 and 20638).
In some embodiments the sense strand and the antisense strand are selected from the
sequence pair set forth in MYD88_ll. In some ments the nse strand and the
sense strand are selected from the sequence pair set forth in MYD88_ll (SEQ ID
NOS:l2l78 and . In some embodiments the nucleic acid molecule (e.g., a siNA
molecule) as disclosed herein includes the sequence pair set forth in ll (SEQ ID
NOS:l2l78 and 12660).
In some embodiments the sense strand and the antisense strand are selected from the
sequence pair set forth in TICAMl_20. In some embodiments the sense strand and the
antisense strand are the sequence pair set forth in TICAMl_20 (SEQ ID NOS:20644 and
20655). In some embodiments the nucleic acid molecule (e.g., a siNA molecule) as sed
herein includes the sequence pair set forth in TICAMl_20 (SEQ ID NOS:20644 and 20655).
In some embodiments the sense strand and the antisense strand are selected from the
sequence pair set forth in TIRAP_l6. In some embodiments the antisense strand and the
sense strand are selected from the sequence pair set forth in TIRAP_l6 (SEQ ID
NOS:2066l and 20673). In some embodiments the nucleic acid molecule (e.g., a siNA
molecule) as disclosed herein includes the ce pair set forth in TIRAP_l6 (SEQ ID
661 and 20673).
In various embodiments the double-stranded molecule comprises a mismatch to the
target mRNA at the 5’ terminal nucleotide of the guide strand (antisense strand).
Accordingly ed are double-stranded c acid molecules having the
following Structure:
(A2) 5’ Nl-(N)X - Z 3’ (antisense strand)
3’ Z’-N2-(N’)y —z” 5’ (sense strand)
wherein each N2, N and N’ is an unmodified or d ribonucleotide, or an
unconventional moiety;
wherein each of (N)x and (N ’)y is an oligonucleotide in which each consecutive N or N’ is
joined to the adjacent N or N’ by a covalent bond;
wherein each of x and y is ndently an integer between 17 and 24;
wherein the sequence of (N’)y is mentary to the sequence of (N)X and (N)X is
mentary to a consecutive sequence in a target RNA selected fiom TLR2, TLR4,
MYD88, TICAM, and TIRAP;
wherein N1 is covalently bound to (N)X and is mismatched to a target RNA or is a
complementary DNA moiety to the target RNA;
wherein N1 is a moiety selected from the group consisting of unmodified or modified
nucleotides selected from uridine (rU), deoxyribouridine (dU), ymidine (rT),
deoxyribothymidine (dT), adenosine (rA) and deoxyadenosine (dA);
wherein z” may be present or absent, but if present is a capping moiety covalently attached
at the 5’ terminus ofNZ- (N’)y; and
wherein each of Z and Z’ is independently t or absent, but if present is
independently l-5 consecutive nucleotides, consecutive non-nucleotide moieties or a
combination thereof covalently attached at the 3’ terminus of the strand in which it is
present.
In some embodiments the sequence of (N’)y is fiJlly complementary to the sequence
of (N)X. In various embodiments sequence of NZ-(N’)y is complementary to the sequence of
Nl-(N)X. In some embodiments (N)X comprises an antisense that is fully complementary to
about 17 to about 24 consecutive nucleotides in a target RNA. In other embodiments (N)x
comprises an antisense that is substantially complementary to about 17 to about 39
utive nucleotides in a target RNA.
In some embodiments N1 and N2 form at least one hydrogen bond. In some
embodiments N1 and N2 form a Watson-Crick base pair. In some embodiments N1 and N2
form a non-Watson-Crick base pair. In some embodiments a base pair is formed between a
cleotide and a deoxyribonucleotide.
In some ments of Structure A2 x=y=18, x =y=l9 or x =y=20. In preferred
embodiments x=y=l 8.
In some embodiments N1 is covalently bound to (N)x and is mismatched to the target
RNA. In various embodiments N1 is covalently bound to (N)x and is a DNA moiety
complementary to the target RNA.
In some embodiments N1 is covalently bound to (N)x and is a DNA moiety
complementary to the target RNA.
In some embodiments N1 is selected from adenosine, deoxyadenosine, deoxyuridine,
ribothymidine or hymidine, and the pairing nucleotide in the target RNA is adenosine.
In preferred embodiments N1 selected from adenosine, deoxyadenosine or ridine.
In some embodiments N1 is selected from adenosine, deoxyadenosine, uridine,
deoxyuridine, ribothymidine or deoxythymidine and the pairing nucleotide in the target RNA
is cytidine. In red embodiments N1 is selected from adenosine, deoxyadenosine,
uridine or deoxyuridine.
In some embodiments N1 is selected from an unmodified or modified adenosine,
deoxyadenosine, uridine, deoxyuridine, ribothymidine or deoxythymidine and the g
nucleotide in the target RNA is ine. In some embodiments N1 comprises a 2’-OMe
sugar modified adenosine, uridine or ribothymidine. In some embodiments N1 comprises a 2’
fluoro or 2’amino sugar modified adenosine, uridine or ribothymidine.
In preferred embodiments N1 is selected from ine, deoxyadenosine, uridine or
deoxyuridine. In some embodiments N1 is ed from ine and deoxyadenosine and
_ 7 _
WO 18911
N2 is e and N1 and N2 form a base pair. In some embodiments N1 is selected from
ur1d1ne or deoxyur1d1ne and N is adenos1ne and N1 and N2 form a base pair.
In some embodiments N1 is selected from deoxyadenosine, deoxyuridine,
ribothymidine or deoxythymidine and n the nucleotide in the pairing nucleotide in the
target RNA is uridine. In preferred embodiments N1 selected from deoxyadenosine or
deoxyuridine.
In some ments N1 is selected from uridine or deoxyuridine and N2 is selected
from adenos1ne or deoxyadenosme and N. . 1 and N2 form a base pair.-
In some embodiments N1 is ed from adenosine or deoxyadenosine and N2 is
selected from uridine or deoxyuridine and N1 and N2 form a base pair. In other embodiments
N1 is deoxyuridine and N2 is adenosine and N1 and N2 form a base pair. In some
embod1ments N. 1 . . 2 . . . .
1s adenos1ne and N is ur1d1ne and N1 and N2 form a base pair.
In some embodiments the sense strand oligonucleotide and the antisense strand
oligonucleotide are selected from the oligonucleotide pairs set forth in SEQ ID NOS:306l-
5260 or 5261-5846 to target TLR2; SEQ ID NOS:86l3-l2040 or l204l-l2l44 to target
TLR4; SEQ ID NOS:l3925-15910 or 15911-16332 to target MYD88; SEQ ID NOS:l6883-
18236 or 18237-18242 to target TICAMl or SEQ ID NOS:l9047-20590 or 20591-20606 to
target TIRAP.
In some ments the sense strand and the antisense strand are selected from the
sequence pairs set forth in TLR2_3l and TLR2_34. In some ments the sense strand
and antisense strand are selected from the sequence pairs set forth in TLR2_3l (SEQ ID
NOS:206l2 and 20619) and TLR2_34 (SEQ ID NOS:206l3 and 20620). In various
embodiments N1 in the antisense strand includes uridine or chemically modified uridine and
N2 in the sense strand includes riboadenine or a chemically modified riboadenine. In some
embodiments the nucleic acid le (e.g., a siNA molecule) as disclosed herein includes
the sequence pair set forth in TLR2_3l (SEQ ID NOS:206l2 and 20619). In some
embodiments the nucleic acid molecule (e.g., a siNA molecule) as disclosed herein es
the sense and the antisense strands of the sequence pair set forth in TLR2_34 (SEQ ID
NOS:206l3 and 20620).
In some embodiments the sense strand and the antisense strand are selected from the
sequence pairs set forth in TICAMl_l5, TICAMl_l6, TICAMl_l7, TICAMl_18,
TICAMl_l9, TICAMl_2l, TICAM1_22, TICAM1_23, TICAM1_24, ,and TICAM1_25. In
some embodiments the sense strand and the antisense strand are ed from the sequence
pairs set forth in TICAMl_l5 (SEQ ID NOS:20639 and 20650), TICAMl_l6 (SEQ ID
NOS:20640 and , _l7 (SEQ ID NOS:20641 and 20652), TICAM1_18 (SEQ
ID NOS:20642 and 20653); TICAM1_19 (SEQ ID NOS:20643 and 20654); TICAMl_2l
(SEQ ID NOS:20645 and 20656), TICAMl_22 (SEQ ID 646 and 20657),
TICAM1_23 (SEQ ID 647 and 20658), TICAM1_24 (SEQ ID NOS:20448 and
20659) and _25 (SEQ ID NOS:20649 and 20660).
In some embodiments the nucleic acid molecule (e.g., a siNA molecule) as disclosed
herein includes the sequence pair set forth in TICAMl_l5 (SEQ ID NOS:20639 and
20650). In some embodiments the nucleic acid molecule (e.g., a siNA molecule) as
disclosed herein includes the sense and the antisense strands of the sequence pair set forth in
TICAMl_l6 (SEQ ID NOS:20640 and 20651). In some embodiments the nucleic acid
le (e.g., a siNA molecule) as disclosed herein includes the sequence pair set forth in
TICAMl_l7 (SEQ ID NOS:2064l and 20652). In some embodiments the c acid
molecule (e.g., a siNA molecule) as disclosed herein includes the sense and the antisense
strands of the sequence pair set forth in TICAMl_18 (SEQ ID NOS:20642 and 20653). In
some embodiments the nucleic acid molecule (e.g., a siNA molecule) as disclosed herein
includes the sequence pair set forth in TICAMl_l9 (SEQ ID 643 and 20654). In
some embodiments the nucleic acid molecule (e.g., a siNA molecule) as disclosed herein
includes the sense and the antisense strands of the sequence pair set forth in TICAMl_2l
(SEQ ID NOS:20645 and 20656). In some embodiments the nucleic acid molecule (e.g., a
siNA le) as disclosed herein includes the ce pair set forth in _22
(SEQ ID NOS:20646 and 20657). In some embodiments the nucleic acid molecule (e.g., a
siNA molecule) as disclosed herein includes the sense and the nse strands of the
sequence pair set forth in TICAMl_23 (SEQ ID NOS:20647 and 20658). In some
ments the nucleic acid le (e.g., a siNA molecule) as disclosed herein includes
the sequence pair set forth in TICAMl_24 (SEQ ID NOS:20448 and 20659). In some
embodiments the nucleic acid molecule (e. g., a siNA molecule) as disclosed herein includes
the sense and the antisense strands of the sequence pair set forth in TICAMl_25 (SEQ ID
NOS:20649 and 20660).
_ 9 _
2012/027174
In some embodiments the sense strand and the antisense strand are selected from the
sequence pairs set forth in TIRAP_17, TIRAP_18, TIRAP_19, TIRAP_20, TIRAP_21,
TIRAP_22, TIRAP_23, TIRAP_24, TIRAP_25, 26 and TIRAP_27. In some
embodiments the sense strand and the antisense strand are selected from the sequence pairs
set forth in TIRAP_17 (SEQ ID NOS:20662 and 20674), TIRAP_l8 (SEQ ID NOS:20663
and ; TIRAP_19 (SEQ ID NOS:20664 and 20676); TIRAP_20 (SEQ ID NOS:20665
and 20677), TIRAP_21 (SEQ ID NOS:20666 and 20678), TIRAP_22 (SEQ ID NOS:20667
and 20679), TIRAP_23 (SEQ ID NOS:20668 and 20680), TIRAP_24 (SEQ ID NOS:20669
and 20681), TIRAP_25 (SEQ ID NOS:20670 and 20682), TIRAP_26 (SEQ ID NOS:2067l
and 20683) and TIRAP_27 (SEQ ID NOS:20672 and 20684).
In some embodiments the nucleic acid molecule (e.g., a siNA molecule) as disclosed
herein includes the sequence pair set forth in TIRAP_l7 (SEQ ID NOS:20662 and 20674).
In some embodiments the nucleic acid molecule (e.g., a siNA le) as disclosed herein
includes the sense and the nse strands of the sequence pair set forth in 18
(SEQ ID NOS:20663 and 20675). In some embodiments the nucleic acid le (e.g., a
siNA molecule) as disclosed herein includes the sequence pair set forth in 19 (SEQ
ID NOS:20664 and 20676). In some embodiments the c acid molecule (e.g., a siNA
molecule) as sed herein es the sense and the antisense strands of the sequence
pair set forth in TIRAP_20 (SEQ ID NOS:20665 and . In some embodiments the
nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes the sequence pair
set forth in TIRAP_21 (SEQ ID NOS:20666 and 20678). In some embodiments the nucleic
acid molecule (e.g., a siNA molecule) as disclosed herein includes the sense and the
nse strands of the sequence pair set forth in TIRAP_22 (SEQ ID NOS:20667 and
20679). In some embodiments the nucleic acid molecule (e.g., a siNA molecule) as
disclosed herein includes the sequence pair set forth in TIRAP_23 (SEQ ID NOS:20668 and
20680). In some embodiments the nucleic acid molecule (e.g., a siNA molecule) as
disclosed herein includes the sense and the antisense s of the sequence pair set forth in
TIRAP_24 (SEQ ID NOS:20669 and 20681). In some embodiments the nucleic acid
molecule (e.g., a siNA molecule) as disclosed herein includes the sequence pair set forth in
TIRAP_25 (SEQ ID NOS:20670 and 20682). In some ments the nucleic acid
molecule (e.g., a siNA molecule) as disclosed herein includes the sense and the antisense
strands of the sequence pair set forth in TIRAP_26 (SEQ ID NOS:2067l and 20683). In
_ 10 _
some embodiments the nucleic acid molecule (e.g., a siNA le) as disclosed herein
es the sense and the antisense strands of the sequence pair set forth in TIRAP_27
(SEQ ID NOS:20672 and 20684).
In various embodiments the double stranded nucleic acid molecules are generated
based on the SEQ ID NOSil3-5846 (targeting TLR2), SEQ ID NOS:5847-12144 (targeting
TLR4), SEQ ID NOS:12145-16332 (targeting MYD88), SEQ ID NOS:16333-18242
(targeting TICAMl) and SEQ ID 243-20606 (targeting TIRAP) or preferably
oligonucleotide pairs set forth in Tables 1-5, infra, and include one or more of the following
modifications according to Structure (Al) and Structure (A2):
a. (N)x =19 or Nl-(N)x =19 and in at least one of positions 5, 6, 7, 8, or 9 from the 5’
terminus of (N)X or Nl-(N)X is selected from a threose nucleic acid (TNA) moiety, a
2’5 ’ nucleotide, a mirror nucleotide, a UNA or an abasic moiety;
b. (N)X =19 or Nl-(N)X =19 at least one of the pyrimidine ribonucleotides in (N)X or N1-
(N)x comprises a 2’ sugar modified ribonucleotide;
c. in (N)X or Nl-(N)X, N in positions 11, 13, 15, 17 and 19 comprises 2’-OMe sugar
modified cleotides and N in ons 10, 12, 14, 16, and 18 comprises
unmodified ribonucleotides;
d. in (N)x or Nl-(N)x, N in positions 1, 3, 5, 9, 11, 13, 15, 17 and 19 comprises 2’-OMe
sugar modified ribonucleotides and N in ons 2, 4, 6, 8, 10, 12, 14, 16, and 18
comprises unmodified ribonucleotides;
e. in (N)X or Nl-(N)X, N in positions 2, 4, 6, 8, 11, 13, 15, 17 and 19 comprises 2’-
OMe sugar modified ribonucleotides;
f Z is covalently attached to the 3’ us of (N)X or Nl-(N)X and includes a non-
nucleotide moiety selected from the group ting of C3OH, C3Pi, C3Pi-C3OH,
and C3Pi-C3Pi;
g. N’ in at least one of positions 7, 8, 9 or 10 from the 5’ terminus of (N’)y or NZ-(N’)y
is selected from a threose nucleic acid moiety, a 2’5’ nucleotide and pseudoUridine;
h. N’ comprises a threose nucleic acid (TNA) moiety or a 2’5’ nucleotide in 4, 5, or 6
consecutive positions at the 3’ terminal or 3’ penultimate positions in (N’)y or N2-
(N ’)y;
i. at least one of the pyrimidine ribonucleotides in (N’)y or NZ-(N’)y is a 2’ sugar
modified cleotide;
j. z” is a cap moiety covalently attached to the 5’ terminus of (N ’)y or NZ-(N’)y and is
selected from an inverted abasic deoxyribose moiety, and inverted abasic ribose
moiety, an abasic deoxyribose moiety, an abasic ribose , a C3 moiety as
defined below, L-DNA, L-RNA;
k. Z’ is covalently attached to the 3’ terminus of (N’)y or NZ-(N’)y and includes one of
C3OH, C3Pi, C3Pi-C3OH, or C3Pi-C3Pi.
In preferred embodiments x=y=l9.
In some embodiments the covalent bond joining each consecutive N or N’ is a
phosphodiester bond. In various embodiments all the covalent bonds are phosphodiester
bonds
In some embodiments of the double stranded nucleic acid molecules of Structure Al
and Structure A2, N in at least one of positions 5, 6, 7, 8, or 9 from the 5’ terminus of the
antisense strand [(N)X or Nl-(N)x] is selected from a e nucleic acid (TNA) moiety, a
2’5 ’ tide, a mirror nucleotide, a UNA or a combination thereof. t wishing to be
bound to , a double stranded nucleic acid molecule having a threose nucleic acid
(TNA) moiety, a 2’5’ tide, a mirror nucleotide at any one or more of the
aforementioned positions s to the double stranded molecule increased get
activity and/or decreased off-target activity and or increased stability to nucleases.
In some embodiments the antisense strand [(N)x of Structure Al or Nl-(N)x of
Structure A2] comprises a TNA moiety in position 5, a TNA moiety in position 6, a TNA
moiety in position 7, a TNA moiety in position 8, a TNA moiety in position 9, TNA moieties
in positions 5-6, TNA moieties in positions 6-7, TNA moieties in positions 7-8, TNA
moieties in positions 8-9, TNA moieties in positions 5-7, TNA es in positions 6-8,
TNA moieties in positions 7-9, TNA moieties in positions 5-8, TNA es in positions 6-
9 or TNA moieties in positions 5-9.
In some embodiments the antisense strand [(N)x of Structure Al or Nl-(N)x of
Structure A2] comprises a 2’-5’ nucleotide in position 5, a 2’-5’ nucleotide in position 6, a
2’-5’ nucleotide in position 7, a 2’-5’ tide in position 8, a 2’-5’ nucleotide in position
9, 2’-5’ nucleotides in positions 5-6, 2’-5’ nucleotides in positions 6-7, 2’-5’ nucleotides in
positions 7-8, 2’-5’ tide in positions 8-9, 2’-5’ nucleotides in positions 5-7, 2’-5’
nucleotides in positions 6-8, 2’-5’ nucleotides in positions 7-9, 2’-5’ tides in positions
-8, 2’-5’ nucleotides in positions 6-9 or 2’-5’ nucleotides in positions 5-9.
In some embodiments the antisense strand [(N)x of Structure Al or Nl-(N)x of
ure A2] comprises a mirror nucleotide in position 5, a mirror nucleotide in position 6, a
mirror nucleotide in position 7, a mirror nucleotide in on 8, a mirror nucleotide in
position 9, mirror nucleotides in positions 5-6, mirror nucleotides in positions 6-7, mirror
nucleotides in positions 7-8, mirror nucleotides in positions 8-9, mirror nucleotides in
positions 5-7, mirror nucleotides in ons 6-8, mirror nucleotides in positions 7-9, mirror
nucleotides in positions 5-8, mirror nucleotides in positions 6-9 or mirror nucleotides in
positions 5-9. In some embodiments the mirror nucleotide comprises L-DNA or L-RNA.
In some embodiments of the double stranded nucleic acid molecules, N’ in at least
one of positions 9 or 10 from the 5’ terminus of the sense strand [(N’)y in Structure Al or
NZ-(N’)y in ure A2] is selected from a threose nucleic acid (TNA) moiety, a 2’5’
nucleotide, a pseudoUridine or a ation thereof. Without Wishing to be bound to
theory, a double ed nucleic acid molecule having a threose nucleic acid (TNA) moiety,
a 2’5’ nucleotide, a pseudoUridine at any one or more of positions 9 or 10 in the sense
(passenger) strand s to the double stranded molecule increased on target activity
and/or increased nuclease stability.
In some embodiments (N’)y in ure Al or NZ- ’
y in Structure A2 comprises a
threose nucleic acid (TNA) moiety in position 9 and/or in position 10.
In some embodiments (N’)y in Structure Al or NZ- ’
y in Structure A2 comprises a
2’5’ nucleotide in position 9 and/or in position 10.
In some embodiments (N’)y in ure Al or NZ- ’
y in ure A2 comprises a
pseudoUridine in position 9 and/or in position 10.
In some embodiments of the double stranded nucleic acid les, N’ comprises 4,
, or 6 utive 2’5’ tides at the 3’ al or penultimate position of the sense
strand [(N’)y in Structure A1 or )y in Structure A2]. Without Wishing to be bound to
theory, a double stranded nucleic acid molecule having 4, 5, or 6 consecutive 2’5’
nucleotides at the 3’ terminal or penultimate position of the sense (passenger) strand confers
increased nuclease stability to the duplex and or reduced off target effect of the sense
(passenger) strand. In some embodiments the sense strand further ses Z’. In some
embodiments Z comprises a C3 moiety (for e C3Pi, C3-OH) or a 3’ terminal
phosphate (Pi).
In some embodiments of Structure A1 and A2 the sense strand comprises four
consecutive 2’5’ nucleotides at the 3’ terminal or penultimate position. In some
embodiments of ure Al x=y=19 and (N’)y comprises 2’5’ nucleotides in positions 15,
16, 17, and 18 or in positions 16, 17, 18, and 19. In some embodiments of Structure A2
x=y=18 and N2-(N’)y comprises 2’5’ nucleotides in positions 15, 16, 17, and 18 or in
positions 16, l7, l8, and 19.
In some embodiments of Structures A1 and A2 the sense strand comprises five
consecutive 2’5’ nucleotides at the 3’ terminal or penultimate position. In some
embodiments of Structure Al x=y=19 and (N’)y comprises 2’5’ nucleotides in positions 14,
, 16, 17, and 18 or in positions 15, 16, 17, 18, and 19. In some embodiments of Structure
A2 x=y=18 and N2-(N’)y comprises 2’5’ nucleotides in positions 14, 15, 16, 17, and 18 or
in positions 15, 16, 17, 18 and N2.
In some embodiments of Structures A1 and A2 the sense strand comprises six
consecutive 2’5’ nucleotides at the 3’ terminal or penultimate on. In some
embodiments of Structure A1 x=y=19 and (N’)y comprises 2’5’ nucleotides in positions 13,
14, 15, 16, 17, and 18 or in positions 14, 15, 16, 17, 18, and 19. In some embodiments of
Structure A2 x=y=18 and N2-(N’)y comprises 2’5’ tides in positions 13, 14, 15, 16,
17, and 18 or in position 14, 15, 16, 17, 18, and N2.
In some embodiments x=y=19 and the double stranded nucleic acid molecule
comprises
N in at least one of positions 5, 6, 7, 8, or 9 from the 5’ terminus of the antisense
strand is selected from a threose c acid moiety, a 2’5’ nucleotide or a mirror
_ 14 _
2012/027174
nucleotide;
N’ in at least one of positions 9 or 10 from the 5’ us of the sense strand is
ed from a threose nucleic acid moiety, a 2’5’ nucleotide and a pseudoUridine; and
At least one pyrimidine cleotide in the antisense strand is a 2’-OMe sugar
modified ribonucleotide.
In some embodiments the double stranded molecule comprises a 2’5’ nucleotide in
position 9 of the antisense strand and a 2’5’ nucleotide in position 5 or 6 in the sense strand.
In additional embodiments the antisense strand further includes 2’-OMe modified pyrimidine
ribonucleotides.
In another embodiment x=y=19 and a double stranded nucleic acid molecule
comprises
N in at least one of positions 5, 6, 7, 8, or 9 from the 5’ us of the antisense
strand is selected from a threose nucleic acid moiety, a 2’5’ nucleotide or a mirror
nucleotide; and
N’ in 4, 5, or 6 consecutive positions starting at the 3’ terminal or imate
position of the sense strand comprises a 2’5’ nucleotide.
In some ments the double stranded nucleic acid le is a double stranded
oligonucleotide including dsRNA, siRNA, siNA or a miRNA. In some embodiments (N)x
and (N’)y comprise oligonucleotide pairs set forth in SEQ ID NOS:13-5846 (targeting
TLR2), SEQ ID NOS:5847-12144 (targeting TLR4), SEQ ID NOS:12145-16332 (targeting
MYD88), SEQ ID NOS:16333-18242 (targeting TICAMl) and SEQ ID NOS:18243-20606
(targeting TIRAP) and preferably include one of the ing pairs of sense and antisense
strands set forth in TLR2_25 (SEQ ID NOS:20607 and 20614), TLR2_28 (SEQ ID
NOS:20608 and 20615), TLR2_42 (SEQ ID NOS:20609 and 20616), TLR2_43 (SEQ ID
NOS:20610 and 20617) ID NOS:20611 and 20618), TLR2_31 (SEQ ID
, TLR2_47 (SEQ
NOS:20612 and 20619), TLR2_34 (SEQ ID NOS:20613 and 20620); or
TLR4_08 (SEQ ID NOS:20621 and 20630), TLR4_10 (SEQ ID NOS:20622 and
20631), TLR4_11 (SEQ ID NOS:20623 and 20632), TLR4_14 (SEQ ID NOS:20624 and
20633), TLR4_15 (SEQ ID NOS:20625 and 20634), 8 (SEQ ID 626 and
20635), TLR4_29 (SEQ ID NOS:20627 and 20636), TLR4_31 (SEQ ID NOS:20628 and
_ 15 _
20637), 3 (SEQ ID NOS:20629 and 20638); or
MYD88_11 (SEQ ID NOS:12178 and 12660); or
TICAM1_20 (SEQ ID NOS:20644 and 20655), TICAM1_15 (SEQ ID NOS:20639
and 20650), _16 (SEQ ID NOS:20640 and 20651), TICAM1_17 (SEQ ID
NOS:20641 and 20652), _18 (SEQ ID NOS:20642 and 20653); TICAM1_19
(SEQ ID NOS:20643 and 20654); TICAM1_21 (SEQ ID NOS:20645 and 20656),
TICAM1_22 (SEQ ID 646 and 20657), TICAM1_23 (SEQ ID 647 and
20658), TICAM1_24 (SEQ ID NOS:20448 and 20659), TICAM1_25 (SEQ ID
649 and 20660); or
TIRAP_16 (SEQ ID NOS:20661 and 20673), TIRAP_17 (SEQ ID NOS:20662 and
20674), TIRAP_18 (SEQ ID NOS:20663 and 20675); TIRAP_19 (SEQ ID NOS:20664 and
; TIRAP_20 (SEQ ID NOS:20665 and 20677), TIRAP_21 (SEQ ID NOS:20666 and
20678), TIRAP_22 (SEQ ID NOS:20667 and 20679), TIRAP_23 (SEQ ID NOS:20668 and
20680), TIRAP_24 (SEQ ID NOS:20669 and 20681), TIRAP_25 (SEQ ID NOS:20670 and
20682), TIRAP_26 (SEQ ID NOS:20671 and 20683) and TIRAP_27 (SEQ ID 672
and 20684); or
In some embodiments the double stranded molecule comprises a phosphodiester
bond. In various embodiments the double stranded molecule comprises ribonucleotides
wherein x = y and wherein x is an integer selected from the group consisting of 19, 20, 21,
22, and 23. In some embodiments X = y =19.
In some embodiments (N)X of Structure 1 or N1-(N)X of ure A2 comprise
unmodified ribonucleotides.
In some embodiments (N)X of Structure 1 or N1-(N)X of Structure A2 comprise
modified and fied ribonucleotides, each modified ribonucleotide a 2’-OMe sugar
modified ribonucleotide, wherein N at the 3’ terminus of (N)X is a modified ribonucleotide,
(N)x comprises at least five alternating modified ribonucleotides beginning at the 3’ end and
at least nine modified ribonucleotides in total and each remaining N is an unmodified
ribonucleotide. In additional embodiments (N)x comprises modified ribonucleotides in
alternating positions wherein each N at the 5’ and 3’ termini are 2’-OMe sugar modified
ribonucleotides and the middle ribonucleotide is not modified, e.g. ribonucleotide in position
in a l9-mer strand.
In some embodiments (N)x of Structure 1 or Nl-(N)x of Structure A2 consist of
single alternating 2’-O methyl (2’-OMe) sugar modified and unmodified ribonucleotides, for
example wherein the ribonucleotides at ons 1, 3, 5, 7, 9, ll, 13, 15, 17, and 19 are 2’-
OMe sugar modified ribonucleotides. In other embodiments the ribonucleotides at ons
2, 4, 6, 8, ll, 13, 15, 17, and 19 are 2’-OMe sugar modified cleotides and the
remaining ribonucleotides are unmodified.
In some ments (N’)y in Structure Al or N2-(N’)y in Structure A2 se at
least one unconventional moiety ed from a mirror nucleotide, or a nucleotide joined to
an adjacent nucleotide by a 2’-5’ intemucleotide phosphate bond.
In one embodiment of the above Structure, the compound comprises at least one
mirror nucleotide at one or both termini in (N’)y in Structure Al or )y in Structure
A2. In various embodiments the compound comprises two consecutive mirror nucleotides,
one at the 3’ imate position and one at the 3’ terminus in (N ’)y in Structure Al or N2-
(N’)y in Structure A2. In one preferred embodiment x=y=l9 and (N’)y in Structure Al or
N2-(N’)y in Structure A2 comprise an L-deoxyribonucleotide at position 18.
In some embodiments the mirror nucleotide is selected from an L-ribonucleotide and
an L-deoxyribonucleotide. In various embodiments the mirror nucleotide is an L-
ibonucleotide. In some embodiments y=l9 and (N’)y in Structure A1 or N2-(N’)y in
Structure A2 consists of unmodified ribonucleotides at positions 1-17 and 19 and one L-
DNA at the 3’ penultimate position (position 18). In other embodiments y=l9 and (N ’)y
consists of unmodified ribonucleotides at position 1-16 and 19 and two consecutive L-DNA
at the 3’ penultimate on (positions 17 and 18). In some embodiments (N’)y in ure
Al or )y in ure A2 further include Z’, for example C3OH and or z”, for
example and inverted abasic moiety or an amino moiety.
In another embodiment of the above structure, (N ’)y in Structure A1 or N2-(N’)y in
_ 17 _
Structure A2 comprises at least two consecutive nucleotide joined together to the next
nucleotide by a 2’-5’ phosphodiester bond at one or both i. In certain preferred
embodiments in (N’)y in Structure Al or N2-(N’)y in Structure A2 the 3’ penultimate
nucleotide is linked to the 3’ terminal tide with a 2’-5’ phosphodiester bridge.
In certain preferred embodiments double stranded RNA molecule is a blunt-ended
(i.e. z”, Z and Z’ are absent), double stranded ucleotide structure, x=y=l9, wherein
(N’)y in Structure Al or N2-(N’)y in Structure A2 comprises unmodified ribonucleotides in
which three consecutive nucleotides at the 3’ terminus are joined together by two 2'-5'
phosphodiester bonds; and an antisense strand (AS) of alternating unmodified and 2'-OMe
sugar-modified ribonucleotides.
In one embodiment the double stranded nucleic acid molecule comprises an nse
strand and a sense strand selected from pairs of oligonucleotides set forth in SEQ ID
NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 (targeting TLR4), SEQ ID
NOS:l2l45-l6332 (targeting , SEQ ID 333-l8242 (targeting TICAMl)
and SEQ ID NOS:l8243-20606 (targeting TIRAP), or ably oligonucleotide pairs set
forth in Tables 1-5, infra, the antisense strand includes at least one 2’-OMe sugar modified
pyrimidine ribonucleotide; a TNA, 2’-5’ ribonucleotide a mirror nucleotide, a UNA or an
abasic moiety in at least one of positions 1, 5, 6, or 7 (5’>3’); and a 3’ terminal non-
nucleotide moiety covalently attached to the 3’ terminus; and the sense strand includes at
least one 2’5’ ribonucleotide or 2’-OMe modified ribonucleotide, and a non-nucleotide
moiety ntly attached at the 3’ terminus and a cap moiety covalently attached at the 5’
terminus .
In one embodiment the double stranded nucleic acid molecule comprises an antisense
strand and a sense strand selected from pairs of oligonucleotides in set forth in SEQ ID
NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 ting TLR4), SEQ ID
NOS:l2l45-l6332 (targeting MYD88), SEQ ID NOS:l6333-l8242 (targeting TICAMl)
and SEQ ID NOS:l8243-20606 (targeting TIRAP), or preferably ucleotide pairs set
forth in Tables 1-5, infra, the antisense strand includes at least one 2’-OMe sugar modified
pyrimidine ribonucleotide, a TNA or 2’-5’ ribonucleotide in position 7, and a nucleotide or
non-nucleotide moiety ntly attached at the 3’ us; and the sense strand includes
4-5 consecutive 2’5’ ribonucleotides or TNA in the 3’ terminal positions 16-19 or 15-19
-l8-
(5’>3’) a non-nucleotide moiety covalently attached at the 3’ terminus and a cap moiety
such as an inverted abasic moiety covalently attached at the 5’ terminus; and optionally
includes a 2’-OMe sugar modified ribonucleotide at position I of the antisense strand or a
2’5’ ribonucleotide at position I of the nse strand.
In one embodiment the double stranded nucleic acid molecule ses an antisense
strand and a sense strand selected from pairs of oligonucleotides set forth in set forth in SEQ
ID NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 ting TLR4), SEQ ID
NOSilZl45-l6332 (targeting MYD88), SEQ ID NOS:l6333-18242 (targeting TICAMl)
and SEQ ID NOS:18243-20606 (targeting TIRAP), or preferably ucleotide pairs set
forth in Tables 1-5, infra, the antisense strand includes at least one 2’-OMe sugar modified
pyrimidine cleotide, a 2’-5’ ribonucleotide in position 7, and a nucleotide or C3Pi-
C3OH non-nucleotide moiety covalently attached at the 3’ us; and the sense strand
includes at least one 2’-OMe sugar d pyrimidine ribonucleotide, a TNA or 2’5’
cleotide at position 9, a C3OH or C3Pi non-nucleotide moiety covalently attached at
the 3’ terminus and a cap moiety such as an inverted abasic moiety covalently attached at the
’ terminus.
In one embodiment the double stranded nucleic acid molecule comprises an antisense
strand and a sense strand selected from pairs of ucleotides set forth in set forth in SEQ
ID NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 (targeting TLR4), SEQ ID
NOSilZl45-l6332 (targeting MYD88), SEQ ID NOS:l6333-18242 (targeting TICAMl)
and SEQ ID NOS:18243-20606 (targeting TIRAP), or preferably oligonucleotide pairs set
forth in Tables 1-5, infra, the sense strand includes at least one 2’-OMe sugar modified
pyrimidine ribonucleotide; a nucleotide or non-nucleotide moiety ntly attached at the
3’ terminus; and a cap moiety covalently attached at the 5’ terminus; and the antisense strand
includes at least one 2’-OMe sugar modified cleotide; a TNA or 2’-5’ cleotide
in at least one of positions 5, 6 or 7; and a nucleotide or non-nucleotide moiety covalently
attached at the 3’ terminus.
In one embodiment the double stranded nucleic acid molecule comprises an antisense
strand and a sense strand selected from pairs of oligonucleotides set forth in set forth in SEQ
ID NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 (targeting TLR4), SEQ ID
NOSilZl45-l6332 (targeting MYD88), SEQ ID NOS:l6333-18242 (targeting TICAMl)
2012/027174
and SEQ ID NOS:l8243-20606 (targeting TIRAP), or ably oligonucleotide pairs set
forth in Tables l-5, infra, the sense strand includes at least one 2’-OMe sugar modified
pyrimidine ribonucleotide, a nucleotide or non-nucleotide moiety covalently attached at the
3’ us, and a cap moiety covalently attached at the 5’ terminus; and the antisense strand
includes at least one 2’-OMe sugar modified ribonucleotide; a TNA or 2’-5’ ribonucleotide
at position 7; and a nucleotide or non-nucleotide moiety covalently attached at the 3’
terminus .
In one embodiment the double stranded nucleic acid molecule comprises an nse
strand and a sense strand selected from pairs of ucleotides set forth in set forth in SEQ
ID NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 (targeting TLR4), SEQ ID
NOSilZl45-l6332 (targeting MYD88), SEQ ID NOS:l6333-l8242 (targeting TICAMl)
and SEQ ID NOS:l8243-20606 (targeting TIRAP), or preferably oligonucleotide pairs set
forth in Tables l-5, infra, the sense strand includes at least one 2’-OMe sugar d
dine ribonucleotide; a C3OH moiety covalently attached at the 3’ terminus; and a cap
moiety such as an inverted abasic deoxyribonucleotide moiety covalently attached at the 5’
terminus; and the nse strand includes at least one 2’-OMe sugar modified pyrimidine
ribonucleotide; a TNA or 2’-5’ ribonucleotide at position 7 ); and a nucleotide or
C3Pi-C3OH non-nucleotide moiety covalently attached at the 3 ’ terminus.
In one embodiment the double stranded c acid molecule comprises an antisense
strand and a sense strand ed from pairs of set forth in set forth in SEQ ID NOS:l3-
5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 (targeting TLR4), SEQ ID NOS:l2l45-
16332 (targeting MYD88), SEQ ID NOS:l6333-l8242 (targeting TICAMl) and SEQ ID
NOSil8243-20606 (targeting TIRAP), or preferably oligonucleotide pairs set forth in Tables
l-5, infra, the sense strand includes 2’-5’ ribonucleotides in positions at the 3’ terminus: a
non-nucleotide moiety covalently attached at the 3’ terminus and a cap moiety covalently
attached at the 5’ terminus; and the nse strand includes at least one 2’-OMe sugar
modified ribonucleotide; a TNA or 2’-5’ ribonucleotide in at least one of ons 5, 6 or 7
(5 ’>3 ’) and a nucleotide or non-nucleotide moiety covalently attached at the 3’ terminus.
In one embodiment the double stranded nucleic acid molecule comprises an antisense
strand and a sense strand selected from pairs of oligonucleotides set forth in set forth in SEQ
ID NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 (targeting TLR4), SEQ ID
NOSilZl45-l6332 (targeting MYD88), SEQ ID NOS:l6333-18242 (targeting TICAMl)
and SEQ ID NOS:18243-20606 (targeting TIRAP), or preferably oligonucleotide pairs set
forth in Tables 1-5, infra, the sense strand includes 4-5 utive TNA or 2’-5’
ribonucleotides in positions ) 15-19 or l6-l9, a C3-OH 3’ moiety covalently attached
at the 3’ us and a cap moiety such as an inverted abasic ibonucleotide moiety
covalently ed at the 5’ terminus; and the antisense strand includes at least one 2’-OMe
sugar modified dine cleotide; a TNA or 2’-5’ ribonucleotide in position 7 and a
nucleotide or C3Pi-C3OH moiety covalently attached at the 3’ terminus.
In one embodiment the double stranded nucleic acid molecule comprises an antisense
strand and a sense strand selected from pairs of oligonucleotides set forth in set forth in SEQ
ID NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 (targeting TLR4), SEQ ID
NOSilZl45-l6332 (targeting MYD88), SEQ ID NOS:l6333-18242 (targeting TICAMl)
and SEQ ID NOS:18243-20606 (targeting TIRAP), or preferably oligonucleotide pairs set
forth in Tables 1-5, infra, the sense strand es at least one 2’-OMe sugar modif1ed
pyrimidine ribonucleotide, an optional 2’-5’ ribonucleotide in one of on 9 or 10, a non-
nucleotide moiety covalently attached at the 3’ terminus and a cap moiety covalently
attached at the 5’ terminus; and the antisense strand includes at least one 2’-OMe sugar
modified ribonucleotide, a TNA or 2’5’ ribonucleotide in at least one of positions 5, 6, or 7;
and a nucleotide or non-nucleotide moiety covalently attached at the 3 ’ terminus.
In one embodiment the double stranded nucleic acid molecule comprises an antisense
strand and a sense strand selected from pairs of set forth in set forth in SEQ ID NOS:l3-
5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 (targeting TLR4), SEQ ID NOS:l2l45-
16332 (targeting MYD88), SEQ ID 333-18242 (targeting TICAMl) and SEQ ID
NOS:18243-20606 (targeting , or preferably oligonucleotide pairs set forth in Tables
l-S, infra, the sense strand includes at least one 2’-OMe sugar modified pyrimidine
cleotide, a 2’-5’ ribonucleotide in position 9, a C3OH non-nucleotide moiety
covalently attached at the 3’ terminus and a cap moiety such as an inverted abasic
deoxyribonucleotide moiety covalently attached at the 5’ terminus; and the antisense strand
includes at least one 2’-OMe sugar modified pyrimidine ribonucleotide, a TNA or 2’5’
ribonucleotide in position 6; and a nucleotide or C3Pi-C3OH moiety covalently attached at
the 3’ terminus.
In one embodiment the double stranded nucleic acid molecule comprises an antisense
strand and a sense strand selected from pairs of oligonucleotides set forth in set forth in SEQ
ID NOS:l3-5846 ting TLR2), SEQ ID NOS:5847-l2l44 (targeting TLR4), SEQ ID
NOSilZl45-l6332 (targeting MYD88), SEQ ID NOS:l6333-18242 (targeting )
and SEQ ID NOS:18243-20606 (targeting TIRAP), or preferably oligonucleotide pairs set
forth in Tables 1-5, infra, the sense strand includes at least one 2’-OMe sugar modified
pyrimidine ribonucleotide, a C3OH or C3Pi non-nucleotide moiety ntly attached at the
3’ terminus and a cap moiety such as an inverted abasic deoxyribonucleotide moiety
covalently attached at the 5’ terminus; and the antisense strand includes at least one 2’-OMe
sugar modified pyrimidine ribonucleotide, a 2’5’ ribonucleotide in position 6; and a
nucleotide or C3Pi-C3OH moiety covalently ed at the 3’ terminus.
In some ments the nucleotide moiety ntly attached at the 3’ us
comprises the dinucleotide deT.
According to one aspect, the present invention provides a method of generating a
double stranded RNA le consisting of a sense strand and an antisense strand having
ucleotide sequences forth in SEQ ID NOS:l3-3060 to target TLR2; SEQ ID
NOS:5847-8612 to target TLR4; SEQ ID NOS:12145-l3924 to target MYD88; SEQ ID
NOSil6333-l6882 to target TICAMl; or SEQ ID NOS:18243-l9046 to target TIRAP, the
method comprising the steps
a) synthesizing a sense strand;
b) synthesizing an antisense strand;
c) annealing the sense strand to the nse strand;
thereby generating a double stranded RNA molecule. In some embodiment the synthesis
includes synthesis of a chemically unmodified dsRNA strand. In some embodiments
synthesis includes incorporation of modified nucleotides including 2’-OMe sugar modified
ribonucleotides or unconventional moieties ing 2’5’ linked nucleic acid, abasic and
inverted abasic moieties and the like.
In some embodiments, neither (N)X nor (N’)y are phosphorylated at the 3’ and 5’
termini. In other embodiments either or both (N)X and (N ’)y are phosphorylated at the 3’
termini.
In a second aspect, ed herein are pharmaceutical compositions sing one
or more double stranded molecules as sed herein, in an amount effective to inhibit
target gene expression, and a pharmaceutically acceptable carrier wherein the target gene is
selected from a gene having a mRNA set forth in SEQ ID NOS: 1-12.
In another aspect provided is a cell sing one or more double stranded molecule
as disclosed herein in an amount effective to inhibit target gene expression.
In various embodiments the compound comprises an antisense oligonucleotide (N)x
and a corresponding sense oligonucleotide, the oligonucleotide pairs set forth in SEQ ID
NOSil3-5846 (targeting TLR2), SEQ ID NOS:5847-12144 (targeting TLR4), SEQ ID
NOS:12145-16332 (targeting , SEQ ID NOS:16333-18242 (targeting TICAMl)
and SEQ ID NOS:18243-20606 (targeting , or preferably oligonucleotide pairs set
forth in Tables 1-5, infra.
In other aspects disclosed are oligonucleotide compounds useful in preventing or
treating chronic or acute aseptic inflammation, neuropathic pain, y graft failure,
ischemia-reperfusion injury, reperfilsion injury, reperfusion edema, allograft dysfilnction,
pulmonary reimplantation response and/or primary graft dysfunction (PGD) in organ
transplantation, such as lung transplantation in a t in need thereof.
In another aspect, ed is a method for the treatment of a subject in need of
treatment for a disease or disorder or symptom or condition associated with the disease or
er, associated With the expression of a target gene comprising stering to the
subject an amount of a double stranded molecule as disclosed herein which reduces or
inhibits expression of a target gene. In preferred embodiments the double stranded molecule
is chemically modified as bed herein.
Also provided is a double stranded molecule as described herein for the
treatment of a disease or injury selected from chronic or acute aseptic inflammation,
neuropathic pain, primary graft e, ia-reperfusion injury, reperfusion injury,
reperfusion edema, aft dysfunction, pulmonary reimplantation response and/or primary
graft dysfunction (PGD) in organ transplantation, such as lung transplantation.
Further provided is a double stranded molecule as described herein for the
preparation of a medicament for the treatment of a disease or injury selected from chronic or
acute aseptic inflammation, athic pain, primary graft failure, ischemia-reperfusion ,
reperfusion injury, usion edema, allograft dysfunction, pulmonary reimplantation
response and/or primary graft dysfunction (PGD) in organ transplantation, such as lung
transplantation.
In other aspects the disclosure relates to methods for treating or preventing the
incidence or severity of a posttransplantational (e.g. following lung transplantation)
complication selected from, without being limited to, primary graft failure, ischemiareperfusion
injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary
reimplantation response and/or primary graft dysfunction (PGD), in a subject in need thereof
wherein the complication is associated with expression of a gene selected from a gene set forth
in Table Al. Such s involve administering to a mammal in need of such treatment a
prophylactically or therapeutically effective amount of one or more double stranded molecules
disclosed herein to t or reduce sion or activity of at least one such gene. In other
aspects the disclosure relates to methods for reducing acute or chronic mation in a subject
in need thereof wherein the inflammation is ated with expression of a gene selected from
a gene set forth in Table Al. Such s involve administering to a mammal in need of such
treatment a prophylactically or therapeutically effective amount of one or more double stranded
molecules disclosed herein to inhibit or reduce sion or activity of at least one such gene.
In some embodiments ansplantational complication is present in an organ
transplant recipient (such as a lung transplantation recipient) and the target gene is selected
from TLR2, TLR4, MYD88, TICAM1 and TIRAP, having mRNA polynucleotide sequences
set forth in SEQ ID NOS:l-12. Sense and antisense oligonucleotide pairs useful in ing
dsRNA for inhibiting expression of TLR2, TLR4, MYD88, TICAM1 and TIRAP are set forth
in SEQ ID NOS:13-5846 (targeting TLR2), SEQ ID NOS:5847-12144 (targeting TLR4), SEQ
ID NOS:12145-16332 (targeting MYD88), SEQ ID NOS:16333-18242 (targeting TICAM1)
and SEQ ID 243-20606 (targeting TIRAP) or preferably oligonucleotide pairs set forth
in Tables 1-5, infra.
[00103a] Definitions of the ic embodiments of the invention as claimed herein
follow.
[00103b] According to a first embodiment of the invention, there is provided a double
stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the
s are selected from the ucleotides described as TLR2_25 as set forth in SEQ ID
NOS:20607 and 20614, TLR2_28 as set forth in SEQ ID NOS:20608 and 20615, TLR2_42 as
set forth in SEQ ID NOS:20609 and 20616, TLR2_43 as set forth in SEQ ID NOS:20610 and
20617, TLR2_47 as set forth in SEQ ID 611 and 20618, TLR2_31 as set forth in SEQ
ID NOS:20612 and 20619, and TLR2_34 as set forth in SEQ ID NOS:20613 and 20620.
[00103c] According to a second embodiment of the invention, there is provided a
pharmaceutical composition comprising a double stranded nucleic acid molecule of the first
embodiment in an amount effective to inhibit gene expression, and a pharmaceutically
able carrier wherein the gene encodes a RNA having a polynucleotide sequence set forth
in SEQ ID NO:1.
[00103d] According to a third embodiment of the invention, there is provided use of the
double stranded nucleic acid molecule of the first embodiment or the composition according to
the second embodiment in the manufacture of a medicament for use in therapy; wherein said
y is treatment of a disease or injury selected from the group consisting of chronic or acute
c inflammation, neuropathic pain, primary graft failure, ia-reperfusion injury,
reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation
response and primary graft ction (PGD) in organ transplantation.
[00103e] According to a fourth embodiment of the invention, there is provided use of the
double stranded nucleic acid molecule of the first embodiment or the composition according to
the second embodiment in the manufacture of a medicament for treating a e or disorder or
symptom or ion associated with the expression of a target gene, wherein the gene encodes
an RNA having a polynucleotide sequence set forth in SEQ ID NO:1; wherein the disease o r
disorder or symptom or condition is selected from the group ting of chronic or acute
aseptic inflammation, neuropathic pain, primary graft failure, ischemia-reperfusion injury,
reperfusion injury, reperfusion edema, allograft dysfunction, ary reimplantation
response and primary graft dysfunction (PGD) in organ transplantation.
The methods, materials, and examples that will now be described are illustrative
only and are not intended to be limiting; materials and methods similar or equivalent to those
described herein can be used in practice or testing of the invention. Other features and
[Text continues on page 25.]
- 24a -
2012/027174
advantages of the invention will be apparent from the following detailed description, and
from the claims.
This disclosure is intended to cover any and all adaptations or variations of
combination of features that are disclosed in the various embodiments . Although
specific embodiments have been illustrated and described herein, it should be appreciated
that the invention encompasses any arrangement of the features of these embodiments to
achieve the same purpose. Combinations of the above features, to form embodiments not
ically bed herein, will be apparent to those of skill in the art upon ing
the instant ption.
DETAILED PTION OF THE INVENTION
The present invention relates in general to compounds which down-regulate
expression of certain target genes associated with posttransplantational (e.g. following lung
transplantation) complications and their use in treating a subject suffering from diseases or
ers associated with such posttransplantational cations. Inhibition of expression
of the one or more of the target genes selected from TLR2, TLR4, MYD88, TICAMl and
TIRAP is now shown to be beneficial in treating a subject suffering from an adverse effect of
organ transplantation, for example lung transplantation; more specifically from a
posttransplantational (e.g. following lung transplantation) complication selected from,
without being limited to, primary graft failure, ischemia-reperfusion injury, reperfusion
injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation se and/or
primary graft dysfunction (PGD). The present ion relates in particular to small double
stranded RNA compounds, such as interfering RNA ) compounds which inhibit
sion of TLR2, TLR4, MYD88, TICAMl and TIRAP, and to the use of these siRNA
compounds in the treatment of certain diseases and ers. Preferred sense and antisense
oligonucleotides useful in the preparation of dsRNA compounds are set forth in SEQ ID
NOSil3-5846 (targeting TLR2), SEQ ID NOS:5847-12144 (targeting TLR4), SEQ ID
NOS:12145-16332 (targeting MYD88), SEQ ID NOS:16333-18242 (targeting TICAMl)
and SEQ ID NOS:18243-20606 (targeting TIRAP).
Compounds, compositions and methods for inhibiting target genes having
mRNA set forth in any one of SEQ ID NOS:1-12 are discussed herein at length, and any of
said compounds and/or compositions are beneficially employed in the treatment of a patient
suffering from posttransplantational (e.g. following lung transplantation) complications
encountered following transplantation.
] Provided herein are compositions and methods for inhibiting expression of a
target gene selected from TLR2, TLR4, MYD88, TICAMl and TIRAP genes in vivo. In
general, the method includes stering ibonucleotides, such as dsRNA
nds, including small interfering RNAs (i.e., siRNAs) that target mRNA selected
from SEQ ID NOS:1 (TLR2 mRNA); SEQ ID NO:2—4 (TLR4 mRNA), SEQ ID NO:5-9
(MYD88 mRNA), SEQ ID NO:10 (TICAMl mRNA) or SEQ ID NO:11-12 (TIRAP
mRNA).
Methods for the delivery of chemically modified dsRNA compounds to a subject
are discussed herein at length, and said les and/or compositions may be beneficially
employed in the treatment of a subject suffering from the diseases and disorders disclosed
herein. Treatment may be filll or partial and is readily determined by one with skill in the art.
The compounds disclosed herein possess structures and modifications which
increase activity, increase stability, minimize toxicity, reduce off target effects and/or reduce
immune response when compared to an unmodified dsRNA compound; the novel
modifications of the dsRNAs disclosed herein are beneficially applied to double stranded
ucleotide sequences useful in preventing or attenuating target gene expression, in
particular the target genes discussed herein.
Details of the target genes disclosed herein are presented in Table A1,
below.
Table A1: Target genes
Target SEQ NO, Full name and gi and accession numbers
gene
TLR2 SEQ ID \O:1 >gi 68160956|refl1\M_003264.3| Homo sapiens Toll-like or
2 (TLR2), mRNA
TLR4 SEQ ID \O:2 >gi 620|ref|\IM_138554.3| Homo s toll-like
receptor 4 (TLR4), transcript variant 1, mRNA
SEQ ID \O:3 >gi 207028451|ref|\IR_024168.1| Homo sapiens toll-like receptor
4 (TLR4) transcript variant 3, non-coding RNA
SEQ ID \O:4 >gi 207028550|ref|\IR_024169.1| Homo s toll-like receptor
4 (TLR4) transcript variant 4, non-coding RNA
MYD88 SEQ ID \O:5 >gi 197276653|refl\IM_002468.4| Homo sapiens myeloid
differentiation primary response gene (88) (MYD88), mRNA
SEQ ID NO:6 9546502|ref|NM_001172567.1| Homo sapiens myeloid
differentiation primary response gene (88) (MYD88), transcript t 1,
mRNA
SEQ ID NO:7 >gi|289546580|ref|NM_001172568.1| Homo sapiens myeloid
differentiation y response gene (88) (MYD88), transcript variant 3,
mRNA
SEQ ID NO:8 >gi|289546652|ref|NM_001172569.1| Homo s myeloid
differentiation primary response gene (8 8) ), transcript variant 4,
mRNA
SEQ ID NO:9 >gi|289546499|ref|NM_001172566.1| Homo sapiens myeloid
differentiation primary response gene (88) (MYD88), ript variant 5,
mRNA
TICAMl SEQ ID NO: 10 >gi|197209874|ref|NM_182919.2| Homo sapiens toll-like
receptor adaptor molecule 1 (TICAMl, TRIF), mRNA
TIRAP SEQ ID NO:11 >gi|89111123|ref|NM_148910.2| Homo sapiens toll-interleukin
1 receptor (TIR) domain ning adaptor protein (TIRAP), transcript variant
2, mRNA
SEQ ID NO: 12 >gi|89111121|ref|NM_001039661.1| Homo sapiens toll-
interleukin 1 receptor (TIR) domain ning adaptor protein (TIRAP),
transcript variant 3, mRNA
] Table A1 provides the gi (GeneInfo identifier) and accession numbers for
exemplary polynucleotide sequences of human mRNA to which the oligonucleotide
inhibitors as disclosed herein are directed.
Inhibition of any one of the mRNA polynucleotides set forth in Table A1 is
useful in preventing, treating and/or attenuating acute or chronic inflammation, neuropathic
pain, posttransplantational complication in organ transplant, (for example lung transplant)
patients, such as for e y graft failure, ischemia-reperfilsion injury, reperfusion
injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation se and/or
primary graft ction (PGD).
In various embodiments, disclosed are chemically modified dsRNA molecules,
including small interfering RNAs (siRNAs), and the use of the dsRNAs in the prevention
and treatment of various posttransplantational complications in organ transplant, for example
lung transplant, patients. Diseases and ions to be treated are directed to chronic or
acute aseptic inflammation, neuropathic pain, primary graft failure, ischemia-reperfilsion
injury, reperfusion injury, reperfilsion edema, allograft dysfilnction, pulmonary
WO 18911
reimplantation response and/or primary graft dysfunction (PGD).
Lists of preferred sense and antisense oligonucleotides useful in synthesizing
dsRNA compounds are provided in SEQ ID NOS:13-5846 (targeting TLR2), SEQ ID
NOS:5847-12144 (targeting TLR4), SEQ ID NOS:12145-16332 (targeting MYD88), SEQ
ID NOS:16333-18242 (targeting TICAMl) and SEQ ID NOS:18243-20606 (targeting
TIRAP). The 18- and 19-mer sense oligonucleotides and corresponding antisense
oligonucleotides useful in the synthesis of dsRNA compounds are prioritized based on their
score according to a proprietary algorithm as the best sequences for targeting the human
gene expression. Molecules, compositions and methods, which inhibit target genes are
discussed herein at length, and any of said molecules and/or itions are ially
employed in the treatment of a patient suffering from any of said posttransplantational
complications.
Structural design
In one , provided herein are double stranded nucleic acid molecules
sing a sense strand and an antisense strand, wherein at least one strand comprises 1, 2,
3, 4, or 5 cleotide moieties covalently ed at the 3’ terminal end; wherein the
non-nucleotide moiety is selected from an alkyl carbon) moiety or a derivative thereof
and a phosphate based moiety. In certain preferred embodiment the non-nucleotide moiety
includes an alkyl moiety or an alkyl derivative moiety. In some embodiments the at least one
strand is the antisense stand. In preferred embodiments the antisense strand comprises two
non-nucleotide moieties covalently attached at the 3’ al end, including C3-C3; C3-C3-
Pi; C3-C3-Ps; idAb-idAb moieties as defined hereinbelow.
In various embodiments provided herein is a double stranded nucleic acid
molecule, wherein:
(a) the nucleic acid molecule includes a sense strand and an antisense ;
(b) each strand of the nucleic acid le is independently 17 to 40 nucleotides in
length;
(c) a 17 to 40 nucleotide sequence of the antisense strand is complementary to a
sequence of a mRNA selected from a mRNA encoding TLR2 (e.g., SEQ ID NO: 1), a
mRNA encoding TLR4 (e.g., SEQ ID NOs: 2-4); a mRNA encoding MYD88 (e.g. SEQ ID
_ 28 _
NO:5-9; a mRNA encoding TICAMl (e.g. SEQ ID NO:10) or a mRNA encoding TIRAP
(e.g. SEQ ID NO:11-12);
(d) a 17 to 40 nucleotide sequence of the sense strand is complementary to the
antisense strand and includes a 17 to 40 nucleotide sequence of a mRNA ed from a
mRNA encoding TLR2 (e.g., SEQ ID NO: 1), a mRNA encoding TLR4 (e.g., SEQ ID NOs:
2-4); a mRNA encoding MYD88 (e.g. SEQ ID NO:5-9; a mRNA encoding TICAMl (e.g.
SEQ ID NO:10) or a mRNA encoding TIRAP (e.g. SEQ ID NO:11-12)
In some embodiments, provided are double stranded nucleic acid molecules
having the structure (Al):
(Al) 5’ (N)X — Z 3’ (antisense strand)
3’ Z’-(N’)y —z” 5’ (sense strand)
wherein each of N and N’ is a nucleotide which may be unmodified or d, or an
unconventional moiety;
wherein each of (N)x and (N ’)y is an ucleotide in which each consecutive N or N’ is
joined to the next N or N’ by a covalent bond;
wherein at least one of Z or Z’ is present and comprises a cleotide moiety covalently
attached at the 3 ’ terminus of the strand in which it is present;
wherein z” may be present or absent, but if present is a capping moiety covalently ed
at the 5’ us of (N’)y;
wherein each of x and y is independently an integer between 18 and 40;
wherein the ce of (N’)y has complementarity to the sequence of (N)x; and wherein the
sequence of (N)X has complementarity to a consecutive sequence in a target RNA set forth in
any one of SEQ ID NOS:1-12.
In some embodiments the covalent bond joining each consecutive N or N’ is a
phosphodiester bond.
WO 18911
In some ments x =y=18 to 25 or 19 to 27, for example 18, 19, 20, 21, 22,
23, 24, 25, 26, 27. In some embodiments x = y and each ofx and y is 19, 20, 21, 22 or 23. In
various embodiments X = y =19.
In some embodiments x=y=19 and one of Z or Z' is present and consists of two
non-nucleotide moieties.
In some embodiments x=y=19 and Z’ is present and consists of two non-
nucleotide moieties.
In preferred embodiments x=y=19 and Z is present and consists two non-
nucleotide moieties.
In preferred embodiments x=y=19 and Z is present and consists of two non-
nucleotide moieties; and Z’ is present and consists of one non-nucleotide .
In additional embodiments x=y=19 and Z and Z' are t and each
independently comprises two non-nucleotide moieties.
In some embodiments the double ed nucleic acid molecules comprise a
DNA moiety or a mismatch to the target at position 1 of the antisense strand (5’ terminus).
Such a structure is described herein. ing to one embodiment provided are double
stranded c acid molecules having a structure (A2) set forth below:
(A2) 5’ Nl-(N)X - Z 3’ (antisense strand)
3’ (N’)y —z” 5’ (sense strand)
wherein each of N2, N and N’ is an unmodified or modified ribonucleotide, or an
unconventional moiety;
wherein each of (N)x and (N ’)y is an oligonucleotide in which each consecutive N or N’ is
joined to the adjacent N or N’ by a covalent bond;
wherein each of x and y is independently an integer between 17 and 39;
wherein the sequence of (N ’)y has complementarity to the sequence of (N)x and (N)x has
complementarity to a consecutive sequence in a target RNA set forth in SEQ ID NOS: 1-12;
wherein N1 is covalently bound to (N)x and is mismatched to the target RNA or is a
complementary DNA moiety to the target RNA;
wherein N1 is a moiety selected from the group consisting of natural or modified uridine,
deoxyribouridine, ribothymidine, deoxyribothymidine, adenosine or deoxyadenosine;
wherein z” may be present or absent, but if present is a capping moiety covalently attached
at the 5’ terminus ofNZ- (N’)y; and
wherein at least one of Z or Z’ is present and comprises a non-nucleotide moiety covalently
attached at the 3 ’ terminus of the strand in which it is present.
] In some embodiments x=y=17 to 24 or 18 to 23. In preferred ments x=y-
] In some embodiments x=y=18 and Z’ is present and consists of two non-
nucleotide moieties.
In preferred ments x=y=18 and Z is present and consists two non-
nucleotide moieties.
] In preferred embodiments x=y=18 and Z is present and consists of two non-
nucleotide moieties; and Z’ is present and consists of one non-nucleotide .
In additional embodiments x=y=18 and Z and Z' are present and each
independently comprises two non-nucleotide moieties.
In some embodiments the sequence of (N’)y is fully complementary to the
sequence of (N)X. In various embodiments sequence of )y is complementary to the
sequence of Nl-(N)X. In some embodiments (N)x ses an nse that is fully
mentary to about 17 to about 39 consecutive nucleotides in a target RNA. In other
embodiments (N)X comprises an antisense that is substantially complementary to about 17 to
about 39 consecutive nucleotides in a target RNA.
In some embodiments N1 and N2 form a Watson-Crick base pair. In some
embodiments N1 and N2 form a non-Watson-Crick base pair. In some embodiments a base
pair is formed between a ribonucleotide and a deoxyribonucleotide.
In some embodiments X =y=18, X =y=19 or x =y=20. In preferred embodiments
WO 18911
x=y=18. When x=18 in Nl-(N)X N1 refers to. position 1 and positions 2-19 are included in
(N)1g When y=18 in NZ-(N’)y, N2 refers to on 19 and positions 1-18 are included in
(N018-
In some embodiments N1 is covalently bound to (N)x and is mismatched to the
target RNA. In various embodiments N1 is covalently bound to (N)X and is a DNA moiety
complementary to the target RNA.
In some embodiments a uridine in position 1 of the antisense strand is substituted
with an N1 selected from adenosine, deoxyadenosine, deoxyuridine (dU), ribothymidine or
hymidine. In various embodiments N1 selected from adenosine, deoxyadenosine or
deoxyuridine.
In some embodiments guanosine in position 1 of the antisense strand is
substituted with an N1 selected from adenosine, deoxyadenosine, uridine, deoxyuridine,
ribothymidine or deoxythymidine. In various embodiments N1 is selected from adenosine,
deoxyadenosine, uridine or deoxyuridine.
] In some embodiments cytidine in position 1 of the nse strand is substituted
with an N1 selected from adenosine, deoxyadenosine, uridine, deoxyuridine, ribothymidine
or deoxythymidine. In s embodiments N1 is selected from adenosine, denosine,
e or deoxyuridine.
In some ments adenosine in on 1 of the antisense strand is
substituted with an N1 selected from deoxyadenosine, deoxyuridine, ribothymidine or
deoxythymidine. In various embodiments N1 selected from deoxyadenosine or deoxyuridine.
In some embodiments N1 and N2 form a base pair between uridine or
deoxyuridine, and adenosine or deoxyadenosine. In other embodiments N1 and N2 form a
base pair between deoxyuridine and adenosine.
In some embodiments the double stranded nucleic acid molecule is a double
stranded RNA, such as an siRNA, siNA or a miRNA. The double stranded nucleic acid
molecules as provided herein are also referred to as “duplexes”.
In certain preferred embodiments x =y=18. In some ments N1 and N2
form a Watson-Crick base pair. In other embodiments N1 and N2 form a tson-Crick
base pair. In certain embodiments N1 is selected from the group consisting of riboadenosine,
_ 32 _
modified riboadenosine, deoxyriboadenosine, modified deoxyriboadenosine. In other
embodiments N1 is selected from the group consisting of ribouridine, deoxyribouridine,
modified ribouridine, and modified deoxyribouridine.
In certain ments position 1 in the antisense strand (5’ terminus) comprises
deoxyribouridine (dU) or adenosine. In some embodiments N1 is selected from the group
consisting of riboadenosine, modified riboadenosine, deoxyriboadenosine, modified
deoxyriboadenosine and N2 is selected from the group consisting of idine,
deoxyribouridine, modified ribouridine, and modified deoxyribouridine. In certain
embodiments N1 is selected from the group consisting of riboadenosine and modified
riboadenosine and N2 is selected from the group consisting of ribouridine and modified
ribouridine.
In certain embodiments N1 is selected fiom the group consisting of ribouridine,
deoxyribouridine, modified ribouridine, and d ibouridine and N2 is selected
from the group consisting of riboadenosine, d riboadenosine, deoxyriboadenosine,
modified iboadenosine. In certain embodiments N1 is selected from the group
consisting of ribouridine and deoxyribouridine and N2 is selected from the group consisting
of riboadenosine and modified riboadenosine. In certain embodiments N1 is ribouridine and
2 N . . . . . 1 . . . . . . .
is r1boadenos1ne. In certain embodiments N is deoxyr1bour1d1ne and N2 is r1boadenos1ne.
] In some embodiments of Structure (A2), N1 includes 2’-OMe sugar-modified
ribouracil or 2’-OMe sugar-modified riboadenosine. N1 includes 2’ fiuoro and 2’ amino
sugar-modified acil or 2’ fluoro and 2’ amino sugar-modified riboadenosine. In certain
embodiments of structure (A2), N2 includes a 2’-OMe sugar modified cleotide or
deoxyribonucleotide.
In some embodiments of Structure (A2), N1 includes 2’-OMe sugar-modified
ribouracil or 2’-OMe sugar-modified ribocytosine. In certain embodiments of structure (A2),
N2 includes a 2’-OMe sugar modified ribonucleotide.
The following table, Table A2 provides non-limiting examples of N1 and
corresponding N2.
’ terminal N1 (5’ al position of N2 (3’ terminal on of
nucleotide nucleotide of AS) SEN)
AS With full
2012/027174
--—target
] In some embodiments each of N and N’ is an unmodified nucleotide. In some
embodiments at least one of N or N’ includes a chemically d nucleotide or an
unconventional moiety. In some embodiments the unconventional moiety is selected from a
mirror nucleotide, an abasic ribose moiety and an abasic deoxyribose . In some
embodiments the unconventional moiety is a mirror nucleotide, preferably an L-DNA
moiety. In some embodiments at least one of N or N’ includes a 2’-OMe sugar-modified
ribonucleotide.
In some embodiments the sequence of (N’)y is fully complementary to the
sequence of (N)X. In other ments the sequence of (N’)y is substantially
complementary to the sequence of (N)X.
In some embodiments (N)X includes an antisense sequence that is fully
complementary to about 17 to about 39 consecutive nucleotides in a target RNA. In other
embodiments (N)X es an antisense that is substantially complementary to about 17 to
about 39 consecutive tides in a target RNA.
In some embodiments the nucleic acid molecules disclosed herein are dsRNA
molecules, such as siRNA, siNA or miRNA.
In some embodiments of Structures A1 and A2, Z is present and Z’ is absent. In
other ments Z' is present and Z is absent. In additional embodiments both Z and Z'
are present. In some embodiments Z and Z' are present and are identical. In further
embodiments Z and Z' are present and are different. In some embodiments Z and Z' are
independently 2, 3, 4 or 5 non-nucleotide moieties or a combination of 2, 3, 4, or 5 non-
nucleotide moieties and nucleotides. In some embodiments each of Z and or Z’ consist of
two (2) non-nucleotide moieties covalently attached to the 3’ terminus of the dsRNA strand
via a phosphodiester bond.
A non-nucleotide moiety is selected from the group consisting of an abasic
, an inverted abasic moiety, an alkyl moiety or derivative thereof, and an inorganic
phosphate. In some embodiments a non-nucleotide moiety is an alkyl moiety or derivative
thereof. In some ments the alkyl moiety comprises a terminal fianctional group
selected from the group consisting of an alcohol, a al amine, a terminal ate and
a terminal phosphorothioate moiety.
] In some embodiments Z is present and comprises one or more non-nucleotide
moieties selected from the group consisting of an abasic moiety, an inverted abasic moiety,
hydrocarbon moiety or derivative thereof, and an nic phosphate. In some embodiments
Z is present and consists of two alkyl es or tives thereof
In additional embodiments Z' is t and comprises one or more non-
nucleotide moieties selected from the group consisting of an abasic moiety, an inverted
abasic moiety, a hydrocarbon moiety, and an inorganic phosphate. In some embodiments Z’
is present and comprises one or more alkyl moieties or derivatives thereof.
In some embodiments Z is present and consists of two alkyl moieties or
derivatives f and Z’ is t and consists of a single alkyl moiety or derivative
thereof.
In some embodiments each of Z and Z' includes an abasic moiety, for example a
iboabasic moiety (referred to herein as "dAb") or riboabasic moiety (referred to herein
as . In some embodiments each of Z and/or Z' comprises two covalently linked abasic
moieties and is for example 5’>3’ dAb-dAb or rAb-rAb or dAb-rAb or rAb-dAb. Each
moiety is covalently conjugated to an adjacent moiety via a covalent bond, ably a
phospho-based bond. In some embodiments the phospho-based bond is a phosphorothioate, a
phosphonoacetate or a phosphodiester bond.
In some embodiments each of Z and/or Z' independently includes a C2, C3, C4,
C5 or C6 alkyl moiety, optionally a C3 [propane, -(CH2)3-] moiety or a derivative thereof
e.g. propanol (C3-OH), propanediol, or phosphodiester derivative of propanediol ("C3Pi").
In preferred embodiments each of Z and/or 2' includes two hydrocarbon moieties and in
some examples is C3-C3. Each C3 is covalently conjugated to an adjacent C3 Via a covalent
bond, ably a phospho-based bond. In some embodiments the phospho-based bond is a
phosphorothioate, a phosphonoacetate or a phosphodiester bond.
In some embodiments each of Z and Z’ is independently selected from propanol,
propyl phosphate, propyl phosphorothioate, combinations thereof or multiples f
Non-limiting exemplary cleotide moieties are set forth in the m
below:
O B
E 0
B E 3' terminus-C3Pi
3' terminus-C3-OH
O\P/O\/\/O” O\P/O\/\/O\F|>/O‘
0/ \09 0/ \09 0|
E 0
3' terminus—C3Pi—C3OH
O\P/O\/\/O\ /0\/\/OH'U
0/ \09 I
O B
g 3' terminus-C3Pi-C3Pi
g 0
3' terminus—C3Pi—C3Pi—C3OH
(fl 06
O O O I O O O OH
\P/W \P/W \ /W'U
0/ \06 | |
O 0
In some embodiments of ure A1 and Structure A2 at least one of Z or Z’ is
present and comprises at least two non-nucleotide moieties covalently ed to the strand
in which it is present. In some embodiments each of Z and Z’ independently includes a C3
alkyl, C3 alcohol or C3 ester moiety. In some ments Z’ is absent and Z is present and
includes a cleotide C3 moiety. In some embodiments Z is absent and Z’ is present and
includes a non-nucleotide C3 moiety.
In some ments of Structures A1 and A2, each of N and N’ is an
unmodified nucleotide. In some embodiments at least one ofN or N’ includes a chemically
modified nucleotide or an unconventional moiety. In some embodiments the unconventional
moiety is selected from a mirror nucleotide, an abasic ribose moiety and an abasic
deoxyribose moiety. In some embodiments the unconventional moiety is a mirror
nucleotide, preferably an L-DNA moiety. In some embodiments at least one of N or N’
es a 2’-OMe sugar-modified ribonucleotide.
In some embodiments the sequence of (N’)y is fully complementary to the
sequence of (N)X. In other embodiments the sequence of (N’)y is substantially
complementary to the sequence of (N)X.
In other embodiments the compound of Structure A1 or Structure A2 includes at
least one cleotide modified in the sugar residue. In some embodiments the compound
includes a modification at the 2’ position of the sugar residue. In some embodiments the
ation in the 2’ position includes the presence of an amino, a fiuoro, an alkoxy or an
alkyl moiety. In certain embodiments the 2’ modification includes an alkoxy moiety, In
preferred embodiments the alkoxy moiety is a methoxy moiety (also known as 2’-O-methyl;
2’-OMe; 3). In some embodiments the nucleic acid compound includes 2’-OMe
sugar modified alternating ribonucleotides in one or both of the antisense and the sense
s. In other embodiments the compound includes 2’-OMe sugar modified
ribonucleotides in the antisense strand, (N)X or Nl-(N)X, only. In certain embodiments the
middle ribonucleotide of the nse strand; e.g. ribonucleotide in position 10 in a 19-mer
strand is unmodified. In various embodiments the nucleic acid compound includes at least 5
alternating 2’-OMe sugar modified and unmodified ribonucleotides. In additional
embodiments the compound of ure A1 or Structure A2 includes modified
ribonucleotides in alternating positions n each ribonucleotide at the 5’ and 3’ termini
of (N)x or Nl-(N)x are in their sugar residues, and each ribonucleotide at the 5’ and 3’
termini of (N’)y or NZ-(N)y are unmodified in their sugar residues.
In some embodiments the double stranded le includes one or more of the
following modifications
a) N in at least one of positions 5, 6, 7, 8, or 9 from the 5’ terminus of the antisense
strand is selected from a 2’5’ nucleotide or a mirror nucleotide;
b) N’ in at least one of ons 9 or 10 from the 5’ terminus of the sense strand is
selected from a 2’5’ nucleotide and a pseudoUridine; and
c) N’ in 4, 5, or 6 consecutive positions at the 3’ terminus positions of (N ’)y
comprises a 2’5’ nucleotide.
In some embodiments the double stranded molecule includes a combination of
the following modifications
a) the antisense strand includes a 2’5’ nucleotide or a mirror tide in at least
one of positions 5, 6, 7, 8, or 9 from the 5’ terminus; and
b) the sense strand includes at least one of a 2’5’ nucleotide and a pseudoUridine in
positions 9 or 10 from the 5’ terminus.
In some embodiments the double stranded molecule includes a combination of
the following modifications
a) the antisense strand es a 2’5’ nucleotide or a mirror nucleotide in at least
one of ons 5, 6, 7, 8, or 9 from the 5’ us; and
c) the sense strand includes 4, 5, or 6 consecutive 2’5’ nucleotides at the 3’
penultimate or 3 ’ terminal positions.
In some embodiments, the sense strand [(N)X or Nl-(N)X] includes 1, 2, 3, 4, 5,
6, 7, 8, or 9 2’-OMe sugar modified ribonucleotides. In some embodiments, the antisense
strand includes 2’-OMe modified ribonucleotides at positions 2, 4, 6, 8, 11, 13, 15, 17 and
19. In other embodiments antisense strand es 2’-OMe modified ribonucleotides at
positions 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19. In other embodiments the antisense strand
includes 2’-OMe modified ribonucleotides at positions 3, 5, 7, 9, 11, 13, 15, 17 and 19. In
some embodiments the antisense strand includes one or more 2’-OMe sugar modified
pyrimidines. In some embodiments all the pyrimidine nucleotides in the antisense strand are
2’-OMe sugar d. In some embodiments the sense strand es 2’-OMe sugar
modified dines.
In some embodiments of Structure Al and Structure A2, the sense strand and the
antisense strand are independently orylated or unphosphorylated at the 3’ terminus
and at the 5’ terminus. In some embodiments of Structure Al and ure A2, the sense
strand and the antisense strand are unphosphorylated at the 3’ and 5’ termini. In other
embodiments the sense strand and the antisense strand are phosphorylated at the 3 ’ termini.
In some embodiments of Structure Al and Structure A2 (N)y includes at least
one unconventional moiety ed from a mirror nucleotide, a 2’5’ nucleotide and a TNA.
In some embodiments the unconventional moiety is a mirror nucleotide. In s
embodiments the mirror tide is selected from an L-ribonucleotide (L-RNA) and an L-
ibonucleotide (L-DNA). In preferred embodiments the mirror nucleotide is L-DNA.
In certain embodiments the sense strand comprises an unconventional moiety in position 9 or
(from the 5’ terminus). In preferred embodiments the sense strand includes an
unconventional moiety in position 9 (from the 5’ terminus). In some embodiments the sense
strand is 19 nucleotides in length and comprises 4, 5, or 6 utive unconventional
moieties in positions 15, (from the 5’ terminus). In some embodiments the sense strand
includes 4 consecutive 2’5’ ribonucleotides in positions l5, l6, l7, and 18. In some
embodiments the sense strand includes 5 consecutive 2’5’ ribonucleotides in positions 15,
16, 17, 18 and 19. In various embodiments the sense strand further comprises Z’. In some
embodiments Z’ includes a C3OH moiety or a C3Pi moiety.
In some embodiments of Structure Al (N’)y es at least one L-DNA
moiety. In some embodiments x=y=l9 and (N’)y, consists of fied ribonucleotides at
positions 1-17 and 19 and one L-DNA at the 3’ penultimate position (position 18). In other
embodiments x=y=l9 and (N’)y consists of unmodified ribonucleotides at positions 1-16 and
19 and two consecutive L-DNA at the 3’ penultimate position (positions 17 and 18). In
various ments the unconventional moiety is a nucleotide joined to an adjacent
nucleotide by a 2’-5’ intemucleotide phosphate linkage. According to various embodiments
(N’)y includes 2, 3, 4, 5, or 6 consecutive ribonucleotides at the 3' us linked by 2’-5’
cleotide linkages. In one embodiment, four consecutive nucleotides at the 3’ terminus
of (N’)y are joined by three 2’-5’ phosphodiester bonds, n one or more of the 2’-5’
nucleotides which form the 2’-5’ phosphodiester bonds fiarther includes a 3’-O-methyl
) sugar ation. Preferably the 3’ terminal nucleotide of (N ’)y includes a 2’-
OMe sugar modification. In n embodiments x=y=19 and (N’)y includes two or more
consecutive nucleotides at positions 15, 16, 17, 18 and 19 include a nucleotide joined to an
nt nucleotide by a 2’-5’ intemucleotide bond (2’-5’ nucleotide). In various
embodiments the nucleotide forming the 2’-5’ intemucleotide bond includes a 3’
deoxyribose nucleotide or a 3’ methoxy nucleotide (3’ H or 3’OMe in place of a 3’ OH). In
some embodiments x=y=19 and (N ’)y includes 2’-5’ nucleotides at positions 15, 16 and 17
such that adjacent nucleotides are linked by a 2’-5’ intemucleotide bond n positions
-16, 16-17 and 17-18; or at positions, 15, 16, 17, 18, and 19 such that nt nucleotides
are linked by a 2’-5’ intemucleotide bond between ons 15-16, 16-17, 17-18 and 18-19
and a 3’OH is available at the 3’ terminal nucleotide or at positions 16, 17 and 18 such that
adjacent nucleotides are linked by a 2’-5’ intemucleotide bond between positions 16-17, 17-
18 and 18-19. In some embodiments x=y=19 and (N ’)y includes 2’-5’ nucleotides at
positions 16 and 17 or at positions 17 and 18 or at positions 15 and 17 such that adjacent
nucleotides are linked by a 2’-5’ intemucleotide bond between positions 16-17 and 17-18 or
between positions 17-18 and 18-19 or between positions 15-16 and 17-18, respectively. In
other embodiments the pyrimidine ribonucleotides (rU, rC) in (N’)y are substituted with
nucleotides joined to the adjacent nucleotide by a 2’-5’ intemucleotide bond. In some
embodiments x=y=19 and (N’)y comprises five consecutive nucleotides at the 3’ us
joined by four 2’-5’ linkages, cally the linkages n the nucleotides position 15-
16,16-17,17-18 and 18-19.
In some embodiments x=y=19 and (N’)y comprises five consecutive nucleotides
at the 3’ terminus joined by four 2’-5’ linkages and optionally further includes Z’ and z’
independently selected from an inverted abasic moiety and a C3 alkyl [C3; 1,3-propanediol
mono(dihydrogen phosphate)] cap. In some embodiments the C3 alkyl cap is covalently
linked to the 3’ or 5’ terminal nucleotide. In some embodiments the 3’ C3 terminal cap
further comprises a 3’ phosphate. In some ments the 3’ C3 terminal cap further
_ 40 _
comprises a 3’ terminal hydroxyl group.
In some embodiments x=y=19 and (N’)y comprises an L-DNA position 18; and
(N’)y optionally further includes Z’ and z’ independently selected from an inverted abasic
moiety and a C3 alkyl [C3; opanediol mono(dihydrogen phosphate)] cap.
In some embodiments (N’)y comprises a 3’ terminal phosphate (i.e.
phosphorylated at the 3’ terminus). In some ments (N’)y comprises a 3’ terminal
hydroxyl.
In some embodiments x=y=19 and (N)X includes 2’-OMe sugar modified
ribonucleotides at positions 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 or at positions 2, 4, 6, 8, 11, 13,
, 17, 19 . In some embodiments x=y=19 and (N)X includes 2’-OMe sugar modified
pyrimidines. In some embodiments all pyrimidines in (N)X include the 2’-OMe sugar
modification.
In some embodiments of structure A2 x=y=18 and N2 is a riboadenosine moiety.
In some embodiments x=y=18, and NZ-(N’)y comprises five consecutive tides at the
3’ terminus joined by four 2’-5’ linkages, specifically the es between the nucleotides
position 15-16, 16-17, 17-18 and 18-19. In some embodiments the linkages include
phosphodiester bonds. In some embodiments x=y=18 and NZ-(N’)y comprises five
consecutive nucleotides at the 3’ terminus joined by four 2’-5’ linkages and optionally
further includes Z’ and z’ ndently selected from an inverted abasic moiety and a C3
alkyl [C3; 1,3-propanediol mono(dihydrogen phosphate)] cap. In some embodiments
x=y=18 and NZ-(N’)y comprises an L-DNA position 18; and (N’)y optionally further
includes Z’ and z’ independently selected from an inverted abasic moiety and a C3 alkyl
[C3; opanediol mono(dihydrogen phosphate)] cap. In some embodiments NZ-(N’)y
comprises a 3’ terminal phosphate. In some embodiments )y comprises a 3’ terminal
hydroxyl. In some embodiments x=y=18 and Nl-(N)X includes 2’-OMe sugar modified
ribonucleotides in ons 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 or in ons 1, 3, 5, 9, 11, 13,
, 17, 19, or in positions 3, 5, 9,11,13,15,17, or in positions 2, 4, 6, 8,11,13,15,17,19.
In some embodiments x=y=18 and Nl-(N)X es 2’-OMe sugar modified ribonucleotides
at positions 11, 13, 15, 17 and 19 (from 5’ terminus). In some ments x=y=18 and N1-
(N)X includes 2’-OMe sugar modified ribonucleotides in positions 1, 3, 5, 7, 9, 11, 13, 15,
17, 19 or in positions 3, 5, 7, 9, 11, 13, 15, 17, 19. In some embodiments x=y=18 and N1-
(N)X es 2’-OMe sugar modified ribonucleotides in positions 2, 4, 6, 8, 11, 13, 15, 17,
] In some ments x=y=18 and Nl-(N)X includes 2’-OMe sugar modified
dines. In some embodiments all pyrimidines in (N)X include the 2’-OMe sugar
modification. In some embodiments the antisense strand further comprises an L-DNA or a
2’-5’ nucleotide in position 5, 6 or 7 (5’>3’). In other embodiments the antisense strand
further comprises a ribonucleotide, which generates a 2’5’ intemucleotide linkage in
between the ribonucleotides in positions 5-6 or 6-7 (5’>3’).
In onal embodiments Nl-(N)X r includes Z wherein Z ses a
cleotide overhang. In some embodiments the non-nucleotide ng is C3 —C3
[1 ,3-propanediol mono(dihydrogen phosphate)]2.
In some embodiments of Structure A2, (N)y includes at least one L-DNA
moiety. In some embodiments x=y=18 and (N’)y consists of unmodified ribonucleotides at
positions 1-16 and 18 and one L-DNA at the 3’ penultimate position (position 17). In other
embodiments x=y=18 and (N’)y consists of unmodified ribonucleotides at position 1-15 and
18 and two consecutive L-DNA at the 3’ penultimate position (positions 16 and 17). In
various embodiments the unconventional moiety is a nucleotide joined to an adjacent
nucleotide by a 2’-5’ cleotide phosphate linkage. According to various embodiments
(N’)y includes 2, 3, 4, 5, or 6 consecutive ribonucleotides at the 3' terminus linked by 2’-5’
intemucleotide linkages. In one embodiment, four consecutive nucleotides at the 3’ terminus
of (N’)y are joined by three 2’-5’ phosphodiester bonds, wherein one or more of the 2’-5’
nucleotides which form the 2’-5’ phosphodiester bonds fiarther includes a 3’-O-methyl
(3’OMe) sugar modification. Preferably the 3’ terminal nucleotide of (N’)y includes a 2’-
OMe sugar modification. In certain embodiments x=y=l8 and in (N’)y two or more
consecutive nucleotides at positions 14, 15, 16, 17, and 18 include a nucleotide joined to an
adjacent nucleotide by a 2’-5’ intemucleotide bond. In various embodiments the nucleotide
forming the 2’-5’ intemucleotide bond includes a 3’ deoxyribose nucleotide or a 3’ methoxy
nucleotide. In some embodiments x=y=18 and (N’)y includes nucleotides joined to the
adjacent nucleotide by a 2’-5’ intemucleotide bond between ons 15-16, 16-17 and 17-
18 or between positions 16-17 and 17-18. In some embodiments x=y=18 and (N’)y includes
nucleotides joined to the adjacent nucleotide by a 2’-5’ cleotide bond between
ons 14-15, 15-16, 16-17, and 17-18 or between positions 15-16, 16-17, and 17-18 or
between positions 16-17 and 17-18 or between positions 17-18 or n ons 15-16
and 17-18. In other embodiments the pyrimidine ribonucleotides (rU, rC) in (N’)y are
substituted with nucleotides joined to the adjacent nucleotide by a 2’-5’ intemucleotide
bond.
In some embodiments of Structure A1 and Structure A2 each N consists of an
unmodified ribonucleotide. In some embodiments of Structure A1 and Structure A2 each N’
consists of an unmodified tide. In red embodiments, at least one ofN and N’ is a
d ribonucleotide or an unconventional moiety.
In other embodiments the molecule of Structure A1 or ure A2 includes at
least one ribonucleotide modified in the sugar residue. In some embodiments the compound
es a modification at the 2’ position of the sugar residue. In some embodiments the
modification at the 2’ position includes the presence of an amino, a fiuoro, an alkoxy or an
alkyl moiety. In certain embodiments the 2’ modification includes an alkoxy moiety, In
preferred embodiments the alkoxy moiety is a y moiety (also known as 2’-O-methyl;
2’-OMe; 2’-OCH3). In some ments the nucleic acid compound includes 2’-OMe
sugar modified alternating ribonucleotides in one or both of the antisense and the sense
strands. In other ments the compound includes 2’-OMe sugar modified
ribonucleotides in the antisense strand, (N)X or N1-(N)X, only. In certain embodiments the
middle ribonucleotide of the antisense strand; e.g. ribonucleotide in position 10 in a 19-mer
strand is unmodified. In s embodiments the nucleic acid compound includes at least 5
alternating 2’-OMe sugar modified and unmodified ribonucleotides.
In additional ments the compound of Structure A1 or Structure A2
includes modified ribonucleotides in alternating positions wherein each ribonucleotide at the
’ and 3’ termini of (N)X or N1-(N)X are modified in their sugar residues, and each
cleotide at the 5’ and 3’ termini of (N’)y or NZ-(N)y are unmodified in their sugar
residues.
In some embodiments, (N)X or Nl-(N)X includes 2’-OMe modified
ribonucleotides at positions 2, 4, 6, 8, 11, 13, 15, 17 and 19. In other embodiments (N)X (N)X
or Nl-(N)X includes 2’-OMe modified ribonucleotides at positions 1, 3, 5, 7, 9, 11, 13, 15, 17
and 19. In some embodiments (N)X or Nl-(N)X includes 2’-OMe modified pyrimidines. In
some embodiments all the dine nucleotides in (N)x or Nl-(N)x are 2’-OMe modified.
In some embodiments (N’)y or NZ-(N’)y includes 2’-OMe modified dines. In
onal embodiments the compound of ure A1 or Structure A2 es modified
ribonucleotides in alternating positions wherein each ribonucleotide at the 5’ and 3’ termini
of (N)x or Nl-(N)x are modified in their sugar residues, and each ribonucleotide at the 5’ and
3’ termini of (N’)y or NZ-(N)y are unmodified in their sugar residues.
The nucleic acid molecules disclosed herein may have a blunt end on one end,
for example when Z and z” are absent or wherein Z’ is absent. The nucleic acid molecule
may be modified with modified nucleotides or unconventional moieties that may be located
at any on along either the sense or antisense strand. The nucleic acid molecule may
include about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 modified nucleotides. The
nucleic acid molecule may e about 1, 2, 3, 4, 5, 6, 7, or 8 unconventional es.
The nucleic acid molecule may include a group of about 1, 2, 3, 4, 5, 6, 7, or 8, preferably 1,
2, 3 or 4 contiguous modified nucleotides or unconventional moieties. Modified nucleic
acids may be present in the sense strand only, the antisense strand only, or in both the sense
strand and the antisense strand. In some embodiments the modified nucleotide comprises a
2’ sugar modified nucleotide, including 2’O-methyl modified nucleotide, 2’deoxyfluoro
modified nucleotide, no modified nucleotide. In some embodiments the
unconventional moiety comprises a mirror nucleotide (i.e. L-DNA or L-RNA) or a
nucleotide able to form a 2’-5’ linkage (2’5’ nucleotide).
As used , the term “duplex region” refers to the region in the double
stranded molecule in which two complementary or substantially complementary
oligonucleotides form base pairs with one another, typically by Watson-Crick base pairing or
by any other manner that allows for a duplex formation. For example, an oligonucleotide
strand having 19 tide units can base pair with a complementary ucleotide of 19
nucleotide units, or can base pair with 15, 16 17 or 18 bases on each strand such that the
x region” consists of 15, 16 17 or 18 base pairs. The remaining base pairs may, for
example, exist as 5’ and 3’ overhangs. Further, within the duplex region, 100%
complementarity is not ed; substantial complementarity is allowable within a duplex
region. The overhang region may consist of nucleotide or non-nucleotide moieties. As
disclosed herein at least one overhang region consists of one or more non-nucleotide
moieties.
_ 44 _
Generic non-limiting c acid molecule patterns are shown below where N’
= sense strand nucleotide in the duplex region; z” = 5’-capping moiety covalently attached at
the 5’ terminus of the sense strand; C3 = 3 carbon non-nucleotide moiety; N = antisense
strand nucleotide in the duplex ; idB = inverted abasic deoxyribonucleotide non-
nucleotide moiety. Each N, N’, is independently modified or unmodified or an
unconventional moiety. The sense and antisense strands are each independently 18-40
tides in length. The examples provided below have a duplex region of 19 nucleotides;
however, nucleic acid molecules sed herein can have a duplex region anywhere
between 18 and 40 nucleotides and where each strand is independently between 18 and 40
nucleotides in length. In each duplex the antisense strand (N)x is shown on top. The
preferred l9-mer sense sequences and antisense sequences useful in generating dsRNA
according to ure A1 are set forth in SEQ ID NOS:l3-3060 (targeting TLR2), SEQ ID
NOS:5847-86l2 ting TLR4), SEQ ID NOS:l2l45-l3924 (targeting MYD88), SEQ ID
NOS:l6333-l6882 ting TICAMl) and SEQ ID NOS:18243-l9046 (targeting TIRAP).
The preferred l8-mer sense sequences and nse sequences useful in generating dsRNA
according to Structure A2 are set forth in SEQ ID NOS: 3061-5846 (targeting TLR2), SEQ
ID NOS: 8613-12144 (targeting TLR4), SEQ ID NOS: 13925-16332 (targeting MYD88),
SEQ ID NOS:l6883-18242 (targeting TICAMl) and SEQ ID NOS: 19047-20606 ting
TIRAP). Certain red oligonucleotide pairs useful in generating dsNA are set forth in
Tables 1-5.
In some embodiments a double stranded c acid molecule has the following
structure, wherein each N or N’ comprises an unmodified or modified ribonucleotide, or an
unconventioanl moiety:
’ NNNNNNNNNNNNNNNNNNN-C3Pi-C3Pi
3’ N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N
’ NNNNNNNNNNNNNNNNNNN-C3Pi-C3Pi
3/ NININININININININININININININININININI_ZII
’ NNNNNNNNNNNNNNNNNNN-C3Pi-C3Pi
3’ PiC3-PiC3-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’
VV()2012/118911
/ N N N N N N N N N N N N N N N N N N N-C3Pi-C3Pi
3/ PiC3-PiC3-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’-Z”
/ N N N N N N N N N N N N N N N N N N N-C3Pi-C3Pi
3/ PiC3 _NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
/ N N N N N N N N N N N N N N N N N N N-C3Pi -C3Pi
3/ PiC3-N,N,NIN,N,N,N,NIN/N/N/N/N/N/N/N/N/NINI _Z//
/ N N N N N N N N N N N N N N N N N N N-C3Pi -C3Pi
3/ ’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’
/ N N N N N N N N N N N N N N N N N N N-C3Pi -C3Pi
3/ HOC3-N,N,NIN,N,N,N,NIN/N/N/N/N/N/N/N/N/NINI _Z//
/ N N N N N N N N N N N N N N N N N N N-a%—a
3/ N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’
/ N N N N N N N N N N N N N N N N N N N-a%—a
3/ N,N,NIN,N,N,N,NIN/N/N/N/N/N/N/N/N/NINI _Z//
/ N N N N N N N N N N N N N N N N N N N—id
3/ %—N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’
/ N N N N N N N N N N N N N N N N N N N—a%—a%
3/ a%—a%—N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’—z”
/ N N N N N N N N N N N N N N N N N N N—C3Pi—C3Pi
3/ Pic3—N'N'N'N'N'N'N'N'N'N'N'N'N'N'N'N'N'N'N
/ N N N N N N N N N N N N N N N N N N N—C3Pi—C3Pi
3/ a%-a%—N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’
/ N N N N N N N N N N N N N N N N N N —C30H
3/ N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N
/ N N N N N N N N N N N N N N N N N N N—C3Pi—C30H
3/ N,N,NIN,N,N,N,NIN/N/N/N/N/N/N/N/N/NINI _Z//
/ N N N N N N N N N N N N N N N N N—C3Pi—C30H
3/ PiC3—PiC3—N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’
/ N N N N N N N N N N N N N N N N N N N—C3Pi—C30H
3/ PiC3—PiC3—N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’—z”
/ NNNNNNNNNNNNNNNNNNN-CBPi-CBOH
3/ PiCB-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’
/ NNNNNNNNNNNNNNNNNNN-CBPi-CBOH
3/ PiCB-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’ - Z],
’ N N N N N N N N N N N N N N N N N N N-C3Pi-CBOH
3’ HOC3-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’
’ N N N N N N N N N N N N N N N N N N N-C3Pi-CBOH
3’ HOC3-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’-Z”
’ N N N N N N N N N N N N N N N N N N N-C3Pi-C3Ps
3’ N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N
’ N N N N N N N N N N N N N N N N N N -C3Ps
3’ N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’-Z”
’ N N N N N N N N N N N N N N N N N N N-C3Pi-C3Ps
3’ OHC3-PiC3-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’
’ N N N N N N N N N N N N N N N N N N N-C3Pi-C3Ps
3’ OHC3-PiC3-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’-z”
In some preferred embodiment c acid molecules disclosed herein have the
following structure
’ N N N N N N N N N N N N N N N N N N N-C3Pi-C30H
3’ HOC3-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’-Z”
’ N N N N N N N N N N N N N N N N N N N-C3Pi-C30H
3’ iPC3-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’-z”
wherein of N and N’ is independently a ribonucleotide which may be unmodified or
d, or is an unconventional moiety;
wherein each N is linked to the adjacent N by a covalent bond;
wherein each N’ is linked to the adjacent N’ by a covalent bond; and
wherein z” is a capping moiety covalently attached to the 5 ’ terminus of the sense strand.
The term “aB” refers to an abasic moiety which can be riboabasic moiety or a
deoxyriboabasic moiety, or an inverted riboabasic moiety or an inverted deoxyriboabasic
moiety.
In some embodiments the nucleic acid molecules sed herein comprise Z. In
other embodiments the nucleic acid molecules disclosed herein comprise Z'. In additional
embodiments both Z and Z' are present. In some ments Z and Z' are both present and
identical. In r embodiments both Z and Z' are present and are different. In some
ments Z and Z' independently comprise 1 or 2 non-nucleotide moieties. In some
embodiments Z and Z' independently comprise 2 cleotide moieties.
In some embodiments Z is present and ses one or more non-nucleotide
moieties selected from an abasic moiety an inverted abasic moiety, an alkyl moiety or
derivative thereof, and an inorganic phosphate moiety.
In additional embodiments Z' is present and comprises one or more non-
nucleotide moieties ed from an abasic moiety an inverted abasic moiety, an alkyl
moiety or derivative f or an inorganic phosphate moiety.
In additional embodiments Z and/or Z' are t and independently comprise a
combination of one or more nucleotide and one or more non-nucleotide moiety selected from
the moieties disclosed herein.
In some embodiments each of Z and Z' es an abasic moiety, optionally
deoxyriboabasic (referred to herein as "dAb") or riboabasic (referred to herein as "rAb")
nucleotides. In some embodiments each of Z and/or Z' is dAb-dAb or rAb-rAb.
In some embodiments each of Z and/or Z' independently includes an alkyl
moiety, optionally a phosphodiester derivative of propanediol ((CH2)3-Pi, referred to herein
also as "C3Pi") modif1ed moiety. In some embodiments Z and/or Z' are C3Pi-C3Pi. In a
_ 49 _
specific embodiment x=y=19 and Z comprises two propanediol derivatives, C3-C3 (i.e. -C3-
Pi-C3-Pi). In various ments the C3 moiety is covalently linked to the 3’ terminus of
the sense or antisense strand via a phosphodiester bond.
In additional embodiments Z and/or Z' comprise a combination of one or more
abasic moieties and unmodified nucleotides or a combination of one or more hydrocarbon
moieties and unmodified nucleotides or a combination of one or more abasic and
hydrocarbon moieties. In such embodiments, Z and/or Z’ are ally C3-rAb or C3-dAb.
] In further embodiments relating to ure A1 or A2, the nucleic acid
molecules further comprises 2'-OMe sugar d ribonucleotides at positions 2, 4, 6, 8,
11, 13, 15, 17 and 19 of the antisense strand. In additional embodiments the compound also
comprises an L-DNA nucleotide at position 18 of the sense strand. In additional
ments the nd ses a nucleotide joined to an adjacent nucleotide by a 2’-
’ intemucleotide phosphate bond. In additional embodiments x=y=19 and the nucleotides at
positions 15-19 or 16-19 or 17-19 in (N’)y are joined to adjacent nucleotides by 2’-5’
intemucleotide phosphate bonds. In some embodiments x=y=19 and the nucleotides at
positions 15-19 or 16-19 or 17-19 or 15-18 or 16-18 in (N’)y are joined to the nt
nucleotides by 2’-5’ intemucleotide phosphate bonds.
According to certain embodiments provided herein are dsRNA compounds, such
as siRNA compounds r comprising one or more modified nucleotide, wherein the
modified nucleotide possesses a modification in the sugar moiety, in the base moiety or in
the intemucleotide e moiety.
In some embodiments (N)X comprises modified and unmodified ribonucleotides,
each modified ribonucleotide a 2’-OMe sugar modified ribonucleotide, n N at the 3’
terminus of (N)X is a modified ribonucleotide, (N)X comprises at least five alternating
modified ribonucleotides beginning at the 3’ end and at least nine modified ribonucleotides
in total and each remaining N is an unmodified ribonucleotide.
In some embodiments at least one of (N)X and (N ’)y comprises at least one mirror
nucleotide. In some embodiments in (N’)y at least one unconventional moiety is present,
which unconventional moiety may be an abasic ribose moiety, an abasic deoxyribose moiety,
a modified or unmodified deoxyribonucleotide, a mirror nucleotide, and a nucleotide joined
to an adjacent nucleotide by a 2’-5’ cleotide phosphate bond, or any other
WO 18911
unconventional moiety disclosed herein.
In some embodiments an unconventional moiety is an L-DNA mirror nucleotide;
in additional embodiments at least one unconventional moiety is present at positions 15, 16,
17, or 18 in (N’)y. In some embodiments the unconventional moiety is selected from a
mirror tide, an abasic ribose moiety and an abasic deoxyribose moiety. In some
embodiments the unconventional moiety is a mirror nucleotide, ably an L-DNA
moiety. In some embodiments the L-DNA moiety is present at position 17, position 18 or
positions 17 and 18.
In some embodiments (N)x comprises nine alternating modified ribonucleotides.
In other embodiments (N)X comprises nine alternating modified ribonucleotides r
comprising a 2’ modified nucleotide at position 2. In some embodiments (N)X comprises 2’-
OMe modified ribonucleotides at the odd numbered positions 1, 3, 5, 7, 9, ll, 13, 15, l7, 19.
In other embodiments (N)x further comprises a 2’-OMe sugar modified ribonucleotide at one
or both of positions 2 and 18. In yet other embodiments (N)X comprises 2’-OMe sugar
modified ribonucleotides at positions 2, 4, 6, 8, ll, 13, 15, l7, 19. In some embodiments at
least one pyrimidine cleotide in (N)X comprises a 2’-OMe sugar modification. In
some embodiments all pyrimidine cleotides in (N)X comprises a 2’-OMe sugar
modification. In some embodiments 2, 3, 4, 5, 6, 7, 8, 9, 1‘0, 11, 12, 13, 14, or 15 pyrimidine
ribonucleotides in N(X) comprise a 2’-OMe sugar modification
In various embodiments z” is present and is selected from an abasic ribose
, a deoxyribose moiety; an inverted abasic ribose moiety, a deoxyribose moiety; C6-
amino-Pi; a mirror nucleotide.
In one embodiment of the nucleic acid molecules (N’)y comprises at least two
nucleotides at either or both the 5’ and 3’ i of (N’)y are joined by a 2’-5’
odiester bond. In certain embodiments x=y=l9; in (N)x the nucleotides alternate
between d ribonucleotides and fied ribonucleotides, each modified
ribonucleotide being a 2’-OMe sugar modified ribonucleotide located at the middle of (N)x
being fied; and three nucleotides at the 3’ terminus of (N’)y are joined by two 2’-5’
phosphodiester bonds. In other embodiments, x=y=l9; in (N)x the nucleotides alternate
between modified ribonucleotides and unmodified ribonucleotides, each modified
ribonucleotide a 2’-OMe sugar modified ribonucleotide located at the middle of (N)x being
_ 51 _
unmodified; and four consecutive nucleotides at the 5’ terminus of (N’)y are joined by three
2’-5’ phosphodiester bonds. In a further embodiment, an additional nucleotide located in the
middle position of (N)y may be a 2’-OMe sugar modified ribonucleotide. In another
embodiment, in (N)x the nucleotides ate between 2’-OMe sugar modified
ribonucleotides and unmodified ribonucleotides, and in (N’)y four consecutive nucleotides
at the 5’ terminus are joined by three 2’-5’ phosphodiester bonds and the 5’ terminal
nucleotide or two or three consecutive tides at the 5’ terminus comprise e
sugar modifications.
In certain embodiments of Structure (Al), x=y=l9 and in (N’)y the nucleotide in
at least one position comprises a mirror nucleotide, a deoxyribonucleotide and a nucleotide
joined to an nt nucleotide by a 2’-5’ intemucleotide bond;.
In certain embodiments of Structure (Al), x=y=l9 and (N’)y ses a mirror
nucleotide. In various embodiments the mirror nucleotide is an L-DNA nucleotide. In certain
embodiments the L-DNA is L-deoxyribocytidine. In some embodiments (N’)y comprises L-
DNA at position 18. In other ments (N ’)y comprises L-DNA at positions 17 and 18.
In certain embodiments (N’)y comprises L-DNA tutions at positions 2 and at one or
both of positions 17 and 18. Other embodiments of Structure (A1) are envisaged in wherein
x=y=2l or n x=y=23; in these embodiments the modifications for (N ’)y discussed
above instead of being on positions l5, l6, 17, 18 are on positions 17, 18, 19, 20 for 21 mer
and on positions 19, 20, 21, 22 for 23 mer; similarly the modifications at one or both of
positions 17 and 18 are on one or both of positions 19 or 20 for the 21 mer and one or
both of positions 21 and 22 for the 23 mer. All modifications in the 19 mer are similarly
adjusted for the 21 and 23 mers.
According to various embodiments of ure Al or A2 in 2, 3, 4, 5, 6, 7, 8 , 9,
, 11, 12, 13 or 14 consecutive ribonucleotides at the 3' terminus in (N’)y or N2-(N’)y are
linked by 2’-5’ intemucleotide linkages In one embodiment, four consecutive nucleotides at
the 3’ terminus of (N’)y are joined by three 2’-5’ phosphodiester bonds, wherein one or more
of the 2’-5’ nucleotides which form the 2’-5’ phosphodiester bonds further ses a 3’-
O-methyl sugar modification. Preferably the 3’ al nucleotide of (N’)y comprises a 2’-
O-methyl sugar modification. In certain embodiments of Structure (A1), x=y=19 and in
(N’)y two or more consecutive tides at positions l5, l6, l7, l8 and 19 comprise a
nucleotide joined to an adjacent nucleotide by a 2’-5’ intemucleotide bond. In various
embodiments the nucleotide forming the 2’-5’ intemucleotide bond comprises a 3’
deoxyribose nucleotide or a 3’ methoxy nucleotide. In some embodiments the nucleotides at
positions 17 and 18 in (N’)y are joined by a 2’-5’ intemucleotide bond. In other
ments the nucleotides at positions 16, 17, 18, 16-17, 17-18, or 16-18 in (N ’)y are
joined by a 2’-5’ intemucleotide bond.
In certain embodiments (N’)y comprises an L-DNA at position 2 and 2’-5’
intemucleotide bonds at positions 16, 17, 18, 16-17, 17-18, or 16-18. In certain embodiments
(N’)y ses 2’-5’ intemucleotide bonds at ons l6, l7, 18, 16-17, 17-18, or 16-18
and a 5’ terminal cap tide.
In one embodiment of the nucleic acid molecules, the 3’ terminal nucleotide or
two or three consecutive nucleotides at the 3’ terminus of (N ’)y are L-deoxyribonucleotides.
In other embodiments the nucleic acid les, in (N’)y 2, 3, 4, 5, 6, 7, 8, 9,
, 11, 12, 13 or 14 consecutive cleotides at either terminus or 2-8 modified
nucleotides at each of the 5’ and 3' termini are independently 2’ sugar modified nucleotides.
In some ments the 2’ sugar modification comprises the presence of an amino, a
fiuoro, an alkoxy or an alkyl moiety. In certain ments the 2’ sugar modification
comprises a methoxy moiety (2’-OMe).
In one embodiment, three, four or five consecutive nucleotides at the 5’ terminus
of (N’)y comprise the 2’-OMe modification. In another embodiment, three utive
tides at the 3’ terminus of (N’)y comprise the 2’-OMe sugar modification.
In some embodiments of Structure A1 or A2 in (N’)y or N2-(N’)y or more
consecutive ribonucleotides at either terminus or 2-8 modified nucleotides at each of the 5’
and 3' termini are independently bicyclic nucleotide. In various embodiments the bicyclic
nucleotide is a locked nucleic acid (LNA). A 2'-O, 4'-C-ethylene-bridged nucleic acid
(ENA) is a species ofLNA .
In various ments (N’)y or N2-(N’)y comprises d nucleotides at
the 5’ terminus or at both the 3’ and 5’ termini.
In some embodiments of Structure A1 or A2 at least two nucleotides at either or
both the 5 ’ and 3 ’ termini of (N ’)y are joined by P-ethoxy backbone modifications. In certain
embodiments x=y=l9 or x=y=23; in (N)x the nucleotides ate between modified
ribonucleotides and unmodified ribonucleotides, each modified ribonucleotide being a 2’-
OMe sugar modified cleotide and the ribonucleotide located at the middle position of
(N)X being unmodified; and four consecutive tides at the 3’ terminus or at the 5’
terminus of (N’)y are joined by three P-ethoxy backbone modifications. In another
embodiment, three consecutive nucleotides at the 3’ terminus or at the 5’ terminus of (N’)y
are joined by two P-ethoxy backbone ations.
In some embodiments of Structure Al or A2 in (N’)y or N2-(N’)y 2, 3, 4, 5, 6, 7
or 8, consecutive ribonucleotides at each of the 5’ and 3' termini are independently mirror
nucleotides, nucleotides joined by 2’-5’ phosphodiester bond, 2’-OMe sugar modified
nucleotides or bicyclic tide. In one embodiment, the modification at the 5’ and 3’
termini of (N’)y is identical. In one ment, four consecutive nucleotides at the 5’
terminus of (N’)y are joined by three 2’-5’ phosphodiester bonds and three consecutive
nucleotides at the 3’ terminus of (N’)y are joined by two 2’-5’ phosphodiester bonds. In
another ment, the modification at the 5’ terminus of (N’)y is different from the
ation at the 3’ terminus of (N’)y. In one embodiment, the modified nucleotides at
the 5’ terminus of (N’)y are mirror nucleotides and the d nucleotides at the 3’
terminus of (N’)y are joined by 2’-5’ phosphodiester bond. In another specific embodiment,
three consecutive nucleotides at the 5’ terminus of (N ’)y are LNA nucleotides and three
consecutive nucleotides at the 3’ terminus of (N’)y are joined by two 2’-5’ phosphodiester
bonds. In (N)X the nucleotides alternate between modified ribonucleotides and unmodified
ribonucleotides, each modified ribonucleotide being a 2’-OMe sugar d
ribonucleotide and the ribonucleotide located at the middle of (N)x being unmodified, or the
ribonucleotides in (N)X being unmodified
In r embodiment of Structure Al ed herein are compounds wherein
x=y=l9; in (N)x the nucleotides alternate between modified ribonucleotides and unmodified
ribonucleotides, each modified cleotide being modified to a 2’-OMe sugar modified
ribonucleotide and the ribonucleotide located at the middle of (N)x being fied; three
nucleotides at the 3’ terminus of (N’)y are joined by two 2’-5’ phosphodiester bonds and
three nucleotides at the 5’ terminus of (N’)y are LNA such as ENA; and Z and/or Z'
independently comprise one or more non-nucleotide moiety selected from the group
consisting of an abasic moiety, an inverted abasic moiety, a hydrocarbon moiety, and an
_ 54 _
inorganic phosphate, or a combination of one or more non-nucleotide moiety and one or
more nucleotide. In some embodiments Z is selected from C3Pi-C3Pi, 3OH; C3Pi-
rAb; C3Pi-dAb; dAb-dAb and rAb-rAb.
In another embodiment five consecutive nucleotides at the 5’ terminus of (N’)y
or N2-(N’)y comprise the 2’-O-methyl sugar modification and two consecutive nucleotides
at the 3’ terminus of (N ’)y are L-DNA.
According to other embodiments in N’)y or N2-(N’)y the 5’ or 3’ terminal
nucleotide, or 2, 3, 4, 5 or 6 consecutive nucleotides at either termini or 1-4 modified
nucleotides at each of the 5’ and 3' i are independently phosphonocarboxylate or
inocarboxylate nucleotides (PACE nucleotides). In some embodiments the PACE
nucleotides are deoxyribonucleotides. In some embodiments in N’)y or N2-(N’)y, 1 or 2
consecutive tides at each of the 5’ and 3' termini are PACE nucleotides. Examples of
PACE nucleotides and analogs are disclosed in US Patent Nos. 6,693,187 and 7,067,641
both incorporated by nce.
In one embodiment of Structure (A1), x=y=19; (N)X comprises unmodified
cleotides in which two consecutive nucleotides linked by one 2'-5' intemucleotide
linkage at the 3’ terminus; (N ’)y comprises unmodified ribonucleotides in which two
consecutive nucleotides linked by one 2'-5' intemucleotide linkage at the 5’ terminus; and Z
and/or Z' independently comprise one or more non-nucleotide moiety selected from the
group consisting of an abasic moiety, an ed abasic moiety, a hydrocarbon moiety, and
an inorganic phosphate, or a ation of one or more non-nucleotide moiety and one or
more nucleotide. In some embodiments Z is selected from C3Pi-C3Ps; C3Pi-C3OH; C3Pi-
C3Pi; C3Pi-rAb; C3Pi-dAb; dAb-dAb and rAb-rAb, each C3, rAb, dAb covalently linked to
the adjacent C3Pi, rAb, dAb via a phospho-based bond. In some embodiments the o-
based bond is a phosphodiester bond or a phosphorothiophosphate bond.
In some embodiments, ; (N)X comprises unmodified ribonucleotides in
which three consecutive nucleotides at the 3’ us are joined together by two 2'-5'
phosphodiester bonds; (N ’)y comprises unmodified ribonucleotides in which four
consecutive nucleotides at the 5’ terminus are joined together by three 2'-5' odiester
bonds; and. Z and/or Z' independently comprise one or more non-nucleotide moiety selected
from the group consisting of an abasic moiety, an inverted abasic moiety, a hydrocarbon
moiety, and an inorganic phosphate, or a combination of one or more non-nucleotide moiety
and one or more nucleotide. In some embodiments Z is selected from C3Pi-C3Ps; C3Pi-
C3OH; C3Pi-C3Pi; C3Pi-rAb; C3Pi-dAb; dAb-dAb and rAb-rAb wherein each C3Pi, rAb,
dAb covalently linked to the adjacent C3Pi, rAb, dAb via a phospho-based bond. In some
embodiments the phospho-based bond is a phosphodiester bond or a
phosphorothiophosphate bond.
[0022l] According to one embodiment of Structure Al or A2 four utive
nucleotides at the 5’ terminus of (N’)y or (N ’)y-N2, respectively are joined by three 2’-5’
phosphodiester bonds; three utive nucleotides at the 3’ us of (N’)X are joined by
two 2’-5’ phosphodiester bonds; and Z and/or Z' independently comprise one or more non-
nucleotide moiety selected from the group consisting of an abasic , an inverted abasic
moiety, a hydrocarbon moiety and an inorganic phosphate, or a combination of one or more
non-nucleotide moiety and one or more nucleotide. In some embodiments Z is selected from
C3Pi-C3Ps; C3Pi—C3OH; C3Pi-C3Pi; C3Pi-rAb; C3Pi-dAb;; C3-dAb; dAb-dAb and rAb-
rAb. Three tides at the 5’ terminus of (N’)y and two nucleotides at the 3’ terminus of
(N’)x may also comprise e sugar modifications.
In one embodiment of Structure Al or A2, five consecutive nucleotides at the 5’
terminus of (N’)y or (N’)y-N2, respectively comprise the 2’-O-Me sugar modification and
five utive nucleotides at the 3’ terminus of (N’)X comprise the 2’-O-Me sugar
modification. In another embodiment ten consecutive nucleotides at the 5’ terminus of (N ’)y
comprise the 2’-O-Me sugar modification and five consecutive nucleotides at the 3’ terminus
of (N’)X comprise the 2’-O-Me sugar modification. In another embodiment en
consecutive nucleotides at the 5’ terminus of (N’)y se the 2’-O-Me sugar
modification; five utive nucleotides at the 3’ terminus of (N ’)x comprise the 2’-O-Me
sugar modification; and Z and/or Z' independently comprise one or more non-nucleotide
moiety selected from the group consisting of an abasic , an inverted abasic moiety, a
hydrocarbon moiety and an inorganic phosphate, or a combination of one or more non-
nucleotide moiety and one or more nucleotide. In some embodiments Z is ed C3Pi-
C3Ps; C3Pi-C3OH; C3Pi-C3Pi; C3Pi-rAb; Ab; dAb-dAb and rAb-rAb.
In specific embodiments five consecutive tides at the 5’ terminus of (N’)y
or (N’)y-N2, respectively comprise the 2’-O-Me sugar modification and two consecutive
nucleotides at the 3’ terminus of (N’)y are L-DNA. In on, the nd may filrther
se five consecutive ethyl modified nucleotides at the 3’ terminus of (N ’)x and
Z and/or Z' may independently comprise one or more non-nucleotide moiety selected from
the group consisting of an abasic moiety, an inverted abasic moiety, a hydrocarbon moiety,
and an inorganic phosphate, or a combination of one or more non-nucleotide moiety and one
or more nucleotide. In some ments Z is selected from C3Pi-C3Ps; C3Pi-C3OH;
C3Pi-C3Pi; Ab; C3Pi-dAb; dAb-dAb and rAb-rAb.
In various embodiments of Structure A1 or A2 the modified tides in (N)x
are different from the modified nucleotides in (N ’)y. For example, the modified nucleotides
in (N)x are 2’ sugar modified tides and the modified nucleotides in (N’)y are
nucleotides linked by 2’-5’ intemucleotide linkages. In another e, the d
nucleotides in (N)x are mirror nucleotides and the modified tides in (N’)y are
nucleotides linked by 2’-5’ intemucleotide linkages. In another example, the modified
nucleotides in (N)x are nucleotides linked by 2’-5’ intemucleotide linkages and the modified
nucleotides in (N’)y are mirror nucleotides.
In some embodiments N'(y) comprises 2, 3, 4, 5, 6, 7, or 8 nucleotides joined to
an adjacent nucleotide by a 2’-5’ intemucleotide bond at the 3’ terminus. In some
embodiments N'(y) comprises 2, 3, 4, 5, 6, 7, or 8 nucleotides joined to an adjacent
nucleotide by a 2’-5’ intemucleotide bond at the 3’ penultimate position. In some
embodiments x=y =19 and N'(y) comprises 2, 3, 4, or 5 nucleotides joined to an adjacent
nucleotide by a 2’-5’ cleotide bond at the 3’ terminus. In some embodiments x=y
=19 and N'(y) comprises 5 nucleotides joined to an adjacent nucleotide by a 2’-5’
intemucleotide bond at the 3’ terminus i.e. in position 15, l6, l7, l8 and 19 (5’>3’). In some
embodiments (N)x comprises 2’-OMe sugar modified ribonucleotides. In some embodiments
(N)x comprises 2’-OMe sugar modified pyrimidine ribonucleotides. In some embodiments
(N)x comprises 2’-OMe sugar modified ribonucleotides alternating with unmodified
ribonucleotides. In some embodiments x=y=l9 and (N)x comprises 2’-OMe sugar modified
ribonucleotides in position (5’>3’) 3, 5 and ll, 13, 15, 17, and 19. In some embodiments
(N)x further comprises a mirror nucleotide or a 2’5’ nucleotide in positions 6 or 7.
In some embodiments the sequence of (N)x has complementarity to the sequence
of (N’)y; and the sequence of (N’)y has identity to a sequence Within an mRNA encoded by
a target gene.
In some preferred ment nucleic acid molecules disclosed herein have the
following structure
’ NNNNNNNNNNNNNNNNNNN-CBPi-CBOH
3’ HOCB-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’ -Z”
’ NNNNNNNNNNNNNNNNNNN-CBPi-CBOH
3’ iPCB-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’ -Z”
wherein of N and N’ is independently a ribonucleotide which may be unmodified or
modified, or is an unconventional moiety;
wherein each N is linked to the adjacent N by a covalent bond;
n each N’ is linked to the adjacent N’ by a covalent bond;
wherein l to 10 ofN are 2’-O Me sugar modified ribonucleotides;
wherein N at position 5, 6, 7, 8 or 9 (5’>3’) is a 2’5 nucleotide or a mirror nucleotide;
wherein N’ at positions 15-19 (5 ’>3’ )are 2’5’ ribonucleotides;
wherein z” is a capping moiety covalently attached to the 5 ’ terminus of the sense .
In some preferred embodiment nucleic acid les disclosed herein have the
following ure
’ NNNNNNNNNNNNNNNNNNN-C3Pi-C30H
3’ HOCB-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’ -Z”
’ NNNNNNNNNNNNNNNNNNN-C3Pi-C30H
3’ iPCB-N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’N’ -Z”
WO 18911
wherein of N and N’ is independently a ribonucleotide which may be unmodified or
modified, or is an unconventional moiety;
wherein each N is linked to the adjacent N by a covalent bond;
wherein each N’ is linked to the adjacent N’ by a covalent bond;
wherein l to 10 ofN are 2’-O Me sugar modified ribonucleotides;
wherein N at position 5, 6, 7, 8 or 9 ) is a 2’5 nucleotide or a mirror nucleotide;
n N’ comprises one or more 2’-O Me sugar modified pyrimidine ribonucleotides;
wherein N at position 9 or 10 (5’>3’) is a 2’5 nucleotide; and
wherein z” is a capping moiety covalently attached to the 5 ’ terminus of the sense strand.
In some ments of Structures (Al — A2), either the sense strand or the
antisense strand or both the sense strand and the antisense strand comprise an inorganic
phosphate moieties at the 3' termini.
In some embodiments of the double ed c acid molecules, N at the 3'
us is a modified ribonucleotide and (N)X comprises at least 8 modified
ribonucleotides. In some embodiments the modified cleotides comprise 2’-OMe sugar
modified ribonucleotides. In other embodiments at least 5 of the at least 8 d
ribonucleotides are alternating beginning at the 3' end.
[0023 1] In some embodiments of the double stranded nucleic acid molecules z” is present
and is selected from an abasic ribose moiety, a deoxyribose moiety; an inverted abasic ribose
moiety, a deoxyribose moiety; C6-amino-Pi; a mirror nucleotide.
In some embodiments of the double stranded nucleic acid molecules in (N’)y at
least one additional unconventional moiety is present, which unconventional moiety may be
an abasic ribose , an abasic deoxyribose moiety, a modified or unmodified
deoxyribonucleotide, a mirror nucleotide, a non-base pairing nucleotide analog or a
nucleotide joined to an adjacent nucleotide by a 2’-5’ intemucleotide phosphate bond. In
some embodiments, neither (N)x nor (N’)y are phosphorylated at the 3’ and 5’ termini. In
other ments either or both (N)X and (N’)y are phosphorylated at the 3’ termini. In yet
2012/027174
another embodiment, either or both (N)X and (N ’)y are phosphorylated at the 3’ termini
using non-cleavable phosphate groups. In yet another embodiment, either or both (N)X and
(N’)y are phosphorylated at the terminal 2’ termini position using cleavable or non-cleavable
phosphate groups.
In certain embodiments for all of the above-mentioned structures, Z is present. In
other embodiments Z' is present. In onal embodiments both Z and Z' are t. In
some embodiments Z and Z' are both present and identical. In further embodiments both Z
and Z' are present and are ent. In some embodiments Z and Z' are independently l, 2, 3,
4 or 5 non-nucleotide moieties or a combination of a non-nucleotide moiety and a
nucleotide.
In some embodiments Z is present and comprises one or more non-nucleotide
moiety selected from an abasic moiety, an inverted abasic moiety, a hydrocarbon moiety
such as , and an inorganic phosphate moiety.
In additional embodiments Z' is present and comprises one or more non-
nucleotide moiety selected from an abasic moiety, an inverted abasic moiety, a hydrocarbon
moiety such as (CH2)3, and an inorganic phosphate moiety.
In some embodiments each of Z and/or Z' comprises one or two non-nucleotide
moieties and fiarther comprises a nucleotide.
] In some embodiments Z and/or Z' comprise abasic moieties, optionally
deoxyribo-abasic (referred to herein as "dAb") or riboabasic (referred to herein as "rAb")
moieties. In some embodiments each of Z and/or Z' is dAb-dAb or rAb-rAb.
In some embodiments Z and/or Z' comprise one or more hydrocarbon moieties,
optionally (CH2)3-Pi (referred to herein as "C3Pi"). In some embodiments Z and/or Z' is
C3Pi-C3Ps; C3Pi-C3OH; or C3Pi-C3Pi.
In onal embodiments Z and/or Z' se a combination of abasic
moieties and unmodified nucleotides or a combination of hydrocarbon ed moieties
and unmodified nucleotides or a combination of abasic es and hydrocarbon modified
moieties. In such ments, Z and/or Z' are ally C3Pi-rAb. In a ular
embodiment only Z is present and is C3Pi-C3Ps; C3Pi-C3OH; C3Pi-C3Pi.
In the embodiments of the above-mentioned Structures, the compound
_ 60 _
comprises at least one 3’ overhang (Z and or Z’) comprising at least one non-nucleotide
. Z and Z’ independently comprises one cleotide moiety and one or more
covalently linked modified or non-modified nucleotides or unconventional moiety, for
e inverted dT or dA; dT, LNA, mirror nucleotide and the like. The siRNA in which Z
and/or Z’ is present has improved ty and/or stability and/or off-target activity and or
reduced immune se when compared to an siRNA in which Z and /or Z’ are absent or
in which Z and/or Z’ is deT.
In certain embodiments for all the above-mentioned Structures, the compound
comprises one or more phosphonocarboxylate and /or phosphinocarboxylate nucleotides
(PACE nucleotides). In some embodiments the PACE nucleotides are deoxyribonucleotides
and the phosphinocarboxylate nucleotides are phosphinoacetate nucleotides. Examples of
PACE nucleotides and analogs are disclosed in US Patent Nos. 6,693,187 and 7,067,641,
both incorporated herein by reference.
] In certain embodiments for all the above-mentioned Structures, the compound
comprises one or more locked nucleic acids (LNA) also defined as bridged nucleic acids or
bicyclic nucleotides. Exemplary locked nucleic acids include 2’-O, 4’-C-ethylene
nucleosides (ENA) or 2’-O, 4’-C-methylene nucleosides. Other examples of LNA and ENA
nucleotides are disclosed in WO 98/39352, WO 00/47599 and W0 99/14226, all
orated herein by reference.
In certain embodiments for all the above-mentioned Structures, the compound
comprises one or more altritol monomers (nucleotides), also defined as 1,5 o
deoxy-D-altrito-hexitol (see for e, , et al., 1998. Nucleosides & Nucleotides
17:1523-1526; Herdewijn et al., 1999. Nucleosides & Nucleotides 18:1371-1376; Fisher et
al., 2007, NAR 35(4): 1064-1074; all incorporated herein by reference).
The present invention explicitly es double stranded compounds in which
each of N and /or N’ is a deoxyribonucleotide (dA, dC, dG, dT). In n embodiments
(N)x and (N’)y may comprise independently 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
deoxyribonucleotides. In certain embodiments provided herein a nd wherein each of
N is an unmodified ribonucleotide and the 3’ terminal nucleotide or 2, 3, 4, 5, 6, 7, 8, 9, or
, consecutive nucleotides at the 3’ terminus of (N ’)y are deoxyribonucleotides. In further
embodiments the 5’ terminal nucleotide or 2, 3, 4, 5, 6, 7, 8, or 9 consecutive nucleotides at
the 5’ terminus and l, 2, 3, 4, 5, or 6 utive nucleotides at the 3’ termini of (N)x are
deoxyribonucleotides and each of N’ is an unmodified ribonucleotide. In yet further
embodiments (N)x comprises unmodified ribonucleotides and l or 2, 3 or 4 consecutive
deoxyribonucleotides independently at each of the 5’ and 3’ termini and 1 or 2, 3, 4, 5 or 6
consecutive deoxyribonucleotides in internal positions; and each of N’ is an unmodified
ribonucleotide. In some embodiments the 5’ terminal nucleotide of N or 2 or 3 consecutive
of N and 1,2, or 3 of N’ is a ibonucleotide. Certain examples of active DNA/RNA
siRNA chimeras are disclosed in US patent publication 2005/0004064, and Ui-Tei, 2008
(NAR 36(7):2l36-2l5 l) orated herein by reference in their entirety.
A covalent bond refers to an cleotide linkage linking one nucleotide
monomer to an adjacent nucleotide monomer. A covalent bond es for example, a
phosphodiester bond, a phosphorothioate bond, a P-alkoxy bond, a P-carboxy bond and the
like. The normal intemucleoside linkage of RNA and DNA is a 3' to 5' phosphodiester
linkage. In certain embodiments a covalent bond is a phosphodiester bond. nt bond
encompasses non-phosphorous-containing intemucleoside linkages, such as those disclosed
in inter alia. Unless otherwise indicated, in embodiments of the structures
discussed herein the covalent bond between each consecutive N or N’ is a odiester
bond.
In some embodiments the oligonucleotide sequence of (N)x is fiJlly
complementary to the ucleotide sequence of (N')y. In other embodiments (N)x and
(N’)y are substantially complementary. In certain embodiments (N)x is fillly complementary
to a utive sequence in a target mRNA. In other embodiments (N)x is substantially
mentary to consecutive sequence in a target mRNA.
Definitions
For convenience certain terms employed in the specification, examples and
claims are described herein.
It is to be noted that, as used herein, the singular forms “a”, “an” and “the”
include plural forms unless the content clearly dictates otherwise.
An “inhibitor” is a compound, which is e of reducing (partially or fully)
the expression of a gene or the activity of the t of such gene to an extent sufficient to
achieve a desired biological or physiological effect. The term "inhibitor" as used herein
refers to a double stranded nucleic acid inhibitor.
A “dsRNA inhibitor” or dsNA inhibitor refers to a double stranded nucleic acid
compound or le which is capable of reducing the expression of a gene or the activity
of the product of such gene to an extent sufficient to achieve a desired biological or
physiological effect. The term "siRNA inhibitor" as used herein refers to one or more of a
siRNA, shRNA, synthetic shRNA; miRNA. As used herein, the term “inhibit”, “down-
regulate”, or “reduce” with respect to gene expression means that the expression of a target
gene, or level of RNA molecules or equivalent RNA molecules encoding one or more
proteins or protein subunits (e.g., mRNA), or activity of one or more proteins or protein
subunits, is reduced below that ed in the absence of an inhibitor (such as a nucleic
acid le, e. g., a dsNA, for example having structural features as described ); for
example the sion may be reduced to 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%,
%, 5% or less than that observed in the absence of an inhibitor.
As used herein, the term “inhibition” of a target gene means inhibition of the
gene expression (transcription or translation) or polypeptide activity of a target gene wherein
the target gene is ian gene selected from the group consisting of TLR2, TLR4,
MYD88, TICAMl and TIRAP or variants thereof. The polynucleotide sequence of the
target mRNA sequence, or the target gene having a mRNA sequence refer to the mRNA
sequence or any homologous sequences thereof ably having at least 70% identity,
more preferably 80% identity, even more preferably 90% or 95% identity to the mRNA of
TLR2, TLR4, MYD88, TICAMl and TIRAP. ore, polynucleotide sequences derived
from the mammalian gene selected from the group consisting of TLR2, TLR4, MYD88,
TICAMl and TIRAP RNA and mRNA which have one mutations, alterations or
modifications as described herein are encompassed in the present invention. The terms
“mRNA polynucleotide sequence”, “mRNA ce” and “mRNA” are used
interchangeably.
As used herein, the terms “polynucleotide” and “nucleic acid” may be used
interchangeably and refer to nucleotide sequences comprising deoxyribonucleic acid (DNA),
and cleic acid (RNA). The terms should also be understood to include, as equivalents,
analogs of either RNA or DNA made from nucleotide analogs. Throughout this application
mRNA sequences are set forth as representing the target of their corresponding genes. The
terms “mRNA cleotide sequence” and mRNA are used interchangeably.
“Oligonucleotide” or “oligomer” refers to a deoxyribonucleotide or
ribonucleotide sequence from about 2 to about 50 nucleotides. Each DNA or RNA
nucleotide may be independently l or synthetic, and or modified or unmodified.
Modifications include changes to the sugar moiety, the base moiety and/or the linkages
between nucleotides in the oligonucleotide. An oligonucleotide disclosed herein encompass
molecules comprising deoxyribonucleotides, ribonucleotides, modified
deoxyribonucleotides, modified ribonucleotides and combinations thereof. As used herein,
the terms “non-pairing tide analog” means a nucleotide analog which comprises a
non-base pairing moiety including but not limited to: 6 des amino adenosine arine), 4-
Me-indole, 3-nitropyrrole, 5-nitroindole, Ds, Pa, N3-Me ribo U, N3-Me riboT, N3-Me dC,
N3-Me-dT, Nl-Me-dG, Nl-Me-dA, N3-ethyl-dC, N3-Me dC. In some embodiments the
non-base pairing nucleotide analog is a ribonucleotide. In other embodiments it is a
deoxyribonucleotide.
Provided herein are methods and compositions for ting expression of a
target gene in vivo. In general, the method es administering oligoribonucleotides, such
as double stranded RNAs, in particular small ering RNAs (i.e., siRNAs) or a nucleic
acid material that generates siRNA in a cell, to target a mammalian mRNA in an amount
sufficient to down-regulate expression of a target gene by an RNA interference mechanism.
In particular, the method is useful for inhibiting expression of the gene for treatment of a
subject suffering from a disease d to expression of that gene. As disclosed herein the
dsRNA les or inhibitors of the target gene are used as drugs to treat various
pathologies.
“siRNA compound” and ic acid molecule” may be used interchangeably
herein.
“Nucleotide” is meant to encompass a compound consisting of a nucleoside (a
sugar, usually ribose or deoxyribose, and a purine or pyrimidine base) and a phospho linker;
such as a deoxyribonucleotide and a ribonucleotide, which may be natural or synthetic, and
be modified or unmodified. Modifications e changes and substitutions to the sugar
moiety, the base moiety and/or the internucleotide linkages.
A hate based” moiety includes inorganic phosphate (Pi) and
phosphorothioate (Ps).
All analogs of, or modifications to, a nucleotide / oligonucleotide may be
employed with the les disclosed herein, ed that said analog or modification
does not substantially adversely affect the fianction of the nucleotide / oligonucleotide.
Acceptable ations include modifications of the sugar moiety, modifications of the
base moiety, ations in the intemucleotide linkages and ations thereof.
What is sometimes referred to as an "abasic nucleotide" or c nucleotide
analog" is more properly referred to as a -nucleotide or an unconventional moiety. A
nucleotide is a monomeric unit of nucleic acid, consisting of a ribose or ibose sugar, a
phosphate, and abase (adenine, guanine, thymine, or cytosine in DNA; adenine, guanine,
uracil, or cytosine in RNA). A modified nucleotide comprises a modification in one or more
of the sugar, phosphate and or base. The abasic pseudo-nucleotide lacks a base, and thus is
not strictly a nucleotide. Abasic deoxyribose moiety includes for example abasic
deoxyribose-3 ’-phosphate; l,2-dideoxy-D-ribofuranosephosphate; l,4-anhydrodeoxy-
D-ribitolphosphate. Inverted abasic deoxyribose moiety includes inverted
deoxyriboabasic; 3’,5’ inverted deoxyabasic 5’-phosphate. In general, an inverted abasic
moiety is covalently ed to a 3’ terminal nucleotide via a 3’-3’ linkage; an inverted
abasic moiety is covalently attached to a 5’ terminal nucleotide via a 5’-5’ linkage; an
inverted abasic moiety is generally covalently attached to an inverted abasic moiety via a 5’-
3’ linkage.
] The term ng moiety” (z”) as used herein includes a moiety which can be
covalently linked to the 5' terminus of (N’)y and includes abasic ribose moiety, abasic
deoxyribose moiety, modified abasic ribose and abasic deoxyribose moieties including 2’ 0
alkyl modifications; inverted abasic ribose and abasic deoxyribose moieties and
modifications thereof; C6-imino-Pi; a mirror tide including L-DNA and L-RNA;
’OMe nucleotide; and nucleotide analogs including 4',5'-methylene nucleotide; l-(B-D-
erythrofuranosyl)nucleotide; o nucleotide, carbocyclic nucleotide; 5'-amino-alkyl
phosphate; l,3-diaminopropyl phosphate, 3-aminopropyl phosphate; 6-aminohexyl
phosphate; l2-aminododecyl phosphate; hydroxypropyl phosphate; l,5-anhydrohexitol
nucleotide; alpha-nucleotide; threo-pentofuranosyl tide; acyclic 3',4'-seco nucleotide;
3,4-dihydroxybutyl tide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted abasic moiety;
l,4-butanediol phosphate; no; and bridging or non bridging methylphosphonate and 5'-
mercapto es.
[0026l] Certain capping moieties are abasic ribose or abasic deoxyribose moieties;
inverted abasic ribose or inverted abasic ibose moieties; C6-amino-Pi; a mirror
nucleotide including L-DNA and L-RNA. The compounds disclosed herein may be
synthesized using one or more inverted nucleotides, for e inverted thymidine or
inverted adenine (for example see Takei, et al., 2002. JBC 277(26):23800-06.
Chemical modifications also include ed nucleic acids, or UNAs, which are
non-nucleotide, acyclic analogues, in which the C2’-C3 ’ bond is not present (although UNAs
are not truly nucleotides, they are expressly included in the scope of “modified” nucleotides
or modified nucleic acids as contemplated ). In particular embodiments, nucleic acid
molecules with a overhang may be modified to have UNAs at the ng positions (i.e., 2
nucleotide overhand). In other embodiments, UNAs are included at the 3’- or 5’- ends. A
UNA may be located anywhere along a nucleic acid strand, i.e. at position 5, 6, 7, 8, or 9.
Nucleic acid molecules may n one or more than UNA. Exemplary UNAs are
disclosed in Nucleic Acids Symposium Series No. 52 p. 133—134 (2008).
The term “non-nucleotide moiety” refers to a moiety that is not a nucleotide, i.e.
does not e all of the ents of a nucleotide: a sugar. a base and a linker.
The term “unconventional moiety” as used herein refers to the non-nucleotide
moieties including an abasic moiety, an inverted abasic moiety, an alkyl moiety or alcohol,
and an inorganic phosphate and fiarther includes a deoxyribonucleotide, a modified
deoxyribonucleotide, a mirror nucleotide (L-DNA or L-RNA), a non-base pairing nucleotide
analog and a nucleotide joined to an adjacent nucleotide by a 2’-5’ intemucleotide phosphate
bond (also known as 2”)" nucleotide); bridged nucleic acids including LNA and ethylene
bridged nucleic acids, linkage modified (e.g. PACE) and base modified nucleotides as well
as onal moieties explicitly sed herein as unconventional moieties.
When used in reference to the overhangs, an “alkyl moiety” or a “hydrocarbon
moiety” refers to a C2, C3, C4, C5 or C6 straight chain or branched alkyl moiety, including
for example C2 (ethyl), C3 l). When used in reference to the ngs, a
“derivative” of an alkyl or a hydrocarbon moiety refers to a C2, C3, C4, C5 or C6 straight
_ 66 _
2012/027174
chain or branched alkyl moiety comprising a filnctional group which may be selected from
among, inter alia, alcohols, phosphodiester, phosphorothioate, phosphonoacetate, amines,
carboxylic acids, esters, amides and aldehydes.
When used in reference to ation of the ribose or deoxyribose moiety,
“alkyl” is intended to include linear, branched, or cyclic saturated hydrocarbon structures
and combinations thereof. “Lower alkyl”, when used in reference to modification of the
ribose or deoxyribose moiety, refers specifically to alkyl groups of from 1 to 6 carbon atoms.
Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl
and the like. Preferred alkyl groups are those of C20 or below. Cycloalkyl is a subset of
alkyl and includes cyclic saturated arbon groups of from 3 to 8 carbon atoms.
Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbomyl, adamantyl and
the like
“Terminal filnctional group” es halogen, alcohol, amine, carboxylic, ester,
amide, aldehyde, ketone, ether groups.
As used herein, a “mirror” tide (also referred to as a spiegelmer) is a
nucleotide analog with reverse chirality to the naturally occurring or commonly employed
nucleotide, i.e., a mirror image of the naturally occurring or commonly employed tide.
The mirror nucleotide is a ribonucleotide (L-RNA) or a deoxyribonucleotide (L-DNA) and
may further se at least one sugar or base modification and/or a backbone
modification, such as a phosphorothioate or phosphonate moiety. US Patent No. 6,602,858
discloses nucleic acid catalysts comprising at least one eotide tution. Mirror
nucleotide includes for example L-DNA (L-deoxyriboadenosine-3’-phosphate (mirror dA);
yribocytidine-3’-phosphate r dC); L-deoxyriboguanosine-3’-phosphate r
dG); L-deoxyribothymidine-3’-phosphate (mirror image dT)) and L-RNA (L-riboadenosine-
3’-phosphate (mirror rA); L-ribocytidine-3’-phosphate (mirror rC); L-riboguanosine-3’-
phosphate r rG); L-ribouracil-3 ’-phosphate (mirror dU).
Modified deoxyribonucleotide includes, for example S’OMe DNA (5-methyl-
deoxyriboguanosine-3'-phosphate) which may be useful as a tide in the 5’ terminal
position (position number 1); PACE (deoxyriboadenine 3' phosphonoacetate,
deoxyribocytidine 3' phosphonoacetate, deoxyriboguanosine 3' phosphonoacetate,
deoxyribothymidine 3' phosphonoacetate.
_ 67 _
Unconventional moieties include bridged nucleic acids including LNA (2'-O,4'-
C-methylene bridged Nucleic Acid adenosine 3' monophosphate, 2'-O,4'-C-methylene
bridged Nucleic Acid 5-methyl-cytidine 3' monophosphate, 2'-O,4'-C-methylene bridged
Nucleic Acid guanosine 3' monophosphate, 5-methyl-uridine (or thymidine) 3'
monophosphate); and ENA (2'-O,4'-C-ethylene bridged Nucleic Acid adenosine 3'
osphate, 2'-O,4'-C-ethylene bridged Nucleic Acid 5-methyl-cytidine 3'
osphate, 2'-O,4'-C-ethylene d Nucleic Acid guanosine 3' monophosphate, 5-
-uridine (or thymidine) 3' monophosphate).
In some embodiments the unconventional moiety is an abasic ribose moiety, an
abasic deoxyribose moiety, a deoxyribonucleotide, a mirror nucleotide, and a nucleotide
joined to an adjacent nucleotide by a 2’-5’ intemucleotide phosphate bond.
The nucleotides are selected from naturally occurring or synthetic modified
bases. Naturally occurring bases include adenine, guanine, cytosine, thymine and uracil.
Modified bases of nucleotides include inosine, ne, hypoxanthine, 2- aminoadenine, 6-
methyl, 2-propyl and other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza cytosine and
6-aza e, pseudo uracil, 4- thiouracil, 8-halo adenine, 8-aminoadenine, 8-thiol adenine,
8-thiolalkyl adenines, oxyl adenine and other tituted adenines, 8-halo guanines,
8-amino guanine, 8-thiol guanine, 8-thioalkyl guanines, 8- hydroxyl guanine and other
substituted es, other aza and deaza adenines, other aza and deaza guanines, 5-
trifiuoromethyl uracil and 5- trifiuoro cytosine. dsRNA compounds comprising one or more
abasic pseudo-nucleotides are encompassed herein. A nucleotide monomer comprising a
modified base, including abasic -nucleotide monomers, may be substituted for one or
more ribonucleotides of the oligonucleotide. An abasic pseudo-nucleotide monomer may be
ed at the one or more of the terminal positions or as a 5’ terminal cap. A 5’ terminal
cap may also be selected from an ed abasic pseudo-nucleotide analog, an L-DNA
nucleotide, and a C6-imine phosphate.
In addition, analogues of polynucleotides are prepared wherein the structure of
one or more nucleotide is filndamentally altered and better suited as therapeutic or
mental reagents. An e of a nucleotide analog is a peptide nucleic acid (PNA)
wherein the deoxyribose (or ribose) phosphate backbone in DNA (or RNA) comprises a
polyamide backbone which is similar to that found in es. PNA analogs have been
shown to be resistant to enzymatic degradation and to have extended lives in vivo and in
vitro.
Possible modifications to the sugar residue are manifold and include 2’-O alkyl,
o (e.g. 2’ deoxy fluoro), locked nucleic acid (LNA), glycol nucleic acid (GNA),
threose nucleic acid (TNA), arabinoside; altritol (ANA) and other 6-membered sugars
including morpholinos, and cyclohexinyls. Possible modifications on the 2’ moiety of the
sugar residue include amino, fluoro, y alkoxy, alkyl, amino, fluoro, chloro, bromo,
CN, CF, ole, ylate, thioate, C1 to C10 lower alkyl, substituted lower alkyl,
alkaryl or aralkyl, OCF3, OCN, O-, S-, or N- alkyl; O-, S, or N-alkenyl; SOCH3; SOZCH3;
ONOZ; N02, N3; heterozycloalkyl; heterozycloalkaryl; aminoalkylamino; polyalkylamino or
substituted silyl, as, among , described in European patents EP 0 586 520 Bl or EP 0
618 925 B1. One or more deoxyribonucleotides are also tolerated in the compounds
disclosed herein. In some embodiments (N’) ses 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 DNA
] LNA compounds are disclosed in International Patent ation Nos. WO
00/47599, W0 99/14226, and WO 98/39352. Examples of siRNA compounds comprising
LNA nucleotides are disclosed in Elmen et al., (NAR 2005. 33(1):439-447) and in
International Patent Publication No. WO 2004/083430. Six-membered ring nucleotide
analogs are disclosed in Allart, et al (Nucleosides & tides, 1998, l7:l523-l526,; and
Perez-Perez, et al., 1996, Bioorg. and Medicinal Chem Letters -l460)
Oligonucleotides comprising 6-membered ring nucleotide analogs ing hexitol and
altritol nucleotide monomers are disclosed in International patent application publication No.
ne modifications, also known as intemucleotide linkage modifications,
such as ethyl (resulting in a phospho-ethyl triester); propyl (resulting in a phospho-propyl
triester); and butyl (resulting in a phospho-butyl triester) are also possible. Other backbone
modifications include polymer backbones, cyclic backbones, c backbones,
thiophosphate-D-ribose backbones, amidates, phosphonoacetate derivatives. Certain
structures include dsRNA compounds having one or a plurality of 2’-5’ intemucleotide
linkages (bridges or backbone).
In some embodiments, neither (N)x nor (N’)y are phosphorylated at the 3’ and 5’
_ 69 _
termini. In other embodiments either or both (N)x and (N ’)y are phosphorylated at the 3’
termini (3' Pi). In yet another embodiment, either or both (N)x and (N’)y are phosphorylated
at the 3’ i with non-cleavable phosphate groups. In yet another embodiment, either or
both (N)x and (N’)y are phosphorylated at the terminal 2’ termini position using ble or
eavable ate . Further, the inhibitory nucleic acid molecules disclosed
herein may comprise one or more gaps and/or one or more nicks and/or one or more
mismatches. Without wishing to be bound by theory, gaps, nicks and mismatches have the
age of partially destabilizing the nucleic acid / siRNA, so that it may be more easily
processed by endogenous cellular ery such as DICER, DROSHA or RISC into its
inhibitory components.
As used herein, a gap in a nucleic acid refers to the absence of one or more
internal nucleotides in one strand, while a nick in a nucleic acid refers to the absence of an
intemucleotide linkage between two adjacent nucleotides in one strand. Any of the
molecules disclosed herein may contain one or more gaps and/or one or more nicks.
c acid molecules include those with blunt ends, i.e., ends that do not
include any overhanging nucleotides. A nucleic acid molecule can include one or more
blunt ends. The blunt ended nucleic acid molecule has a number of base pairs equal to the
number of nucleotides present in each strand of the nucleic acid molecule. The nucleic acid
molecule can include one blunt end, for example where the 5’-end of the antisense strand
and the 3’-end of the sense strand do not have any overhanging nucleotides. Nucleic acid
molecule may include one blunt end, for example where the 3’-end of the antisense strand
and the 5’-end of the sense strand do not have any overhanging nucleotides. A nucleic acid
molecule may include two blunt ends, for example where the 3’-end of the antisense strand
and the 5’-end of the sense strand as well as the 5’-end of the nse strand and 3’-end of
the sense strand do not have any nging nucleotides. Other nucleotides present in a
blunt ended nucleic acid molecule can include, for example, ches, bulges, loops, or
wobble base pairs to modulate the activity of the nucleic acid molecule, e.g. to mediate RNA
interference.
In certain embodiments of the nucleic acid molecules (e.g., dsNA les)
provided herein, at least one end of the molecule has an overhang of at least one nucleotide
(for example 1 to 8 tides covalently attached to a terminus of the oligonucleotide).
For e, one or both strands of a double stranded nucleic acid molecule disclosed herein
may have an overhang at the 5 ’-end or at the 3 ’-end or both. An overhang may be present at
either or both the sense strand and antisense strand of the nucleic acid molecule. The length
of the overhang may be as little as one nucleotide and as long as l to 8 or more nucleotides
(e.g., l, 2, 3, 4, 5, 6, 7 or 8 nucleotides; in some preferred embodiments an overhang is 2, 3,
4, 5, 6, 7 or 8 nucleotides; for e an overhang may be 2 nucleotides. The
nucleotide(s) forming the ng may be include deoxyribonucleotide(s),
ribonucleotide(s), natural and non-natural nucleobases or any nucleotide modified in the
sugar, base or phosphate group, such as disclosed . A double ed nucleic acid
le may have both 5’- and 3’-overhangs. The overhangs at the 5’- and 3’-end may be
of ent lengths. A overhang may include at least one nucleic acid modification which
may be deoxyribonucleotide. One or more deoxyribonucleotides may be at the 5’-terminus.
The 3’-end of the respective counter-strand of the nucleic acid molecule may not have an
overhang, more preferably not a deoxyribonucleotide overhang. The one or more
deoxyribonucleotide may be at the 3’-terminus. The 5’-end of the respective counter-strand
of the dsRNA may not have an overhang, more preferably not a deoxyribonucleotide
ng. The overhang in either the 5’- or the 3’-end of a strand may be 1 to 8 (e.g., about
1, 2, 3, 4, 5, 6, 7 or 8) unpaired nucleotides, preferably, the overhang is 2-3 unpaired
nucleotides; more preferably 2 unpaired nucleotides. Nucleic acid molecules may include
duplex nucleic acid molecules with overhanging ends of about 1 to about 20 (e. g., about 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, ll, l2, l3, 1, 15, l6, l7, l8, 19 or 20); preferably l-8 (e.g., about 1, 2,
3, 4, 5, 6, 7 or 8) nucleotides, for example, about 2l-nucleotide duplexes with about 19 base
pairs and 3’-terminal cleotide, dinucleotide, or trinucleotide overhangs. Nucleic acid
molecules provided herein may include duplex nucleic acid molecules with blunt ends,
where both ends are blunt, or alternatively, where one of the ends is blunt. Nucleic acid
molecules disclosed herein can include one or more blunt ends, i.e. where a blunt end does
not have any overhanging nucleotides. In one embodiment, the blunt ended c acid
molecule has a number of base pairs equal to the number of nucleotides present in each
strand of the c acid molecule. The nucleic acid molecule may include one blunt end,
for example where the 5’-end of the nse strand and the 3’-end of the sense strand do
not have any overhanging nucleotides. The nucleic acid molecule may include one blunt
end, for example where the 3’-end of the antisense strand and the 5’-end of the sense strand
do not have any overhanging nucleotides. A nucleic acid molecule may include two blunt
ends, for example where the 3’-end of the antisense strand and the 5’-end of the sense strand
as well as the 5’-end of the antisense strand and 3’-end of the sense strand do not have any
overhanging nucleotides. In certain preferred embodiments the nucleic acid compounds are
blunt ended. Other nucleotides present in a blunt ended dsNA molecule can include, for
example, mismatches, bulges, loops, or wobble base pairs to modulate the ty of the
nucleic acid molecule to mediate RNA interference.
In many embodiments one or more, or all, of the overhang tides of a
nucleic acid molecule (e.g., a dsNA molecule) as described herein includes are modified
such as described herein; for example one or more, or all, of the nucleotides may be 2’-
deoxynucleotides.
Amount, on and Patterns of Modifications eic Acid Compounds
[Nucleic acid molecules (e.g., dsNA les) disclosed herein may include
modified nucleotides as a percentage of the total number of nucleotides present in the nucleic
acid le. As such, a nucleic acid molecule may include about 5% to about 100%
modified nucleotides (e.g., about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%,
55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% modified nucleotides). The
actual percentage of modified nucleotides present in a given nucleic acid molecule will
depend on the total number of nucleotides present in the nucleic acid. If the nucleic acid
molecule is single stranded, the percent ation can be based upon the total number of
nucleotides present in the single stranded nucleic acid molecule. se, if the nucleic
acid molecule is double stranded, the percent modification can be based upon the total
number of nucleotides present in the sense strand, antisense strand, or both the sense and
antisense strands.
] [Nucleic acid molecules disclosed herein may include fied RNA as a
percentage of the total nucleotides in the nucleic acid molecule. As such, a nucleic acid
molecule may include about 5% to about 100% unmodified nucleotides (e.g., about 5%,
%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95% or 100% of total nucleotides present in a c acid molecule).
] A nucleic acid molecule (e.g., an dsNA molecule) may include a sense strand
that includes about 1 to about 5, specifically about 1, 2, 3, 4, or 5 phosphorothioate
cleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) xy, 2’-
O-methyl, xy-2’-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more)
universal base modified nucleotides, and optionally a terminal cap le at the 3-end, the
, or both of the 3’- and 5’-ends of the sense strand; and wherein the antisense strand
includes about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5, or more
phosphorothioate intemucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7,
8, 9, 10 or more) 2’-deoxy, 2’-O-methyl, 2’-deoxy-2’-fluoro, and/or one or more (e.g., about
1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and ally a
terminal cap molecule at the 3’-end, the 5’-end, or both of the 3’- and 5’-ends of the
antisense strand. A nucleic acid molecule may include about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or
more, pyrimidine nucleotides of the sense and/or antisense nucleic acid strand are
chemically-modified with 2’-deoxy, ethyl and/or 2’-deoxy-2’-fluoro nucleotides,
with or without about 1 to about 5 or more, for example about 1, 2, 3, 4, 5, or more
orothioate intemucleotide linkages and/or a terminal cap molecule at the 3’-end, the
’-end, or both of the 3 ’- and 5 ’-ends, being present in the same or different strand.
A nucleic acid molecule may include about 1 to about 5 or more (specifically
about 1, 2, 3, 4, 5 or more) orothioate intemucleotide linkages in each strand of the
nucleic acid molecule.
A nucleic acid molecule may include 2’-5’ intemucleotide linkages, for e
at the 3’-end, the , or both of the 3’-end and 5’-end of one or both nucleic acid
sequence strands. In addition, the 2’-5’ intemucleotide linkage(s) can be present at various
other positions within one or both nucleic acid sequence strands, for example, about 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, or more including every intemucleotide linkage of a pyrimidine
nucleotide in one or both strands of the siNA molecule can include a 2’-5’ intemucleotide
linkage, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every intemucleotide linkage
of a purine nucleotide in one or both strands of the siNA molecule can include a 2’-5’
intemucleotide linkage.
A chemically-modified short interfering nucleic acid (dsNA) molecule may
include an antisense region, n any (e.g., one or more or all) pyrimidine nucleotides
present in the antisense region are 2’-deoxy-2’-fluoro pyrimidine tides (e. g., wherein
all pyrimidine nucleotides are 2’-deoxy-2’-fluoro pyrimidine tides or alternately a
plurality of pyrimidine nucleotides are xy-2’-fluoro pyrimidine nucleotides), and
wherein any (e.g., one or more or all) purine nucleotides t in the antisense region are
2’-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2’-deoxy purine
nucleotides or alternately a plurality of purine nucleotides are 2’-deoxy purine nucleotides).
A chemically-modified short interfering nucleic acid (dsNA) molecule may
include an antisense region, wherein any (e.g., one or more or all) pyrimidine nucleotides
present in the antisense region are 2’-deoxy-2’-fluoro pyrimidine nucleotides (e. g., wherein
all pyrimidine nucleotides are 2’-deoxy-2’-fluoro pyrimidine nucleotides or alternately a
plurality of pyrimidine nucleotides are 2’-deoxy-2’-fluoro pyrimidine nucleotides), and
wherein any (e.g., one or more or all) purine tides present in the antisense region are
2’-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are ethyl purine
nucleotides or alternately a plurality of purine nucleotides are 2’-O-methyl purine
nucleotides).
A chemically-modified short interfering nucleic acid (dsNA) molecule capable
of mediating RNA interference (RNAi) t TLR2 and/or TLR4 inside a cell or
reconstituted in Vitro system may include a sense region, wherein one or more pyrimidine
nucleotides present in the sense region are 2’-deoxy-2’-fluoro pyrimidine nucleotides (e. g.,
wherein all pyrimidine nucleotides are 2’-deoxy-2’-fluoro pyrimidine nucleotides or
alternately a plurality of pyrimidine nucleotides are 2’-deoxy-2’-fluoro dine
tides), and one or more purine nucleotides present in the sense region are 2’-deoxy
purine nucleotides (e.g., wherein all purine nucleotides are xy purine nucleotides or
alternately a plurality of purine nucleotides are 2’-deoxy purine tides), and an
antisense region, wherein one or more pyrimidine tides present in the antisense region
are 2’-deoxy-2’-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are
2’-deoxy-2’-fluoro pyrimidine nucleotides or alternately a plurality of dine
nucleotides are 2’-deoxy-2’-fluoro pyrimidine nucleotides), and one or more purine
nucleotides present in the antisense region are 2’-O-methyl purine nucleotides (e.g., wherein
all purine tides are 2’-O-methyl purine nucleotides or alternately a plurality of purine
nucleotides are 2’-O-methyl purine nucleotides). The sense region and/or the antisense
region can have a terminal cap modification, such as any modification, that is optionally
t at the , the 5’-end, or both of the 3’-end and the 5’-end of the sense and/or
_ 74 _
antisense sequence. The sense and/or antisense region can optionally fiarther include a 3’-
terminal nucleotide overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2’-
deoxyribonucleotides. The overhang nucleotides can further e one or more (e.g., about
1, 2, 3, 4 or more) orothioate, phosphonoacetate, and/or thiophosphonoacetate
internucleotide linkages. The purine nucleotides in the sense region may alternatively be 2’-
O-methyl purine nucleotides (e.g., wherein all purine nucleotides are ethyl purine
nucleotides or alternately a plurality of purine tides are 2’-O-methyl purine
nucleotides) and one or more purine nucleotides present in the antisense region are 2’-O-
methyl purine nucleotides (e.g., wherein all purine nucleotides are ethyl purine
nucleotides or alternately a plurality of purine nucleotides are 2’-O-methyl purine
nucleotides). One or more purine nucleotides in the sense region may alternatively be purine
ribonucleotides (e. g., wherein all purine nucleotides are purine ribonucleotides or alternately
a plurality of purine nucleotides are purine cleotides) and any purine nucleotides
present in the antisense region are 2’-O-methyl purine nucleotides (e. g., wherein all purine
nucleotides are 2’-O-methyl purine nucleotides or alternately a plurality of purine
nucleotides are 2’-O-methyl purine nucleotides). One or more purine nucleotides in the
sense region and/or present in the nse region may alternatively be selected from the
group consisting of 2’-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2’-
methoxyethyl nucleotides, 4’-thionucleotides, and 2’-O-methyl nucleotides (e.g., wherein all
purine nucleotides are selected from the group consisting of 2’-deoxy nucleotides, locked
nucleic acid (LNA) nucleotides, 2’-methoxyethyl nucleotides, 4’-thionucleotides, and 2’-O-
methyl nucleotides or alternately a plurality of purine nucleotides are selected from the
group consisting of 2’-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2’-
yethyl nucleotides, 4’-thionucleotides, and 2’-O-methyl tides).
Double stranded Oligonucleotides
The selection and synthesis of dsRNAs, such as siRNA corresponding to known
genes has been widely reported; see for example Ui-Tei et al., J Biomed Biotechnol. 2006;
65052; Chalk et al., BBRC. 2004, 3l9(l):264-74; Sioud & Leirdal, Met. Mol Biol. 2004,
252:457-69; Levenkova et al., Bioinform. 2004, 430-2; Ui-Tei et al., NAR. 2004,
936-48. For examples of the use and tion of modified dsRNA see for e
Braasch et al., Biochem. 2003, 42(26):7967-75; Chiu et al., RNA. 2003, 9(9):1034-48; PCT
2012/027174
Publication Nos. and WO 02/44321 and US Patent Nos. 5,898,031 and
6,107,094.
Provided herein are double-stranded oligonucleotides (e.g. dsRNAs, including
siRNAs), which down-regulate the expression of a desired gene. The dsRNA disclosed
herein are duplex oligoribonucleotides in which the sense strand is derived from the mRNA
sequence of the desired gene, and the antisense strand is at least ntially complementary
to the sense strand. In general, some deviation from the target mRNA sequence is ted
without compromising the siRNA ty (see e. g. Czauderna et al., NAR. 2003,
31(11):2705-2716). The dsRNA disclosed herein inhibit gene expression on a post-
transcriptional level with or without destroying the mRNA. Without being bound by theory,
dsRNA may be siRNA which s the mRNA for specific cleavage and degradation and/
or may inhibit ation from the targeted message.
In other embodiments at least one of the two strands may have an overhang of at
least one nucleotide at the 5'-terminus; the overhang may consist of at least one
deoxyribonucleotide. The length of RNA duplex is from about 16 to about 40
ribonucleotides, preferably 19 ribonucleotides. Further, the length of each strand may
independently have a length selected from the group consisting of about 16 to about 40
bases, preferably 18 to 23 bases and more preferably 19 ribonucleotides.
In certain embodiments the complementarity n said first strand and the
target nucleic acid is perfect. In some embodiments, the strands are substantially
complementary, i.e. having one, two or up to five mismatches between said first strand and
the target mRNA or between the first and the second strands. Substantially complementary
refers to complementarity of greater than about 70%, and less than 100% to another
sequence. For example in a duplex region consisting of 19 base pairs one mismatch results in
94.7% mentarity, two ches results in about 89.5% complementarity, 3
mismatches results in about 84.2% complementarity, 4 mismatches results in about 79%
complementarity and 5 mismatches results in about 74% mentarity, rendering the
duplex region substantially complementary. Accordingly, substantially identical refers to
identity of r than about 70%, to another sequence.
The first strand and the second strand may be linked by a loop structure, which
may be comprised of a cleic acid polymer such as, inter alia, polyethylene glycol.
Alternatively, the loop structure may be comprised of a nucleic acid, including modified and
non-modified ribonucleotides and modified and non-modified deoxyribonucleotides.
Further, the 5'-terminus of the first strand of the dsRNA may be linked to the 3'-
terminus of the second strand, or the 3'-terminus of the first strand may be linked to the 5'-
terminus of the second strand, said linkage being via a nucleic acid linker lly having a
length between 2-100 bases, preferably about 2 to about 30 nucleobases.
In some embodiments, the compounds e alternating ribonucleotides
modified in at least one of the antisense and the sense strands of the compound, for 19 mer
and 23 mer oligomers the ribonucleotides at the 5’ and 3’ termini of the antisense strand are
modified in their sugar residues, and the ribonucleotides at the 5’ and 3’ termini of the sense
strand are unmodified in their sugar es. For 21 mer oligomers the ribonucleotides at
the 5’ and 3’ termini of the sense strand are modified in their sugar residues, and the
ribonucleotides at the 5’ and 3’ termini of the antisense strand are unmodified in their sugar
residues, or may have an optional additional modification at the 3’ terminus. As mentioned
above, in some ments the middle nucleotide of the nse strand is unmodified.
According to one ment, the antisense and the sense strands of the
oligonucleotide / siRNA are phosphorylated only at the 3’-terminus and not at the 5’-
us. According to another embodiment, the antisense and the sense strands are non-
phosphorylated. ing to yet another embodiment, the 5' most ribonucleotide in
the sense strand is modified to abolish any possibility of in viva 5'-phosphorylation.
The dsRNA sequences disclosed herein are prepared having any of the
modifications / structures disclosed herein. The combination of sequence plus structure is
novel and is useful used in the treatment of the conditions disclosed herein.
“Target” or “Target gene” refers to the TLR2, TLR4, MYD88, TICAMl and
TIRAP RNA and mRNA polynucleotide sequences set forth in SEQ ID NO: 1-12, or any
homologous ce thereof preferably having at least 70% identity, more preferable 80%
identity, even more preferably 90% or 95% ty. This encompasses any sequences
derived from SEQ ID NO: l-l2 which have undergone ons, alterations,
polymorphisms or modifications as described herein.
Provided herein are novel unmodified and chemically modified oligonucleotides
and ibonucleotide compounds that possess therapeutic properties. In particular,
provided herein are ally modified dsRNA compounds. The dsRNAs disclosed herein
possess novel structures and novel modifications which have one or more of the following
advantages: increased activity or reduced ty or reduced off-target effect or reduced
immune response or increased stability; the novel modifications of the dsRNAs are
beneficially applied to double stranded RNA useful in down regulating, inhibiting or
attenuating TLR2, TLR4, MYD88, TICAMl and TIRAP gene expression and to the use of
the novel siRNAs in the treatment of various medical conditions. Particular conditions to be
treated include, without being d to, ting, treating and attenuating
posttransplantational complication in organ lant, for example lung transplant patients,
such as for example primary graft failure, ischemia-reperfilsion injury, reperfilsion injury,
reperfusion edema, allograft dysfunction, pulmonary reimplantation response and/or primary
graft dysfunction (PGD).
The nds disclosed herein possess structures and modifications which
impart one or more of increased activity, increased stability, reduced toxicity, reduced off
target effect, and/or reduced immune se. The double stranded structures disclosed
herein are beneficially applied to double stranded RNA useful in preventing or attenuating
expression of TLR2, TLR4, MYD88, TICAMl and TIRAP gene.
Also sed herein is the use of the chemically d dsRNAs in
ting, treating and/or attenuating ansplantational complication in organ
transplant, such as lung transplant, patients, such as for example primary graft failure,
ischemia-reperfusion injury, reperfilsion injury, reperfusion edema, allograft dysfilnction,
pulmonary reimplantation response and/or primary graft dysfunction (PGD). Sense and
antisense oligonucleotides useful in the synthesis of dsRNA as disclosed herein are provided
in SEQ ID NOS:l3-5846 (targeting TLR2), SEQ ID 47-l2l44 (targeting TLR4),
SEQ ID NOS:l2l45-l6332 (targeting MYD88), SEQ ID NOS:l6333-18242 (targeting
TICAMl) and SEQ ID NOS:18243-20606 (targeting TIRAP).
SEQ ID NOS:l3-3060 e oligonucleotides useful in ting dsRNA
compounds according to Structure (Al) to target TLR2; SEQ ID NOS:306l-5846 provide
oligonucleotides useful in generating dsRNA compounds according to Structure (A2) to
target TLR2. Certain preferred oligonucleotide pairs useful in generating double stranded
nucleic acid molecules for down-regulating sion of TLR2 are set forth in Table l,
hereinbelow.
SEQ ID 47-86l2 provide oligonucleotides useful in generating dsRNA
nds according to Structure (Al) to target TLR4; SEQ ID NOS:86l3-l2l44 provide
oligonucleotides useful in generating dsRNA compounds according to Structure (A2) to
target TLR4.
SEQ ID NOS:l2l45-l3924 provide oligonucleotides useful in generating
dsRNA compounds according to Structure (Al) to target MYD88; SEQ ID NOS:l3925-
16332 e ucleotides useful in generating dsRNA compounds according to
Structure (A2) to target MYD88. A preferred oligonucleotide pair useful in generating
double stranded nucleic acid molecule for down-regulating expression of MYD88 is set forth
in Table 3, hereinbelow.
SEQ ID NOS:l6333-l6882 provide oligonucleotides useful in generating
dsRNA nds according to Structure (Al) to target TICAMl; SEQ ID NOS:l6333-
18242 provide oligonucleotides useful in generating dsRNA compounds according to
Structure (A2) to target TICAMl. Certain red oligonucleotide pairs useful in
generating double stranded nucleic acid molecules for down-regulating expression of
TICAMl are set forth in Table 4, hereinbelow.
SEQ ID NOS:l8243-l9010 provide oligonucleotides useful in generating
dsRNA compounds according to Structure (Al) to target TIRAP; SEQ ID NOS:l9011-
20606 provide oligonucleotides useful in generating dsRNA compounds according to
Structure (A2) to target TIRAP. Certain preferred oligonucleotide pairs useful in generating
double stranded c acid molecules for down-regulating expression of TIRAP are set
forth in Table 5, hereinbelow.
Additional 21- or 23-mer dsRNA sequences are generated by 5’ and/or 3’
extension of the l9-mer oligonucleotide sequences disclosed herein. Such extension is
preferably mentary to the ponding mRNA sequence.
] Methods, molecules and compositions disclosed herein which inhibit the TLR2,
TLR4, MYD88, TICAMl and TIRAP gene are discussed herein at length, and any of said
molecules and/or compositions are beneficially employed in the treatment of a subject
suffering from one or more of said conditions.
] Throughout the specification, nucleotide positions are numbered from 1 to 19
and are d from the 5' end of the antisense strand or the sense strand. For example,
position 1 on (N)X refers to the 5' terminal tide on the antisense oligonucleotide strand
and position 1 on (N’)y refers to the 5' terminal nucleotide on the sense oligonucleotide
strand. In the double stranded nucleic acid molecules according to Structure A2, N1
represents position 1 (5’ terminal nucleotide) in the antisense strand and N2 represents the 3’
terminal tide in the sense strand.
An additional molecule disclosed herein is an oligonucleotide comprising
consecutive nucleotides n a first segment of such nucleotides encode a first inhibitory
RNA molecule, a second t of such nucleotides encode a second inhibitory RNA
molecule, and a third segment of such nucleotides encode a third inhibitory RNA molecule.
Each of the first, the second and the third segment may comprise one strand of a double
stranded RNA and the first, second and third ts may be joined together by a linker.
Further, the oligonucleotide may comprise three double stranded segments joined er
by one or more linker.
Thus, one molecule sed herein is an oligonucleotide comprising
consecutive nucleotides which encode three inhibitory RNA molecules; said oligonucleotide
may possess a triple stranded structure, such that three double stranded arms are linked
together by one or more linker, such as any of the linkers presented hereinabove. This
molecule forms a -like structure, and may also be referred to herein as RNAstar. Such
structures are disclosed in PCT patent publication WO 2007/091269, assigned to the
assignee of the present invention and incorporated herein in its entirety by reference.
Said triple-stranded oligonucleotide may be an oligoribonucleotide having the
l structure:
’ Oligol (sense) LINKER A Olig02 (sense) 3’
3’ Oligol (antisense) LINKER B Oligo3 (sense) 5’
3’ Oligo3 (antisense) LINKER C Olig02 (antisense) 5’
’ Oligol (sense) LINKER A Olig02 (antisense) 3’
3’ Oligol (antisense) LINKER B Oligo3 (sense) 5’
3’ Oligo3 (antisense) LINKER C Olig02 (sense) 5’
’ Oligol (sense) LINKER A Oligo3 (antisense) 3’
3’ Oligol (antisense) LINKER B Olig02 (sense) 5’
’ Oligo3 (sense) LINKER C Olig02 ense) 3’
wherein one or more of linker A, linker B or linker C is present; any combination of two or
more oligonucleotides and one or more of linkers A-C is possible, so long as the polarity of
the strands and the general structure of the molecule remains. Further, if two or more of
linkers A-C are present, they may be identical or different.
Thus, a triple-armed structure is formed, wherein each arm comprises a sense
strand and complementary antisense strand (i.e. Oligol antisense base pairs to Oligol sense
etc.). The triple armed structure may be triple stranded, y each arm possesses base
pairing.
Further, the above triple stranded structure may have a gap instead of a linker in
one or more of the strands. Such a molecule with one gap is technically ple stranded
and not triple stranded; inserting additional gaps or nicks will lead to the molecule having
additional strands. Preliminary results obtained by the inventors of the present invention
indicate that said gapped molecules are more active in inhibiting the TLR2, TLR4, MYD88,
TICAMl and TIRAP target gene than the similar but non-gapped molecules.
In some embodiments, r antisense nor sense s of the novel dsRNA
compounds disclosed herein are phosphorylated at the 3’ and 5’ termini. In other
embodiments either or both the sense and the nse s are phosphorylated at the 3’
i. In yet another embodiment, either or both the sense and the antisense strands are
orylated at the 3’ termini using non-cleavable phosphate groups. In yet another
embodiment, either or both the sense and the antisense s are phosphorylated at the
terminal 5’ termini position using cleavable or eavable phosphate groups. In yet
another embodiment, either or both the sense and the antisense strands are phosphorylated at
the terminal 2’ termini position using cleavable or non-cleavable phosphate groups. In
some embodiments the dsRNA nds are blunt ended and are non-phosphorylated at
the termini; however, comparative experiments have shown that dsRNA compounds
phosphorylated at one or both of the 3’-termini have similar activity in viva compared to the
non-phosphorylated compounds.
Any dsRNA sequence disclosed herein can be prepared having any of the
modifications / Structures disclosed herein. The combination of sequence plus structure is
novel and can be used in the treatment of the conditions disclosed herein.
Unless otherwise indicated, in preferred embodiments of the structures sed
herein the covalent bond n each consecutive N and N’ is a phosphodiester bond.
For all of the structures above, in some embodiments the oligonucleotide
sequence of antisense strand is fiJlly complementary to the oligonucleotide sequence of
sense. In other embodiments the sense and the antisense strands are substantially
complementary. In certain embodiments the antisense strand is fully complementary to about
18 to about 40 utive ribonucleotides a target mRNA set forth in any one of SEQ ID
NOS:1-12.
In other embodiments the antisense strand is ntially complementary to
about 18 to about 40 consecutive ribonucleotides a target mRNA set forth in any one of SEQ
ID NOS:1-12.
In some embodiments, disclosed herein is an expression vector comprising an
nse oligonucleotide disclosed in any one of SEQ ID NOS: 13-20606. In some
embodiments the expression vector r comprises a sense oligonucleotide having
complementarity to the antisense oligonucleotide. In various embodiments are further
provided a cell sing an sion vector comprising a sense and an antisense
oligonucleotide disclosed in any one of SEQ ID NOS: 13-20606 or 20602-20684. Further
sed herein is a siRNA expressed in a cell comprising an expression vector comprising
a sense and an antisense oligonucleotide disclosed in any one of SEQ ID NOS: 13-20606, or
20602-20684, a pharmaceutical composition sing same and use thereof for treatment
of any one of the disorders disclosed herein.
In other embodiments, disclosed herein is a first expression vector comprising an
antisense oligonucleotide sed in any one of SEQ ID NOS: 13-20606 and a second
expression vector comprising a sense oligonucleotide having complementarity to the
nse ucleotide comprised in the first expression vector. In various embodiments
disclosed herein is a cell comprising a first expression vector comprising an antisense
oligonucleotide disclosed in any one of SEQ ID NOS: 13-20606 and a second expression
vector sing a sense oligonucleotide having mentarity to the nse
ucleotide comprised in the first expression vector. Further disclosed herein is a
dsRNA expressed in a cell comprising such first and second expression vector, a
pharmaceutical ition comprising same and use thereof for treatment of any one of the
diseases and disorders disclosed herein.
RNA interference
RNA interference (RNAi) is a phenomenon involving -stranded (ds)
RNA-dependent gene specific posttranscriptional silencing. RNAi refers to the process of
sequence-specific post-transcriptional gene silencing in mammals mediated by small
interfering RNAs (siRNAs) (Fire et al, Nature 1998. 391, 806) or microRNAs (miRNA;
Ambros, Nature 2004 431:7006,350-55; and Bartel, Cell. 2004. 116(2):281-97). RNAi has
been described in numerous ations, including Gil et al. Apoptosis, 2000. 5:107-114,
Elbashir et al. Nature 2001, 411:494-498 and Caplen et al. PNAS USA 2001, 98:9742-9747.
A siRNA is a -stranded RNA molecule which inhibits, either partially or fully, the
expression of a gene/ mRNA of its endogenous or cellular counterpart, or of an exogenous
gene such as a viral nucleic acid. The mechanism of RNA interference is detailed infra.
Studies have revealed that siRNA is effective in vivo in mammals, including
humans. For reviews of therapeutic applications of siRNAs see for example Barik (Mol.
Med 2005, 83: 764-773), Chakraborty (Current Drug Targets 2007 8(3):469-82); Durcan
(Mol. Pharma. 2008. 5(4):559—566); Kim and Rossi (BioTechniques 2008. 44:613-616);
Grimm and Kay, (JCI, 2007. 117(12):3633-4l).
A number of PCT applications have been published that relate to the RNAi
phenomenon. These include: PCT ation WO 00/44895; PCT publication WO
00/49035; PCT publication WO 00/63364; PCT publication WO 01/36641; PCT publication
WO 01/36646; PCT publication WO 99/32619; PCT publication WO 14; PCT
publication WO 01/29058; and PCT publication WO 01/75164.
RNA interference (RNAi) is based on the ability of dsRNA species to enter a
cytoplasmic n complex, where it is then targeted to the complementary cellular RNA
and cally degrade it. The RNA interference response features an endonuclease
complex containing a dsRNA, commonly referred to as an duced silencing complex
(RISC), which mediates cleavage of single-stranded RNA having a sequence complementary
to the antisense strand of the dsRNA duplex. Cleavage of the target RNA may take place in
the middle of the region complementary to the antisense strand of the dsRNA duplex
(Elbashir et al., Genes Dev., 2001, 15(2):188-200). In more detail, longer dsRNAs are
digested into short (17-29 bp) dsRNA nts (also referred to as short inhibitory RNAs,
“siRNAs”) by type III RNAses (DICER, DROSHA, etc.; Bernstein et al., , 2001,
409(6818):363-6; Lee et al., Nature, 2003, 425(6956):415-9). The RISC n complex
izes these fragments and complementary mRNA. The whole s is culminated by
endonuclease cleavage of target mRNA (McManus & Sharp, Nature Rev Genet, 2002,
3(10):737-47; Paddison & Hannon, Curr Opin Mol Ther. 2003, 5(3):217-24). (For additional
information on these terms and proposed mechanisms, see for example Bernstein et al., RNA
2001, 7(11):1509-21; ura, Cell 2001, 107(4):415-8 and PCT publication WO
01/36646).
The selection and synthesis of dsRNA corresponding to known genes has been
widely reported; see for example Ui-Tei et al., J Biomed Biotechnol. 2006; 2006: 65052;
Chalk et al., BBRC. 2004, : 264-74; Sioud & Leirdal, Met. Mol Biol.; 2004, 252:457-
69; Levenkova et al., Bioinform. 2004, 20(3):430-2; Ui-Tei et al., Nuc. Acid Res. 2004,
32(3):936-48. For examples of the use of, and production of, modified dsRNA see Braasch
et al., Biochem., 2003, 42(26):7967-75; Chiu et al., RNA, 2003, 9(9):1034-48; PCT
publications (Atugen); WO 02/44321 (Tuschl et al), and US Patent Nos.
,898,031 and 6,107,094.
dsRNA synthesis
] Using proprietary algorithms and the known sequence of the target genes
disclosed herein, the sequences of many ial dsRNAs are generated. dsRNA molecules
according to the above specifications are prepared ially as described herein.
The dsRNA compounds disclosed herein are synthesized by any of the methods
that are well known in the art for synthesis of ribonucleic (or deoxyribonucleic)
_ 84 _
oligonucleotides. Such synthesis is, among others, described in Beaucage and Iyer,
Tetrahedron 1992; 3-2311; Beaucage and Iyer, Tetrahedron 1993; 49: 194 and
Caruthers, et. al., s Enzymol. 1987; 154: 287-313; the synthesis of thioates is, among
others, described in in, Ann. Rev. Biochem. 1985; 54: 367-402, the sis of RNA
molecules is described in Sproat, in Humana Press 2005 edited by Herdewijn P.; Kap. 2: 17-
31 and respective downstream processes are, among others, described in Pingoud et al., in
IRL Press 1989 edited by Oliver R.W.A.; Kap. 7: 183-208.
Other synthetic procedures are known in the art, e.g. the procedures described in
Usman et al., 1987, J. Am. Chem. Soc., 109, 7845; Scaringe et al., 1990, NAR., 18, 5433;
Wincott et al., 1995, NAR. 23, 2677-2684; and Wincott et al., 1997, Methods Mol. Bio., 74,
59, may make use of common nucleic acid protecting and coupling groups, such as
oxytrityl at the 5’-end, and phosphoramidites at the 3’-end. The modified (e.g. 2’-O-
methylated) nucleotides and unmodified nucleotides are incorporated as desired.
The oligonucleotides disclosed herein can be sized separately and joined
together post-synthetically, for example, by ligation (Moore et al., 1992, Science 256, 9923;
Draper et al., ational Patent Publication No. WO 69; Shabarova et al., 1991,
NAR 19, 4247; Bellon et al., 1997, Nucleosides & Nucleotides, 16, 951; Bellon et al., 1997,
Bioconjugate Chem. 8, 204), or by hybridization following synthesis and/or deprotection.
It is noted that a cially available machine (available, inter alia, from
Applied Biosystems) can be used; the oligonucleotides are prepared according to the
sequences disclosed herein. Overlapping pairs of chemically synthesized fragments can be
ligated using methods well known in the art (e. g., see US Patent No. 6,121,426). The strands
are sized separately and then are annealed to each other in the tube. Then, the double-
stranded RNAs are separated from the single-stranded oligonucleotides that were not
annealed (e.g. because of the excess of one of them) by HPLC. In relation to the dsRNAs or
dsRNA fragments disclosed herein, two or more such ces can be synthesized and
linked together for use herein.
The nds disclosed herein can also be synthesized via tandem synthesis
methodology, as described for example in US Patent Publication No. US 2004/0019001,
wherein both dsRNA strands are synthesized as a single contiguous oligonucleotide
fragment or strand separated by a cleavable linker which is subsequently cleaved to provide
separate RNA fragments or strands that hybridize and permit purification of the RNA
duplex. The linker is selected from a polynucleotide linker or a non-nucleotide linker.
Pharmaceutical itions
While it is possible for the compounds disclosed herein to be administered as the
raw chemical, it is preferable to present them as a pharmaceutical composition. ingly
disclosed herein is a pharmaceutical composition comprising one or more of the chemically
modified dsRNA compounds disclosed herein; and a pharmaceutically acceptable ent
or r. In some embodiments the pharmaceutical composition ses two or more
novel dsRNA compounds as disclosed herein.
Further disclosed herein is a pharmaceutical ition comprising at least one
double stranded RNA molecule ntly or non-covalently bound to one or more
compounds disclosed herein in an amount effective to inhibit the TLR2, TLR4, MYD88,
TICAMl and TIRAP genes; and a pharmaceutically acceptable r. In some
embodiments the dsRNA compounds are processed intracellularly by endogenous ar
complexes/enzymes to produce one or more molecules as disclosed herein.
Further disclosed herein is a pharmaceutical composition comprising a
pharmaceutically able carrier and one or more of the chemically modified dsRNA
compounds disclosed herein in an amount effective to inhibit expression in a cell of a target
gene, the nd comprising a sequence which is substantially complementary to the
sequence of target mRNA, set forth in SEQ ID NOS:1-12. red oligonucleotide
sequences useful in ting double-stranded nucleic acid molecules for therapeutic use
are set forth in SEQ ID NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44
(targeting TLR4), SEQ ID NOS:l2l45-l6332 (targeting MYD88), SEQ ID NOS:l6333-
18242 (targeting TICAMl) and SEQ ID NOS:18243-20606 (targeting TIRAP), and
preferably SEQ ID NOS:20607-20684.
In some embodiments, the dsRNA compounds disclosed herein are the main
active ent in a pharmaceutical composition. In other embodiments the dsRNA
compounds disclosed herein are one of the active components of a pharmaceutical
composition containing two or more dsRNAs, said pharmaceutical composition filrther being
comprised of one or more additional dsRNA molecule which targets the genes disclosed
herein. In other embodiments the dsRNA compounds disclosed herein are one of the active
ents of a pharmaceutical composition containing two or more dsRNAs, said
pharmaceutical composition fiarther being comprised of one or more additional dsRNA
molecule which targets one or more additional gene. In some embodiments, simultaneous
inhibition of the target gene by two or more dsRNA nds as disclosed herein provides
additive or synergistic effect for treatment of the diseases disclosed . In some
embodiments, simultaneous inhibition of for example TLR2 gene and TLR4 provides
additive or synergistic effect for treatment of the diseases disclosed herein.
In some embodiments, the dsRNA compounds disclosed herein are linked or
bound (covalently or non-covalently) to an antibody or aptamer t cell e
intemalizable molecules expressed on the target cells, in order to achieve enhanced targeting
for treatment of the conditions disclosed herein. In one specific embodiment, anti-Fas
antibody (preferably a neutralizing antibody) is combined (covalently or non-covalently)
with a double stranded RNA molecule, such as an siRNA as disclosed herein. In various
embodiments, an aptamer which acts like a /antibody is combined (covalently or non-
covalently) with a double stranded RNA molecule, such as an siRNA as disclosed herein.
Delivery
The chemically modified double stranded RNA molecule is administered as the
compound per se (e.g. as naked siRNA) or as pharmaceutically acceptable salt and is
administered alone or as an active ingredient in combination with one or more
pharmaceutically acceptable r, solvent, diluent, excipient, adjuvant and vehicle. In
some embodiments, the dsRNA molecules as disclosed herein are delivered to the target
tissue by direct application of the naked molecules prepared with a carrier or a t.
The term "naked siRNA" refers to siRNA molecules that are free from any
delivery vehicle that acts to assist, promote or tate entry into the cell, including viral
sequences, viral particles, liposome formulations, lipofectin or itating agents and the
like. For example, siRNA in PBS is "naked siRNA".
Delivery systems aimed specifically at the enhanced and improved delivery of
dsRNA into ian cells have been developed (see, for example, Shen et al FEBS Let.
539: 4 , Xia et al., Nat. Biotech. 20: 1006-1010 (2002), Reich et al., M01.
Vision 9: 210-216 (2003), Sorensen et al., J. Mol. Biol. 327: 761-766 (2003), Lewis et al.,
Nat. Gen. 32: 107-108 (2002) and Simeoni et al., NAR 31, 11: 2717-2724 (2003)). siRNA
has recently been successfully used for inhibition of gene expression in primates (see for
e, Tolentino et al., Retina 2004. 24(1):132-138).
] Pharmaceutically acceptable carriers, solvents, diluents, excipients, adjuvants
and vehicles generally refer to inert, non-toxic solid or liquid fillers, diluents or
encapsulating material not reacting with the active siRNA compounds disclosed herein. For
example, the siRNA compounds sed herein may be formulated with polyethylenimine
(PEI), with PEI tives, e.g. oleic and stearic acid modified derivatives of branched PEI,
with chitosan or with poly(lactic-co-glycolic acid) (PLGA). Formulating the compositions in
e. g. liposomes, micro- or nano-spheres and nanoparticles, may enhance stability and t
absorption.
] Additionally, the itions may include an artificial oxygen carrier, such as
perfluorocarbons (PFCs) e. g. perfluorooctyl bromide (perflubron), since different respiratory
treatment ties (e.g., liquid ventilation or aerosolized PFCs) have been shown to
decrease pulmonary inflammatory responses in addition to improving lung compliance in
animal models of lung injury and in clinical trials (Lehmler HJ. 2008. Expert Review of
Respiratory Medicine, vol. 2, No. 2: 273-289).
Examples of delivery systems as disclosed herein e US. Patent Nos.
,225,182; 5,169,383; 5,167,616; 4,959,217; 4,925,678; 4,487,603; 4,486,194; 4,447,233;
4,447,224; 4,439,196; and 4,475,196. Many such delivery systems, and modules are well
known to those skilled in the art. In specific embodiments, formulations for inhalation are
selected.
Accordingly, in some embodiments the siRNA molecules disclosed herein are
delivered in liposome formulations and lipofectin formulations and the like and are ed
by methods well known to those skilled in the art. Such methods are described, for example,
in US. Pat. Nos. 5,593,972, 5,589,466, and 859, which are herein orated by
reference.
Additional formulations for improved delivery of the compounds as sed
herein can include conjugation of siRNA molecules to a targeting molecule. The conjugate is
y formed through a covalent attachment of the targeting molecule to the sense strand of
_ 88 _
the siRNA, so as not to disrupt silencing activity. Potential targeting molecules useful herein
include proteins, peptides and aptamers, as well as natural compounds, such as e.g.
cholesterol. For targeting dies, conjugation to a protamine fusion protein has been used
(see for example: Song et al., Antibody mediated in Vivo delivery of small interfering RNAs
Via cell-surface receptors, Nat Biotechnol. 2005. 23(6):709-l7).
The naked siRNA or the pharmaceutical itions comprising the chemically
modified siRNA as disclosed herein are administered and dosed in accordance with good
medical practice, taking into t the clinical condition of the indiVidual patient, the
disease to be treated, the site and method of administration, scheduling of administration,
patient age, sex, body weight and other factors known to medical practitioners.
A peutically effective dose" for purposes herein is thus determined by such
considerations as are known in the art. The dose must be effective to achieve improvement
including but not limited to improved survival rate or more rapid recovery, or improvement
or elimination of symptoms and other indicators as are selected as appropriate es by
those skilled in the art. The siRNA disclosed herein can be administered in a single dose or
in multiple doses.
In general, the active dose of a dsRNA compound for humans is in the range of
from lng/kg to about 20-100 mg/kg body weight per dose, preferably about 0.01 mg to about
2-10 mg/kg body weight per dose, in a regimen of a single dose or a series of doses given at
short (e.g. l-5 minute) intervals, administered within several minutes to several hours after
perfusion.
The chemically modified dsRNA compounds as sed herein are
administered by any of the conventional routes of administration. The chemically modified
dsRNA compounds are administered orally, subcutaneously or parenterally including
enous, intraarterial, intramuscular, intraperitoneally, cular, intracoronary,
transtympanic and asal administration as well as intrathecal and infusion techniques.
Implants of the compounds are also useful.
] Liquid forms are prepared for invasive administration, e.g. ion or for
topical or local administration. The term injection includes subcutaneous, transdermal,
intravenous, intramuscular, intrathecal, intraocular, transtympanic and other parental routes
of administration. The liquid compositions include s ons, with and without
_ 89 _
c co-solvents, aqueous or oil suspensions, emulsions with edible oils, as well as
similar pharmaceutical vehicles.
In embodiments wherein the subject has undergone lung transplantation,
therapeutic compounds and compositions as disclosed herein are preferably administered
into a of the subject by inhalation of an aerosol containing these compositions / compounds,
by intranasal or racheal lation of said compositions or by inhalation via ventilation
machine (e.g. for administration to an unconscious patient). In some embodiments the
siRNA compounds as sed herein are administered by inhalation into the lung of a
subject who has undergone lung lantation. For fiarther information on pulmonary
delivery of pharmaceutical itions see Weiss et al., Human Gene Therapy 1999.
:2287-2293; Densmore et al., Molecular y 1999. 1:180-188; Gautam et al.,
Molecular Therapy 2001. 3551-556; and Shahiwala & Misra, AAPS PharmSciTech 2004.
24;6(3):E482-6. Additionally, respiratory formulations for siRNA are described in US.
Patent Application ation No. 2004/0063654. Respiratory formulations for siRNA are
described in US Patent Application Publication No. 2004/0063654. International Patent
Publication No. WC 2008/132723 to the assignee of the present invention, and hereby
orated by reference in its entirety discloses therapeutic delivery of siRNA to the
respiratory system.
In some embodiments, the chemically modified dsRNA compounds as disclosed
herein are formulated for systemic delivery for example by intravenous administration.
In addition, in certain embodiments the compositions for use in the novel
treatments disclosed herein are formed as aerosols, for example for intranasal stration.
In certain embodiments the compositions for use in the novel treatments sed herein are
formed as nasal drops, for example for intranasal instillation.
s of Treatment
In one aspect disclosed herein is a method of treating a subject suffering from a
posttransplantational complication, injury or condition ated with TLR2, TLR4,
MYD88, TICAMl and TIRAP expression or ty comprising administering to the subject
a therapeutically effective amount of an siRNA compound as disclosed herein. In preferred
embodiments the subject being treated is a warm-blooded animal and, in particular, mammal
including human.
"Treating a subject" refers to administering to the subject a therapeutic substance
ive to ameliorate symptoms associated with a condition, a complication or an injury, to
lessen the severity or cure the condition, or to prevent the condition from ing.
"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures,
wherein the object is to t a condition, a complication or an injury or reduce the
symptoms f. Those in need of treatment include those already experiencing the
condition, those prone to having the condition, and those in which the condition is to be
prevented. The compounds disclosed herein are administered before, during or subsequent to
the onset of the condition. In various embodiments the subject is being treated after organ
transplantation (such as lung transplantation) for a condition, a complication or an injury
selected from, without being limited to, chronic or acute aseptic inflammation, neuropathic
pain, primary graft failure, ischemia-reperfusion injury, reperfiasion injury, reperfusion
edema, allograft dysfunction, pulmonary reimplantation response and/or primary graft
dysfunction (PGD).
A “therapeutically effective dose” refers to an amount of a pharmaceutical
compound or composition which is effective to achieve an improvement in a subject or his
physiological s including, but not limited to, improved survival rate, more rapid
recovery, or improvement or elimination of symptoms, and other indicators as are selected as
appropriate determining measures by those skilled in the art.
The methods of ng the diseases disclosed herein e administering a
TLR2, TLR4, MYD88, TICAMl and TIRAP dsRNA inhibitor in ction or in
combination with an additional inhibitor, a substance which improves the cological
properties of the active ingredient (e.g. siRNA) as detailed below, or an additional compound
known to be effective in the treatment of a subject suffering from or susceptible to any of the
hereinabove mentioned conditions, complications and ers (e.g. immunosuppressants).
In another aspect, provided herein is a combination of a eutic double stranded RNA
le together with at least one additional therapeutically active agent. Additionally, the
ed is a method of down-regulating the expression of a target gene by at least 40% as
compared to a control, comprising contacting a target gene mRNA with one or more of the
ally modified RNA nds as disclosed herein.
In one embodiment the chemically d dsRNA compound as disclosed
herein ts or down-regulates the mammalian TLR2, TLR4, MYD88, TICAMl and
TIRAP gene whereby the inhibition or down-regulation is selected from the group
comprising inhibition of down-regulation of gene fianction, inhibition or down-regulation of
polypeptide and tion and down-regulation ofmRNA sion.
Disclosed herein is a method of inhibiting the expression of the TLR2, TLR4,
MYD88, TICAMl and TIRAP gene by at least 40%, preferably by 50%, 60% or 70%, more
preferably by 75%, 80% or 90% as compared to a control comprising contacting an mRNA
transcript of the TLR2, TLR4, MYD88, TICAMl and TIRAP gene with one or more of the
dsRNA compounds disclosed .
In one embodiment the effect of inhibition by the chemically modified siRNA
compound disclosed herein is determined by examining siRNA effect on the mRNA or on
the corresponding protein whereby the inhibition is selected from the group consisting of
inhibition of function (which is examined by, for example, an enzymatic assay or a binding
assay with a known interactor of the native gene / polypeptide, inter alia), inhibition of
protein (which is examined by, for example, n blotting, ELISA or immuno-
itation, inter alia) and inhibition of target gene mRNA expression (which is examined
by, for example, Northern blotting, quantitative RT-PCR, in-situ hybridization or microarray
hybridization, inter alia).
In one ment the chemically ed double stranded RNA molecule is
down-regulating the TLR2, TLR4, MYD88, TICAMl and TIRAP gene or polypeptide,
whereby the down-regulation is selected from the group consisting of down-regulation of
function (which is ed by, for example, an enzymatic assay or a binding assay with a
known interactor of the native gene / polypeptide, inter alia), down-regulation of protein
(which is ed by, for example, Western blotting, ELISA or immuno-precipitation,
inter alia) and down-regulation of target gene mRNA expression (which is examined by, for
example, Northern blotting, quantitative RT-PCR, in-situ hybridization or microarray
hybridization, inter alia).
In additional embodiments there is provided a method of treating a t after
organ transplantation (such as lung transplantation), wherein the subject is suffering from or
susceptible to any condition, complication or er accompanied by an elevated level of a
mammalian TLR2, TLR4, MYD88, TICAMl and TIRAP gene, the method comprising
administering to the subject a ally modified siRNA compound or composition as
disclosed herein in a therapeutically effective dose thereby treating the subject.
Provided herein is the use of a compound which down-regulates the expression
of a mammalian gene selected from TLR2, TLR4, MYD88, TICAMl and TIRAP gene,
ularly to novel small interfering RNAs (siRNAs), in the treatment of chronic or acute
aseptic inflammation, neuropathic pain, primary graft e, ischemia-reperfusion injury,
reperfilsion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation
se and/or y graft dysfunction (PGD) in which inhibition of the expression of
the mammalian TLR2, TLR4, MYD88, TICAMl and TIRAP gene is beneficial.
Methods, novel ally modified dsRNA les and ceutical
itions comprising said dsRNA compounds which t a mammalian TLR2, TLR4,
MYD88, TICAMl and TIRAP gene or polypeptide expression are sed herein at
length, and any of said dsRNA molecules and/or pharmaceutical compositions are
beneficially employed in the treatment of a subject suffering from or susceptible to any of
said conditions. It is to be explicitly understood that known compounds are excluded from
the present invention. Novel methods of treatment using known nds and
compositions fall within the scope of the present invention.
The method disclosed herein includes stering a therapeutically effective
amount of one or more of the chemically modified dsRNA compounds disclosed herein
which down-regulate expression of a TLR2, TLR4, MYD88, TICAMl and TIRAP gene.
Also disclosed herein is a process of preparing a pharmaceutical composition,
which comprises:
providing one or more chemically modified double stranded RNA molecule; and
admixing said compound with a pharmaceutically acceptable carrier.
In a preferred embodiment, the dsRNA compound used in the preparation of a
pharmaceutical composition is admixed with a carrier in a pharmaceutically effective dose.
In one embodiment the chemically modified dsRNA compound as disclosed herein is
conjugated to a steroid or to a lipid or to another suitable targeting le e. g. to protein,
peptide, aptamer, natural compound (e.g. cholesterol, xylose).
2012/027174
Combination Therapy
The methods of treating the diseases disclosed herein include stering a
novel chemically modified double stranded RNA molecule in conjunction or in combination
with an additional TLR2, TLR4, MYD88, TICAMl and TIRAP inhibitor, a nce which
improves the pharmacological properties of the chemically modified dsRNA compound, or
an additional compound known to be effective in the treatment of a subject suffering from or
susceptible to a cation or injury post organ lantation, for example lung
transplantation, such as, without being limited to, primary graft failure, ischemia-reperfusion
injury, reperfusion injury, reperfilsion edema, aft dysfilnction, pulmonary
reimplantation response and/or primary graft dysfunction (PGD), chronic or acute aseptic
inflammation, or neuropathic pain.
In another aspect, provided herein is a pharmaceutical composition comprising a
combination of a therapeutic double stranded RNA molecule together with at least one
additional therapeutically active agent. By “in conjunction with” or “in combination with” is
meant prior to, simultaneously or subsequent to. Accordingly, the individual components of
such a combination are administered either sequentially or simultaneously from the same or
separate pharmaceutical formulations.
Combination therapies comprising known ents for ng a subject prone
to a complication or injury post organ transplantation, for example, lung lantation,
such as, without being limited to, primary graft failure, ia-reperfusion injury,
reperfilsion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation
se and/or primary graft dysfunction (PGD), in conjunction with the novel chemically
modified dsRNA compounds and therapies described herein are considered part of the
current invention. Such known ents include, without being limited to, pharmacological
immunosuppression.
In addition, the dsRNA compounds disclosed herein are used in the preparation
of a medicament for use as adjunctive therapy with a second therapeutically active
compound (e.g. immunosuppressive agent) to treat such ions. Appropriate doses of
known second therapeutic agent for use in combination with a chemically modified double
stranded RNA molecule are readily appreciated by those d in the art.
In some embodiments the combinations ed to above are presented for use in
_ 94 _
the form of a single pharmaceutical formulation.
] The administration of a pharmaceutical composition comprising any one of the
pharmaceutically active siRNA compounds disclosed herein is carried out by any of the
many known routes of stration, including intravenously, intra-arterially, by intranasal
or intratracheal instillation or by inhalation as determined by a d practitioner. Using
specialized formulations, it is le to administer the compositions intracoronary, via
inhalation or via intranasal instillation.
By “in ction with” is meant that the additional pharmaceutically effective
compound is administered prior to, at the same time as, or subsequent to administration of
the pharmaceutical itions of present invention. The individual components of such a
combination referred to above, therefore, are administered either sequentially or
simultaneously from the same or separate pharmaceutical formulations. As is the case for the
present siRNA compounds, a second eutic agent is administered by any as detailed
above, for example, but not limited to oral, buccal, inhalation, sublingual, rectal, vaginal,
transurethral, nasal, topical, aneous (i.e., transdermal), or parenteral (including
enous, intramuscular, subcutaneous, and intracoronary) administration.
In some embodiments, a chemically modified double stranded RNA molecule
disclosed herein and the second therapeutic agent are administered by the same route, either
provided in a single composition or as two or more different pharmaceutical compositions.
However, in other embodiments, a ent route of administration for the novel double
stranded RNA molecule disclosed herein and the second therapeutic agent is possible.
Persons d in the art are aware of the best modes of administration for each therapeutic
agent, either alone or in combination.
] In another aspects, provided herein is a pharmaceutical composition comprising
two or more dsRNA molecules for the treatment of any of the cations and conditions
mentioned herein. In some embodiments the two or more dsRNA molecules or formulations
comprising said molecules are admixed in the ceutical composition in amounts which
generate equal or otherwise beneficial activity. In certain embodiments the two or more
dsRNA molecules are covalently or non-covalently bound, or joined together by a nucleic
acid linker of a length ranging from 2-100, preferably 2-50 or 2-30 nucleotides. In one
embodiment, the two or more dsRNA molecules target mRNA to TLR2, TLR4, MYD88,
TICAMl and TIRAP. In some embodiments at least one of the two or more dsRNA
compounds target TLR2, TLR4, MYD88, TICAMl and TIRAP RNA. In some embodiments
at least one of the RNA compounds ses an antisense sequence ntially identical
to an antisense sequence set for the in any one of SEQ ID NOS: 13-20606. In some
embodiments the dsRNA sense and nse oligonucleotides are selected from sense and
corresponding ementary) antisense oligonucleotides set forth in any one of SEQ ID
NOS: 13-20606. Preferred sense and antisense oligonucleotide pairs are set forth in Tables 1-
, herein below.
In some embodiments the pharmaceutical compositions disclosed herein further
comprise one or more additional dsRNA molecule, which s one or more additional
gene. In some embodiments, simultaneous inhibition of said additional gene(s) provides an
additive or synergistic effect for treatment of the complication, injury or er disclosed
herein.
The ent regimen disclosed herein is carried out, in terms of administration
mode, timing of the administration, and dosage, so that the functional recovery of the patient
from the adverse consequences of the ions disclosed herein is improved.
In some embodiments the pharmaceutical compositions disclosed herein further
comprise one or more additional dsRNA molecule, which targets one or more additional
gene. In some embodiments, simultaneous tion of said additional gene(s) es an
additive or synergistic effect for treatment of the diseases disclosed herein.
[003 83] The treatment regimen disclosed herein is carried out, in terms of administration
mode, timing of the administration, and dosage, so that the functional recovery of the patient
from the adverse consequences of the conditions disclosed herein is improved or so as to
postpone the onset of a disorder. ive concentrations of individual nucleic acid
molecule in a cell may be about 1 femtomolar, about 50 femtomolar, 100 femtomolar, l
picomolar, l.5 picomolar, 2.5 picomolar, 5 picomolar, 10 picomolar, 25 picomolar, 50
picomolar, 100 picomolar, 500 picomolar, l nanomolar, 2.5 nanomolar, 5 nanomolar, 10
nanomolar, 25 nanomolar, 50 nanomolar, 100 nanomolar, 500 nanomolar, l micromolar, 2.5
micromolar, 5 micromolar, 10 micromolar, 100 micromolar or more.
] An appropriate dosage for a mammal may be from 0.01 mg to l g per kg of body
weight (e.g., 0.1 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg,
_ 96 _
100 mg, 250 mg, 500 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 250 mg, or
500 mg per kg).
Dosage levels of from about 0.01 mg to about 100 mg per kilogram of body
weight per day are useful in the treatment of the above-indicated conditions. The amount of
active ingredient that can be ed with a carrier to produce a single dosage form varies
depending upon the host treated and the particular mode of administration. Dosage unit
forms generally contain between from about 0.1 mg to about 500 mg of an active ingredient.
Dosage units may be ed for local delivery, for e for intravitreal delivery of for
transtympanic delivery.
Kits
In another aspect a kit is provided comprising a therapeutic agent consisting of a
double-stranded c acid that targets TLR2; optionally with instructions for use. In some
embodiments the -stranded nucleic acid that targets TLR2 comprises a
oligonucleotide having a sequence set forth in SEQ ID NOS: 13-5 846.
In another aspect a kit is provided comprising a therapeutic agent consisting of a
double-stranded nucleic acid that s TLR4; optionally with instructions for use. In some
embodiments the double-stranded nucleic acid that targets TLR4 comprises a
oligonucleotide having a sequence set forth in SEQ ID NOS:5847-12144.
In another aspect a kit is provided comprising a therapeutic agent ting of a
double-stranded nucleic acid that targets MYD88; optionally with instructions for use. In
some embodiments the double-stranded nucleic acid that targets MYD88 comprises a
oligonucleotide having a sequence set forth in SEQ ID NOS: 12145-16332 .
[003 89] In r aspect a kit is provided comprising a therapeutic agent consisting of a
double-stranded nucleic acid that targets TICAMl; optionally with instructions for use. In
some ments the double-stranded nucleic acid that targets TICAMl comprises a
oligonucleotide having a sequence set forth in SEQ ID NOS: 16333-18242.
In another aspect a kit is provided comprising a therapeutic agent consisting of a
double-stranded nucleic acid that targets TIRAP; optionally with instructions for use. In
some embodiments the -stranded nucleic acid that targets TIRAP comprises a
ucleotide having a sequence set forth in SEQ ID NOS:l8243-20606.
_ 97 _
] In another aspect ed is a kit comprising at least two therapeutic agents
wherein the two agents are selected from the group consisting of a TLR2 inhibitor, a TLR4
inhibitor, a MYD88 inhibitor, a TICAMl inhibitor and a TIRAP inhibitor; optionally with
instructions for use.
In some embodiments of the kit each therapeutic agent is independently selected
from the group consisting of a short ering nucleic acid (siNA), a short interfering RNA
(siRNA), a double-stranded RNA (dsRNA), a micro-RNA (miRNA) or short n RNA
(shRNA) that binds a nucleotide sequence (such as an mRNA sequence) encoding the target
gene selected from TLR2, TLR4, MYD88, TICAMl and TIRAP. In some embodiments
each nucleic acid le is a double-stranded RNA (dsRNA) or a short interfering RNA
(siRNA). In some embodiments each nucleic acid molecule is selected from the group
consisting of a dsRNA targeting TLR2, TLR4, MYD88, TICAMl and TIRAP. In some
ments the kit provided herein comprises a combined inhibitor by which it is meant a
single agent which is capable of ting at least two genes and/or gene products selected
from the group consisting of TLR2, TLR4, MYD88, TICAMl and TIRAP; optionally with
instructions for use.
In some embodiments each therapeutic agent of the kit comprises a nucleic acid
molecule, wherein:
(a) the nucleic acid molecule includes a sense strand and an antisense strand;
(b) each strand of the nucleic acid molecule is ndently 17 to 40 nucleotides in
length;
(c) a 17 to 40 nucleotide sequence of the antisense strand is complementary to a
sequence of an mRNA selected from an mRNA encoding TLR2, TLR4, MYD88, TICAMl
or TIRAP
(d) a 17 to 40 nucleotide sequence of the sense strand is mentary to the
antisense strand and includes a 17 to 40 nucleotide sequence of a mRNA selected from a
mRNA encoding TLR2, TLR4, MYD88, TICAMl or TIRAP
tions
Lung Injupv_, Lung Ischemia Reperfusion Injupv_
Lung transplantation
Lung transplantation is a surgical procedure in which a patient's diseased lungs
are partially or totally ed by lungs which come from a donor. Lung transplantation has
become a treatment of choice for patients with advanced / end-stage lung diseases. Within
last decades, donor management, organ preservation, immunosuppressive regimens and
control of infectious complications have been ntially improved and the operative
techniques of transplantation procedures have been developed. Nonetheless, primary graft
dysfunction (PGD) affects an estimated 10 to 25% of lung lants and is the g
cause of early post-transplantation morbidity and ity for lung recipients (Lee JC and
Christie JD. 2009. Proc Am Thorac Soc, vol. 6: 39-46). PGD has variably been referred to as
primary graft failure, ischemia-reperfilsion injury, reperfusion injury, reperfusion edema,
allograft dysfunction, and pulmonary reimplantation se. In addition, there is some
evidence to suggest a relationship between reperfiJsion injury, acute rejection, and the
subsequent development of c graft dysfianction.
ive oligonucleotide based therapies useful in preventing or treating c
or acute aseptic inflammation, neuropathic pain, primary graft failure, ischemia-reperfusion
injury, reperfusion injury, reperfiasion edema, allograft dysfilnction, pulmonary
reimplantation response and/or primary graft dysfianction (PGD) after organ transplantation,
in particular in lung transplantation, would be ofgreat therapeutic value.
In various embodiments the chemically modified dsRNA nds disclosed
herein are useful for treating or preventing complications or injury post lung transplantation,
such as, without being limited to, chronic or acute aseptic inflammation, athic pain,
primary graft e, ischemia-reperfilsion injury, reperfusion injury, reperfusion edema,
allograft dysfilnction, ary reimplantation response and/or primary graft dysfianction
(PGD).
The term “lung transplantation” is meant to encompass a surgical procedure in
which a patient's diseased lungs are partially or totally replaced by lungs which come from a
donor. Although a xenotransplant can be contemplated in certain ions, an allotransplant
is y preferable.
Indications for lung transplantation e chronic obstructive pulmonary
disease (COPD), pulmonary hypertension, cystic fibrosis, idiopathic pulmonary fibrosis, and
enger syndrome. Typically, four different surgical techniques are used: single-lung
transplantation, bilateral sequential transplantation, combined heart-lung transplantation, and
lobar transplantation, with the majority of organs obtained from deceased donors.
The dsRNA compounds disclosed herein are particularly useful in treating a
subject experiencing a medical complication of lung transplantation, including, t
being limited to, ameliorating, attenuating, treating or preventing any of the following:
chronic or acute c inflammation, neuropathic pain, y graft failure, ia-
reperfilsion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary
reimplantation response and/or primary graft dysfunction (PGD).
In some embodiments the target gene is ed from MYD88, TICAMl, TLR2,
TLR4 and TIRAP. In yet other embodiments the sense and nse oligonucleotide
sequences useful in synthesizing siRNA compounds are set forth in set forth in SEQ ID
NOS:l3-5846 (targeting TLR2), SEQ ID NOS:5847-l2l44 ting TLR4), SEQ ID
NOS:lZl45-l6332 (targeting MYD88), SEQ ID 333-18242 ting TICAMl)
and SEQ ID NOS:18243-20606 (targeting TIRAP) .
Acute Lung Injury (ALI)/ Acute Respiratory Distress Syndrome (ARDS)
] Acute respiratory distress syndrome (ARDS), also known as respiratory distress
syndrome (RDS) is a serious reaction to various forms of injuries to the lung. This is the
most relevant disorder resulting in increased permeability pulmonary edema
ARDS is a severe lung disease caused by a variety of direct and indirect insults.
It is characterized by inflammation of the lung parenchyma g to impaired gas
ge with concomitant systemic release of inflammatory mediators which cause
inflammation, hypoxemia and frequently result in failure of multiple organs. This condition
is life threatening and often lethal, usually requiring mechanical ventilation and ion to
an intensive care unit. A less severe form is called acute lung injury (ALI).
In some embodiments the molecules and methods disclosed herein are useful for
treating or preventing the incidence or severity of acute lung injury, in particular conditions
which result from ischemic/reperfusion injury or oxidative stress. For example, acute
atory distress syndrome (ARDS) due to coronavirus infection or endotoxins, severe
acute respiratory syndrome (SARS), ischemia reperfusion injury associated with lung
transplantation and other acute lung injuries.
Inflammatom conditions
Inflammatory conditions where the present nds find use are asthmatic
conditions, Crohn's disease, ulcerous colitis, reperfusion injury, auto-immune diseases,
inflammatory bowel disease (IBD), atherosclerosis, restenosis, coronary heart disease,
diabetes, rheumatoidal diseases, ological diseases, such as psoriasis and seborrhea,
graft rejection, and inflammation of the lungs, heart, kidney, oral cavity, uterus.
Neuropathic pain
Neuropathic pain is complex, c pain state often accompanied by tissue
injury or dysfunction. Neuropathic pain may occur due to lesions or diseases affecting the
somatosensory system and is chacterized by hyperalgesia, spontaneous pain and allodynia.
nia is pain in se to a nonnociceptive stimulus or pain due to a us which
does not normally e a pain response and can be elicited as a hypersensitivity to either
thermal or mechanical stimuli that are not normally sensed as pain.
Neuropathic pain may be caused by spinal cord injury (SCI), or injury of
eral nerves (PNI), dorsal root ganglions or the brain. In humans, chronic pain elicited
as g, stabbing and/or electric-like sensations can develop within months after .
r cause of neuropathic pain is diabetes mellitus. Diabetic athy is one of the
most common complications of diabetes mellitus and allodynia is one of its symptoms.
Additional causes of neuropathic pain include herpes zoster infection, HIV-related
neuropathies, limb amputation, nutritional deficiencies, toxins, genetic and immune
mediated disorders. Neuropathic pain may appear in cancer patients due to tumors ng
on peripheral nerves or as a side effect of treatment (e.g. chemotherapy with taxanes).
Allodynia and Spinal Cord Injug [SCI]
Chronic pain is one of the more frequent and troublesome sequelae of SCI, often
interfering with the effective rehabilitation of the patient. In addition to the chronic pain
-lOl-
syndromes seen in the non-SCI population, e.g., migraine and postherpetic neuralgia,
patients with SCI may also suffer from pain syndromes unique to SCI. The reported
prevalence of chronic SCI pain varies between 25% and 94%, with almost one-third of these
patients experiencing severe pain (Bonica I]. Introduction: semantic, epidemiologic, and
educational . In: Casey KL, ed. Pain and l nervous system disease: the central
pain syndromes. New York: Raven Press, 1991:13—29; Siddall P], et al. Pain 1999;81:187—
97; Gerhart KA, et al. Paraplegia 1992;30:282—7). Several s have reported the
prevalence of the various types of SCI pain. Musculoskeletal pain was the most common
type experienced at 6 mo after injury (40%) ll PJ, Pain 1999;81:187—97) and at 5 yr
after SCI (59%) (Siddall P], et al. Pain 2003;] 03:249—5 7). An increase in the prevalence of
at-level and below-level neuropathic pain has likewise been observed more than 5 yr after
SCI. Variables that influence the pment of SCI pain remain unclear. Factors such as
the level of the injury, completeness of the injury, cause of injury, and psychosocial factors
have been considered (Siddall P], et al. In: Yezierski RP, Barchiel KJ, eds. Spinal cord
injury pain: assessment, isms, management. Progress in Pain Research and
Management. V01. 23 e: [ASP Press, 2002:9—24). Musculoskeletal pain was more
common in patients with thoracic level injuries and was reported to be more prevalent in
those who had surgical intervention 2 wk after SCI (Sved P, et al. Spinal Cord 1997;35:526—
). athic pain that was associated with allodynia was observed to be more common
in patients with incomplete spinal cord lesions, in cervical than thoracic cord injuries, and in
central cord syndrome (Siddall P], et al. Pain 1999;81:187—97).
Post-SCI Pain Types
In addition to the four major types of SCI pain under Tier 2, there are other
recognized pain conditions, most of which are under Tier 3 in the International ation
for the Study of Pain Taxonomy (Siddall P], et al. International Association for the Study of
Pain Newsletter 2000;3.‘3—7). These need to be clinically identified so that appropriate
treatment may be instituted.
Musculoskeletal Pain
Mechanical instability of the spine: This type of pain is brought about by
disruption of ligaments/joints or res of bone, resulting in instability of the spine. It
occurs early after injury and is located in the region of the spine close to the site of SCI. It is
related to position, worsened by activity and decreased by rest. sis is aided by
radiographs, computerized aphy or MRI to identify the nature and site of pathology.
Muscle spasm pain: Spasticity is defined as a motor disorder characterized by a
ty-dependent increase in the tonic stretch reflexes (muscle tone) with exaggerated
tendon reflexes, resulting from xcitability of the stretch reflex. An imbalance in any of
the numerous excitatory and inhibitory modulatory synaptic influences on the or motor
neuron and muscle results in hyperactivity of the stretch reflex arc. This pain type usually
occurs late after SCI, and is often seen in people with incomplete SCI.
At-Level Neuropathic Pain
Segmental deafferentation/Girdle or Border or transitional zone pain: This is a
variation of el athic pain that occurs within a band of two to four segments
above or below the level of SCI. It often occurs on the border of normal sensation and
anesthetic skin.
Syringomyelia: Pain due to a syrinx (i.e., an abnormal cyst in the spinal cord)
often occurs with a delayed onset, a mean of 6 yr. The damage to the central part of the
spinal cord with cervical es results in the central cord syndrome characterized by pain
and weakness of the arms and relatively strong but spastic leg function. The pain of
syringomyelia is sometimes described as a constant burning pain with allodynia.
Below-Level Neuropathic Pain
] Central dysaesthesia syndrome/central pain/deafferentation pain: pain diffilsely
located caudal to the level of SCI, i.e., over the entire body from the shoulders to the feet,
typical of below-level athic pain. The pain may be associated with lgesia and
may gradually worsen over time. It occurs with spontaneous and/or evoked episodes, and is
often worsened by infections, sudden noise, and jarring movements.
Pathophysiology and isms of SCI Pain
Pain associated with SCI is a consequence of both injury characterized by
pathological changes from mechanical trauma and vascular compromise of the cord
parenchyma. It is influenced by the nature of the lesion, the neurological structures damaged,
and the secondary pathophysiological changes of the ing tissue. There are at least three
proposed basic mechanisms underlying SCI pain: increased neuronal hyperexcitability,
reduced inhibition, and neuronal reorganization or plasticity.
Increased Neuronal Hyperexcitability
An initial consequence of SCI after traumatic or ischemic SCI is the brief but
dramatic increase of excitatory amino acids, which rs an injury cascade of secondary
pathological changes. The major components of this spinal “central injury cascade” include
anatomical, neurochemical, excitotoxic, and inflammatory events that collectively interact to
increase the responsiveness of the neurons at the level of , resulting in the generation
of the clinical symptoms of allodynia and hyperalgesia (Yezierski RP. Pathophysiology and
animal models of spinal cord injury pain. In: Yezierski RP, Barchiel KJ, eds. Spinal cord
injury pain: assessment, mechanisms, management. ss in pain research and
management. Vol. 23. Seattle: [ASP Press, 2002:117—36).
Periodontitis
Periodontitis occurs when inflammation or infection of the gums is left untreated
or treatment is delayed. Infection and inflammation spreads from the gingiva to the
ligaments and bone that support the teeth, ultimately resulting in tooth loss. Inflammation
caused by plaque and tartar accumulating at the base of the teeth traps the plaque in a pocket
that forms between the teeth and the gingiva. Continued inflammation eventually causes
destruction of the tissues and bone surrounding the tooth.
Synthesis of d compounds
The compounds disclosed herein can be synthesized by any of the methods that
are well known in the art for synthesis of ribonucleic (or deoxyribonucleic) ucleotides.
Such synthesis is, among others, bed in Beaucage and Iyer, Tetrahedron 1992;
48:2223-2311; Beaucage and Iyer, Tetrahedron 1993; 49: 6123-6194 and Caruthers, et. al.,
Methods Enzymol. 1987; 154: 287-313; the synthesis of thioates is, among others, described
in in, Annu. Rev. Biochem. 1985; 54: 367-402, the synthesis of RNA les is
bed in Sproat, in Humana Press 2005 edited by Herdewijn P.; Kap. 2: 17-31 and
tive downstream processes are, among others, described in d et. al., in IRL
Press 1989 edited by Oliver R.W.A.; Kap. 7: 183-208.
Other tic procedures are known in the art e. g. the procedures as described
in Usman et al., J. Am. Chem. Soc., 1987, 45; Scaringe et al., NAR, 1990, 18:5433;
Wincott et al., NAR 1995. 23:2677-2684; and Wincott et al., s Mol. Bio., 1997,
74:59, and these procedures may make use of common nucleic acid protecting and coupling
groups, such as dimethoxytrityl at the 5’-end, and phosphoramidites at the . The
modified (e.g. 2’-O-methylated) nucleotides and unmodified nucleotides are orated as
desired.
The oligonucleotides disclosed herein can be synthesized separately and joined
together post-synthetically, for example, by ligation (Moore et al., Science 1992, 256:9923;
International Patent Publication No. WO 93/23569; Shabarova et al., NAR 1991, 19:4247;
Bellon et al., Nucleosides & Nucleotides, 1997, 16:951; Bellon et al., Bioconjugate Chem
1997, 8:204), or by hybridization following synthesis and/or deprotection.
It is noted that a commercially ble machine (available, inter alia, from
Applied Biosystems) can be used; the oligonucleotides are prepared according to the
sequences disclosed herein. Overlapping pairs of chemically synthesized nts can be
ligated using methods well known in the art (e. g., see US Patent No. 6,121,426). The strands
are synthesized tely and then are annealed to each other in the tube. Then, the double-
stranded oligonucleotides are separated from the single-stranded oligonucleotides that were
not annealed (e. g. because of the excess of one of them) by HPLC. In relation to the siRNAs
or siRNA fragments disclosed , two or more such sequences can be synthesized and
linked together for use herein.
The compounds as disclosed herein can also be synthesized via tandem synthesis
methodology, as described for example in US Patent Publication No. 019001
(McSwiggen), wherein both dsRNA s are synthesized as a single contiguous
oligonucleotide fragment or strand separated by a cleavable linker which is subsequently
cleaved to e separate RNA fragments or strands that hybridize and permit purification
of the RNA duplex. The linker is selected from a polynucleotide linker or a non-nucleotide
linker.
The term “Covalent bonding” as used herein refers to chemical bonding that is
characterized by the g of pairs of electrons between atoms.
The term “noncovalent bonding” as used herein refers to a variety of interactions
that are not nt in nature between molecules or parts of molecules that provide force to
hold the molecules or parts of molecules er, usually in a specific orientation or
conformation. These noncovalent interactions include: ionic bonds, hydrophobic
interactions, hydrogen bonds, Van der Waals forces and dipole-dipole bonds.
EXAMPLES
Without r elaboration, it is believed that one skilled in the art can, using the
preceding description, utilize the present invention to its filllest extent. The following
preferred specific ments are, therefore, to be construed as merely rative, and not
limitative of the claimed invention in any way.
Standard molecular biology protocols known in the art not specifically described
herein are generally followed essentially as in Sambrook et al., Molecular cloning: A
laboratory manual, Cold s Harbor Laboratory, New-York (1989, 1992), and in
Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore,
Maryland (1988), and as in Ausubel et al., Current Protocols in Molecular Biology, John
Wiley and Sons, Baltimore, nd (1989) and as in Perbal, A Practical Guide to
Molecular Cloning, John Wiley & Sons, New York (1988), and as in Watson et al.,
Recombinant DNA, Scientific American Books, New York and in Birren et al (eds) Genome
Analysis: A Laboratory Manual Series, Vols. 1-4 Cold Spring Harbor Laboratory Press, New
York (1998) and ology as set forth in US Patent Nos. 4,666,828; 202;
4,801,531; 5,192,659 and 5,272,057 and incorporated herein by reference. Polymerase chain
reaction (PCR) was carried out as in rd PCR Protocols: A Guide To Methods And
Applications, Academic Press, San Diego, CA (1990). In situ PCR in combination with Flow
Cytometry (FACS) can be used for detection of cells containing ic DNA and mRNA
sequences (Testoni et al., Blood 1996, 87:3822.) Methods of performing qPCR and RT-PCR
are well known in the art.
Example 1: Generation of sequences for active siRNA compounds to the target genes and
production of the siRNAs
Using proprietary algorithms and the known sequence of the genes of disclosed
herein, the nse and corresponding sense ces of siRNA were generated. In
addition to the algorithm, 20-, 21-, 22-, and 23-mer oligomer sequences are generated by 5’
and/or 3’ extension of the l9-mer sequences. The sequences that have been generated using
this method are fiJlly complementary to a segment of ponding mRNA sequence.
SEQ ID NOS; 13-20606 provide oligonucleotide sequences useful in the
preparation of dsRNA compounds as disclosed herein. Each oligonucleotide sequence is
presented in 5’ to 3’ orientation.
For each gene there is a separate list of l9-mer sense and corresponding
antisense oligonucleotide ces, which are prioritized based on their score in the
proprietary algorithm as the best sequences for targeting the human gene sion.
] The dsRNA nds disclosed herein are synthesized by any methods
described herein, infra.
[0043l] Tables 1 —5 hereinbelow provide sequence pairs useful in generating double
stranded nucleic acid molecules.
] Table 1: ed oligonucleotides useful in generating double-stranded nucleic
acid compounds to target TLR2.
SEQ SEQ
name ID NO: SENSE 5'>3' ID NO ANTISENSE 5'>3' Structure
--A—_
--A—_
--—AA
20617UUGUGGCUCUUUUCAAUGG A1
20618AGGUCUUGGUGUUCAUUAU A1
20619UGCAGCUCUCAGAUUUACC A2
20620 UGAAAUGGGAGAAGUCCAG A2
Table 2. Selected oligonucleotides useful in generating double-stranded nucleic
acid compounds to target TLR4.
name SEQ SENSE 5'>3' SEQ ANTISENSE 5'>3'
ID ID NO
TLR4_08 20621 AACUUAAUGUGGCUCACAA 20630 UUGUGAGCCACAUUAAGUU
TLR4_10 20622 GGCUGGCAAUUCUUUCCAA 20631 UUGGAAAGAAUUGCCAGCC
1 20623 GAUUUAUCCAGGUGL GAAA 20632 LUUCACACCUGGAUAAAUC A1
-20629 AUGGCUGGCAAUUCLUUCA
Table 3. Selected oligonucleotides useful in generating a double-stranded
nucleic acid compound to target MYD88
name SEQ ID SENSE 5'>3' SEQ ID ANTISENSE 5'>3' Struct
NO NO ure
MYD88_11 12178 GAAUGUGACUUCCAGACCA 12660 UGGUCUGGAAGUCACAUUC
Table 4. Selected oligonucleotides useful in ting double-stranded nucleic
acid compounds to target TICAMl
Stru
SEQ ctur
name : SENSE 5'>3' ID NO NSE 5'>3' e
TICAVI1_15 20639 GGGUGAAGGGUCUUGGUGA 20650LCACCAAGACCCUUCACCC A2
TICA\/I1_16 20640 CUGGAAUCAUCAUCGGAAA 20651 LUCCGAUGAUGAUUCCAG A2
TICA\/I1_17 20641 GGACGAACACUCCCAGAUA 20652 AUCUGGGAGUGUUCGUCC A2
TICA\/I1_18 20642 GGCACUGAACGCAGCCUAA 20653 LAGGCUGCGUUCAGUGCC A2
I1_19 20643 CCAGCAACUUGGAAAUCAA 20654 LGAUUUCCAAGUUGCUGG A2
TICA\/I1_20 20644 AGCCCUUCAUUUAGGACAA 20655 AAAUGAAGGGCU A1
TICA\/Il_21 20645 GGGUAUUGCUACGGUCUUA 20656 GUAGCAAUACCC A2
TICA\/I1_22 20646 CCGGGAGCCCUUCAUUUAA 20657 LAAAUGAAGGGCUCCCGG A2
TICA\/I1_23 20647 GGCAGAAUGACCGCGUGUA 20658 ACACGCGGUCAUUCUGCC A2
TICA\/Il_24 20648 GCGCCUUCGACAUUCUAGA 20659 CUAGAAUGUCGAAGGCGC A2
TICA\/Il_25 20649 CCUACUUCUCACCUCCAAA 20660 UUGGAGGUGAGAAGUAGG A2
Table 5. Selected oligonucleotides useful in generating double-stranded nucleic
acid compounds to target TIRAP.
SEQ struct
ID NO: SENSE 5'>3' ANTISENSE 5'>3' Cre
20661 CUAAGAAGCCUCUAGGCAA 20673 LUGCCUAGAGGCLUCUUAG A1
20662 UAAGAAGCCUCUAGGCAAA—2
20663 GGAGCAAAGACUAUGACGA—2
20664 GCAAAGACUAUGACGUCUA—2
20665 GGCGCUAUAGUGUCCGAGA—A2
20666 GCCUCAGCUCAGUCACGUA—A2
20667 CUAAGAAGCCUCUAGGCAU 20679 AUGCCUAGAGGCLUCUUAG
20668 CAGCCUACCUCAA—A2
20669 UAAGAAGCCUCUAGGCAAU UUGCCUAGAGGCUUCUUA A2
20670 CAAAGAAGCUGUCAUGCGA—A2
20671 GGUGCAAGUACCAGAUGCA—A2 20672— 20684 LUAGUACAUGAAUCGGAGC iIIIIiIIIIII[\D2
Table 6 hereinbelow provides a sequence code of the modified
nucleotides/unconventional moieties utilized in preparing the dsRNA oligonucleotides
ing to Structure (A1)
anie Batch Sense 5->3 ‘ ntisense 5->3
umber
1_S1 138977 rUng;rG;rA;rU;rG;rC;rC;rU n1U;rA;n1G;rC;mA;rG;mA;r
29 ;rU;rC;rA;rU;rC;rU;rG;rC;L U;n1G;rA;mA;rG;n1G;rC;n1
MYD88_1_S5 138978
MYD88_11_S 138983
MYD88_11_S 138984
MYD88_1 1_S 60241388 c6Np;rG;mA;rA;n1U;rG;n1U n1U;rG;n1G;rU;n1C;rU;n1G;r
870 ;rG;mA;rC;n1U;rU;n1C;rC;n1 G;mA;rA;n1G;rU;n1C;rA;n1C
A;rG;mA;rC;n1C;rA$ ;rA;n1U;rU;n1C;dT;dT$
MYD88_1 1_S 60241391 c6Np;rG;mA;rA;rnU;rG;rnU mU;rG;rG;dT;mC;dT;rnG;r
;rG;mA;rC;mU;mU;rnC;dC; G;mA;rA;rnG;dT;mC;rA;m
‘ ‘ ‘ ‘ C;rA;rnU;dT;rnC;dT;dT$
MYD88_11_S 60241394 c6Np;rG;mA;rA;rnU;rG;rnU mU;rG;mG;rU;rnC;rU;rnG;r
872 ;rC;rnU;rU;rnC;dC; G;mA;rA;rnG;rU;mC;rA;rnC
' ' ' ' ' ;rA;rnU;rU;rnC;dT;dT$
1 1_S 97 rG;mA;rA;mU;rG;rnU;rG;m mU;rG;mG;rU;rnC;rU;rnG;r
873 A;rC;mU;rU;rnC;rC;mA;rG; G;mA;rA;rnG;rU;rnC;rA;rnC
' ' ' ;rA;rnU;rU;rnC;dT;dT$
MYD88_1 1_S 60241400 rG;mA;rA;mU;rG;rnU;rG;m mU;rG;mG;dT;mC;dT;rnG;r
874 A;rC;mU;rU;mC;rC;mA;rG; G;mA;rA;rnG;rU;mC;rA;rnC
' ' ' ;rA;rnU;rU;rnC;dT;dT$
MYD88_1 1_S c6Np;rG;mA;rA;rnU;rG;rnU mU;rG;rG;dT;mC;dT;rnG;r
971 ;rG;mA;dC;rnU;mU;rnC;dC; G;mA;rA;rnG;dT;mC;rA;m
mA;rG;mA;dC;dC;rA$ U;dT;rnC;dT;dT$
MYD88_1 1_S c6Np;rG;mA;rA;rnU;rG;rnU mU;rG;rG;rnU;rnC;rnU;rG;r
972 ;rG;mA;dC;rnU;dT;dC;dC; G;mA;rA;rG;rnU;rnC;rA;rnC
mA;rG;mA;dC;dC;dA$ ;rA;rnU;rnU;rnC;dT;dT$
MYD88_1 1_S c6Np;rG;rA;rA;dT;rG;dT;rG mU;rG;rG;dT;mC;dT;rnG;r
973 dngngC;dC;rA;rG; G;mA;rA;rnG;dT;mC;rA;m
' ' ' C;rA;rnU;dT;rnC;dT;dT$
MYD88_11_S
TIRAP_1_S73
TIRAP_2_S73
_S710
TLR2_1_S814 140417
TLR2_1_S815 140418
TLR2_15_S73
C;rU;rnU;rG;mA;rA;mC;rA; U;rnC;rA;mA;rG;mA;rC;rnU
' ' ' ;rG;mC;rC;mC$
TLR2_16_S73 60274507 rG;mA;rG;n1U;rG;n1G;rU;n1 mG;rU;n1U;rC;mA;rU;mA;r
- G;rC;mA;rA;n1G;rU;mA;rU; C;n1U;rU;n1G;rC;mA;rC;n1C
60274508 n1G;rA;n1A;rC$ ;rA;n1C;rU;n1C$
TLR2_16_S93 60274509 rG;mA;rG;n1U;rG;n1G;rU;n1 n1U;rU;n1U;rC;mA;rU;mA;r
;rA;n1C;rU;n1C$
Table 7 hereinbelow provides a sequence code of the modified
nucleotides/unconventional moieties utilized in preparing the dsRNA ucleotides
ing to Structure (A2)
anie Batch Sense 5->3 nse 5->3
umbers
13_S7 60206348 rG;n1G;rA;n1G;rA;n1U;rG;n1 n1U;rA;n1G;rU;n1U;rG;n1C;
3 A;rU;n1C;rC;n1G;rG;n1C;rA; rC;n1G;rG;mA;rU;n1C;rA;
mA;rC;n1U;rA$ niU;rC;n1U;rC;n1C$
MYD88_18_S7 60238315 rG;n1C;rC;n1U;rA;n1U;rC;n1 n1U;rU;n1C;rA;mA;rG;mA;
3 G;rC;n1U;rG;n1U;rU;n1C;rU; rA;n1C;rA;n1G;rC;n1G;rA;
n1U;rG;mA;rA$ niU;rA;n1G;rG;n1C$
TIRAP_7_S73 60227223 rC;n1G;rG;mA;rA;n1C;rU;n1 n1U;rA;n1C;rA;n1U;rG;mA;
C;rC;n1G;rA;n1U;rU;n1C;rA; rA;n1U;rC;n1G;rG;mA;rG;
n1U;rG;n1U;rA$ n1U;rU;n1C;rC;n1G$
9_S73 60227229 rG;mA;rU;n1U;rC;mA;rU;n1 n1U;rC;n1C;rA;n1C;rA;n1U;
A;rC;n1U;rA;n1U;rG; rA;n1G;rU;mA;rC;mA;rU;
TIRAP_15_S7 60238354 rC;n1C;rA;n1C;rA;n1G;rU;n1 n1U;rA;mA;rA;n1U;rC;n1C;
3 G;rA;n1G;rG;mA;rG;n1G;rA; rU;n1C;rC;n1U;rC;n1A;rC;
TLR2_3_S73 60205160 rC;n1G;rG;n1G;rC;mA;rA;n1 ;mA;rA;n1U;rG;mA;
A;rU;n1G;rG;mA;rU;n1C;rA; rU;n1C;rC;mA;rU;n1U;rU;
TLR2_3_S818 140422 idB;rC;rG;rG;rG;rC;rA;rA;r rA;n1C;rA;rA;n1U;rG;rA;n1
_M1 A;dT;rG;rG;rA;dT;rC;rA;rU U;rC;rC;rA;n1U;rU;n1U;rG
' ' ' ;n1C;rC;n1C;rG$
TLR4_1_SSOO 126174 rG;mG;rC;mU;rG;mG;rC;m mU;rU;mU;rG;mA;rA;mA
A;rA;mU;rU;mC;rU;mU;rU; ;rG;mA;rA;mU;rU;mG;rC;
TLR4_3_SSOO 126176 rG;mA;rU;mC;rU;mU;rG;m mU;rU;mU;rA;mA;rA;mU
G;rG;mA;rG;mA;rA;mU;rU; ;rU;mC;rU;mC;rC;mC;rA;
_SSOO 126178 rG;mU;rU;mG;rG;mU;rG;m mU;rA;mU;rU;mC;rA;mA;
U;rA;mU;rC;mU;rU;mU;rG; rA;mG;rA;mU;rA;mC;rA;
Table 8. Code of the modified nuc1eotideS/unconventiona1 moieties
_0demodification
c6Np (5’ cap) Amino-C6-Phosphate or Amino modifier C6 (Glen
rch)_deoxvriboaden0Sine-3’-nh0thate
EE_abaSic deoxvribOSe-3’-nh0Shhate
_ddeoxvribocvtidine-3’-nh0thate
Example 2: RNAi activity of exemplapv double stranded oligonucleotide compounds
Activity:
Single stranded oligonucleotides (sense strand and nse strand) are
synthesized using standard synthesis procedures. DMT-propane-Diol phosphoramidite
ChemGenes; CLP-9908) is coupled at a concentration of 0.05M. Duplexes are generated by
ing complementary single stranded oligonucleotides. In a laminar flow hood, a
~500uM Stock Solution of single stranded ucleotide is ed by diluting in WFI
(water for injection, Norbrook). Actual ssRNA (single stranded) concentrations are
determined by diluting each 500uM ssRNA 1:200 using WFI, and measuring the OD using
Nano Drop. The procedure is repeated 3 times and the average concentration is calculated.
The Stock Solution was then diluted to a final concentration of 250uM. Complementary
single strands were annealed by heating to 850C and allowing to cool to room temperature
over at least 45 minutes. Duplexes were tested for complete annealing by testing Sul on a
% rylamide gel and staining. s were stored at —800C.
The double stranded nucleic acid molecules disclosed herein were tested for
activity as s: About 105 tested cells (HeLa cells and/or 293T cells for siRNA
targeting human genes and NRK52 (normal rat kidney proximal tubule cells) cells and/or
NMuMG cells (mouse mammary epithelial cell line) for siRNA targeting the rat/mouse
gene) were seeded per well in 6 wells plate (70-80% confluent).
About 24 hours later, cells were transfected with modified siRNA compounds
using the LipofectamineTM 2000 reagent (Invitrogen) at final concentrations of from 0.001
nM to about 50 nM. The cells were incubated at 370C in a C02 tor for 72h.
As positive control for transfection PTEN—Cy3 labeled modified siRNA
compounds are used. GFP siRNA compounds are used as negative control for siRNA
At 72h after transfection cells are harvested and RNA was extracted from cells.
Transfection efficiency is tested by fluorescent microscopy.
The percent of inhibition of gene expression using specific preferred siRNA
ures is determined using qPCR analysis of a target gene in cells expressing the
endogenous gene.
: Table 9: Activity of n preferred TLR2 compounds
Sense sequence Antisense sequence
TLR2_31 GGUAAAUCUGAGAGCUGCA UCUCAGAUUUACC 14, 7,16
TLR2 42 GGGUAAAUCUGAGAGCUGC
TLR2_25 GGGUGGAGAACCUUAUGGU AGGUUCUCCACCC 14,17,90,54
42,84,13,29
TLR2_28 GGCAAGUGGAUCAUUGACA UGUCAAUGAUCCACUUGCC 4,21,30,39
12,48,64
TLR2_34 CUGGACUUCUCCCAUUUCA UGAAAUGGGAGAAGUCCAG 9,28,30,28 (16,37,84)
TLR2_43 CCAUUGAAAAGAGCCACAA UUGUGGCUCUUUUCAAUGG 34,24,18,19(6,29,46)
TLR2_47 AUAAUGAACACCAAGACCU AGGUCUUGGUGUUCAUUAU 31,35,33,37
The IC50 value of the tested R1\Ai activity is determined by ucting a dose-
response curve using the activity results obtained with the various final siRNA
concentrations. The dose response curve is constructed by plotting the relative amount of
residual target mRNA versus the logarithm of transfected siRNA concentration. The curve is
calculated by fitting the best sigmoid curve to the measured data. The method for the
sigmoid fit is also known as a 3-point curve fit.
100 — Bot
Y=Bot+
where Y is the residual target mRNA response, X is the logarithm of transfected
siRNA concentration, Bot is the Y value at the bottom plateau, LogIC50 is the X value when
Y is halfway between bottom and top plateaus and HillSlope is the steepness of the curve.
Serum Stability
The double stranded c acid molecules were tested for duplex stability in
human serum or human tissue extract, as s:
dsRNA molecules at final concentration of 7uM are ted at 370C in 100%
human serum (Sigma Cat# H4522). (siRNA stock 100uM diluted in human serum 1:14.29 or
human tissue extract from various tissue types). Five ul (5ul) are added to 15ul 1.5xTBE-
loading buffer at different time points (for example 0, 30min, 1h, 3h, 6h, 8h, 10h, 16h and
24h). Samples are immediately frozen in liquid nitrogen and are kept at -20°C.
Each sample is loaded onto a non-denaturing 20% acrylamide gel, prepared
according to s known in the art. The oligos are ized with ethidium bromide
under UV light.
In general, the dsRNAs having specific sequences that are selected for in vitro
testing are specific for human and a second species such as rat or rabbit genes.
Stability to exonucleases
To study the stabilization effect of 3’ non-nucleotide moieties on a c acid
molecule the sense , the antisense strand and the annealed siRNA duplex are ted
in cytosolic extracts prepared from different cell types. A protocol for testing ity in
HCTl 16 cells is provided below.
Extract: HCTl 16 cytosolic extract (12mg/ml).
Extract buffer: 25mM HEPES pH-7.3 at 370C; 8mM MgCl; 150mM NaCl with
lmM DTT was added fresh immediately before use.
Method: 35ml of test siRNA (100mM), were mixed with 46.5ml contain 120mg
of HCTl 16 cytosolic t. The 46.5ml consists of 12ml of HCTl 16 extract, and 34.5ml of
the extract buffer supplemented with DTT and protease inhibitors cocktail/100 (Calbiochem,
setIII-539134). The final concentration of the siRNA in the incubation tube is 7mM. The
sample is incubated at 370C, and at the indicated time point 5ml are moved to fresh tube,
mixed with 15ml of 1XTBE-50% Glycerol loading buffer, and snap frozen in Liquid N2.
The final concentration of the siRNA in the loading buffer is about 1.75mM (21ng
siRNA/ml). For analyses by native PAGE and EtBr ng 50ng are loaded per lane. For
Northern analyses 1ng of tested siRNA is loaded per lane. Other cell types include HeLa and
c stellate cells (HSC).
The applicants have shown that c acid molecules which include the 3’
terminal alkyl; or alkyl derivative overhang exhibit enhanced stability compared to a blunt
ended nucleic acid molecules and nucleic acid molecules sing 3’ nucleotide
overhangs.
Example 3: Stability of double stranded RNA les in bronchoalveolar lavage fluid
Nuclease resistance of the dsRNA nds sed herein is tested in
human serum and / or in bronchoalveolar lavage fluid (BALF). For stability testing, a
dsRNA compound is diluted in human serum or in oalveolar lavage fluid (BALF) to a
required final concentration (e.g. 7uM). A 5 uL t is transferred to 15 uL of 1.5x
TBE-loading buffer, immediately frozen in liquid nitrogen, and transferred to -20°C. This
represents “Time Point 0”. The remaining dsRNA solution is divided into 5 uL aliquots,
which are incubated at 37°C for 30min, lh, 6h, 8h, 10h, 16h or 24h.
Following incubation, dsRNA compound samples are transferred to 15 uL of
1.5xTBE-loading . 5 uL of each dsRNA compound in loading buffer sample is loaded
onto a non denaturing 20% polyacrylamide gel and electrophoresis is performed. The
positive control, double-strand migration reference (a non-relevant, l9-base pairs, blunt-
ended, double-stranded RNA with similar chemical modifications), and single-strand
ion reference (a non-relevant ssRNA with chemical modifications), as well as the
Time Point 0 sample are loaded on the same gel and electrophoresed in parallel.
For dsRNA visualization the gel is stained with Ethidium bromide solution
(1.0 ug/uL).
Stability of dsRNA compounds disclosed herein is determined by examining the
migration pattern of siRNA samples on PAGE following incubation in human serum and / or
in bronchoalveolar lavage fluid (BALF).
Example 4: Efficacy of Therapeutic activity of dsRNA directed to TLR2 [SEQ ID N01 [2
TLR4 SE ID NO:2-4 ' MYD88 SE ID NOS:5-9 TICAMl SE ID NO:10 and
TIRAP SE ID NOS:ll-l2 in mouse models of orthoto ic vascularized aerated lun
transplantation
Therapeutic efficacy of dsRNA compounds described herein in preventing
primary graft dysfilnction caused by both ged cold ischemia and immune rejection are
tested in eic and allogeneic mouse opic models of lung transplantation. The
method of orthotopic vascularized aerated left lung transplantation in the mouse utilizes cuff
techniques for the anastomosis of pulmonary , pulmonary veins and bronchus. This
method has been reported in several publications (Okazaki et al., Am J Transplant, 2007;
-ll6-
7: 1672-9 and Krupnick et al. Nature Protocols, 2009; vol.4 No. 3).
dsRNA test compounds: test compounds are preferably dsRNA having cross
s specificity to human and mouse or human and rat mRNA target sequences. The
sense and nse sequences of dsRNA compounds that target TLR2 are set forth in SEQ
ID NOS: 13-5846; the sense and antisense sequences of dsRNA compounds that target
TLR4 are set forth in SEQ ID NOS: 5847-12144; The sense and antisense sequences of
dsRNA compounds that target MYD88 are set forth in SEQ ID NOS: l2l45-l6332; The
sense and antisense sequences of dsRNA compounds that target TICAMl are set forth in
SEQ ID NOS: 16333-18242; The sense and antisense sequences of dsRNA compounds that
target TIRAP are set forth in SEQ ID NOS: 18243-20606. Certain preferred oligonucleotide
pairs useful in ting double stranded nucleic acid molecules are set forth in Tables 1-5.
The sense and/or antisense strands are preferably chemically modified as disclosed
, supra.
Dosage and administration: dsRNA compounds are administered at the end of
lung transplantation surgery (immediately after anastomosis g), by intratracheal
lation to the recipient animal. The following doses of individual dsRNA compounds are
tested in these animal models: 6 ug/mouse, l2.5 ug/mouse, 25 ug/mouse and 50 se.
Preferred double stranded nucleic acid molecules are generated using the sequences of the
oligonucleotide pairs set forth in Tables 1-5.
Mouse syngeneic lung lantation gCS7B1/6 -> C57Bl/6]
Experimental design: Both donor and recipient are C57BL/6 mice. Prior to
transplantation, ischemia usion injury is induced by prolonged cold preservation of the
lung transplant for 18 hours in cold e in a low dextrose solution with components
similar to solutions used to ve human lung transplants (18 hours of cold ischemia time
(CIT)). This method induces symptoms consistent with primary graft dysfiJnction 24 hours
post-transplantation. Test dsRNA is administered into the trachea. Lung recipients are
assessed 24 hours later for lung injury.
Administration :By intratracheal instillation of dsRNA solution to the lungs; 1
dose of a dsRNA compound or of a combination of dsRNA compounds is administered
immediately after mosis opening on Day 0 .
Evaluation: Lung recipients are evaluated at 24 hours post transplantation
-ll7-
through assessing lung fianction, as measured by:
° Gross pathology — appearance of pulmonary edema;
0 Pulmonary fianction — Pa02, oxygenation of arterial blood;
0 Intra-airway accumulation of cellular infiltrates; and
0 Total amount and differential counts of bronchoalveolar lavage (BAL) cells
Results: In this syngeneic model, mouse isografts exposed to ged cold
ischemia (18 hours CIT) develop impaired oxygenation, pulmonary edema, increased
inflammatory ne production and graft and intra-airway accumulation of
granulocytes as measured 24 hours post-transplantation. By st, mouse lung recipients
of 1 hour cold preserved grafts (1 hour CIT) show little evidence of lung injury 24 hours
ransplantation
The test e (composition comprising a combination of TLR2 and TLR4
double stranded nucleic acid les; dsRNA specific for TLR2, dsRNA specific for
TLR4 or vehicle) was administered immediately after opening of anastomosis and beginning
of reperfusion. Preferred double stranded nucleic acid les are generated using the
sequences of the oligonucleotide pairs set forth in Tables 1-5.
Example 5: Therapeutic activity of dsRNA directed to TLR2 [SEQ ID NOl [: TLR4 [SEQ ID
NO:2—4[ ; MYD88 [SEQ ID NOS:5-9[, TICAMMSEQ ID NO:10[ and TIRAP [SEQ ID
NOS: 1 1-12] in the Mouse allogeneic lung transplantation gBalb/C -> C57Bl/6]
[0047l] Experimental design: In this model prolonged cold ischemia prevents lung
aft acceptance mediated by immunosuppression. In this model Balb/c lungs are
subjected to 18 hours of cold ischemia time (CIT) and are lanted into C57B1/6
recipients that are treated with immunosuppressants: anti-CD40L on post operative day 0
and CTLA4Ig on day 2. In contrast to recipients who received allografts stored for 1 hour,
these stored for 18 hours acutely rejected their allografts with marked intragraft
accumulation of IFNy+ CD8+ T cells.
Evaluation: Lung recipients were evaluated at 7 days post lantation
through assessing:
° nce of intragraft IFNy+ CD8+ T cells (by FACS)
° Histopathological signs of acute graft rejection, A score
Administration: By racheal instillation of dsRNA solution to the lungs; 2
doses of a dsRNA compound or of a combination of dsRNA compounds are administered
immediately after anastomosis opening on Day 0 and on Day 1 post Tx.
Example 6: Animal models of Neuropathic Pain: _eutic activity of dsRNA directed to
TLR2 SE ID NOl : TLR4 SE ID NO:2-4 ‘ MYD88 SE ID NOSi5-9 TICAMl SE
ID NO:10 and TIRAP SE ID NOS:11-12 in the S inal Nerve Li ation Model Chun
in rats
] The Chung rat model (Kim and Chung, 1992. Pain. 1992 Sep;50(3):355-63.)
duplicates the symptoms of human patients with causalgia, or burning pain due to injury of a
peripheral nerve. The Chung procedure produces a long-lasting hyperalgesia to noxious heat
and mechanical allodynia of the ed foot. Rats with spinal nerve ligation (SNL) are
useful for identifying active dsRNA compounds for use in alleViating neuropathic pain.
Preferred dsNA molecules are generated using the sequences of the oligonucleotide pairs set
forth in Tables 1-5.
ation Of Neuropathic Pain in Chung Model Rats: The Chung model is
performed on male Sprague-Dawley rats ng 190 to 210 grams to induce an allodynic
state. Animals are acclimated for at least 5 days. During acclimation and throughout the
entire study duration, animals are housed within a limited access rodent facility and kept in
groups with a maximum of 5 rats per cage. Animals are provided ad libitum with a
commercial rodent diet and have free access to ng water. Automatically controlled
environmental conditions were monitored daily. Animals are given a unique animal
fication tail mark.
During the acclimation period, animals are randomly ed to experimental
groups. Each dosing group is kept in separate cages to avoid cross-contamination which can
occur through consumption of fecal matter. 2-3 animals will be housed per cage.
Briefly, the rats are anesthetized with ketamine/xylazine sodium and
subsequently, the left L-S and L-6 spinal nerves is isolated adjacent to the vertebral column
and ligated. The muscle is sutured and the skin closed with a clamp. Seven days day
WO 18911
postoperative recovery period, the s are tested for inclusion into the study. Pain is
ed when one or more of the ia below are met:
Licking of the operated paw, accompanied by gentle biting or g nails with
the mouth; lifting the operated leg in the air; bearing weight on the side contralateral to the
nerve injury; deformities of the hind paw and abnormal walking; weakness of the left hind
paw. The animal has to be able to move it leg to ensure that L4 is intact.
Alzet pump: Animals from some groups are implanted subcutaneously with
osmotic pumps on the day of surgery. A polyethylene tubing is implanted in the intrathecal
space of the spinal cord, ending at level L4 and a cannula was connected to the pump.
Lumbar injections: Animals from some groups are given bolus lumber ions
as follows: An intrathecal tube was inserted into the animals IT space at L4-L5 level and the
test agents were dosed slowly.
It will be readily apparent to one skilled in the art that substitutions and
modifications can be made to the molecules, compositions and methods disclosed herein
without departing from the scope and spirit of the invention. Thus, such onal
embodiments are within the scope of the disclosure and the following claims. The present
disclosures teach one skilled in the art various ations of oligonucleotides and
chemical modifications described herein toward generating therapeutically effective double
stranded nucleic acid molecules to down regulate expression of TLR2, TLR4, MYD88,
TICAMl and TIRAP. The therapeutically effective double stranded nucleic acid molecules
exhibit one or more of stability in biological fluids, bioavailability, high on target activity,
low off target activity. Therefore, the c embodiments described herein are not limiting
and one skilled in the art can readily appreciate that additional specif1c combinations can be
tested without undue experimentation toward identifying therapeutic combinations with
improved ty.
] The terms “comprising3, EChaving, 3) C"1ncluding,” containing”, etc. shall be read
expansively and without tion (e.g., meaning “including, but not limited to,”).
Recitation of ranges of values herein are merely intended to serve as a shorthand method of
ing individually to each separate value falling within the range, unless otherwise
indicated herein, and each separate value is incorporated into the specification as if it were
individually recited herein. All methods described herein can be performed in any suitable
WO 18911
order unless otherwise indicated herein or otherwise clearly contradicted by t. The
use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is
intended merely to better illuminate the invention and does not pose a limitation on the scope
of the invention unless otherwise d. No language in the specification should be
construed as indicating any non-claimed element as essential to the practice of the invention.
Additionally, the terms and sions employed herein have been used as terms of
description and not of limitation, and there is no intention in the use of such terms and
expressions of excluding any equivalents of the features shown and described or portions
thereof, but it is recognized that various modifications are possible within the scope of the
invention claimed.
The disclosure has been described broadly and generically herein. Each of the
narrower species and neric groupings falling within the generic disclosure also form
part of the invention. This es the generic description of the invention with a proviso or
negative limitation removing any subject matter from the genus, regardless of whether or not
the excised material is specifically recited herein. Other embodiments are within the
following claims. In on, where features or aspects of the invention are bed in
terms of Markush groups, those skilled in the art will recognize that the invention is also
thereby described in terms of any individual member or subgroup of members of the
Markush group.
] hout this application various patents and publications are cited. The
disclosures of these documents in their entireties are hereby incorporated by reference into
this application to more fillly be the state of the art to which this invention pertains.
Although the above es have illustrated particular ways of carrying out
embodiments, in practice persons skilled in the art will appreciate alternative ways of
carrying out embodiments, which are not shown explicitly herein. It should be understood
that the present disclosure is to be considered as an exemplification of the principles of this
invention and is not intended to limit the invention to the embodiments illustrated.
Those skilled in the art will recognize, or be able to ascertain using no more than
routine mentation, equivalents of the specific embodiments of the invention bed
herein. Such lents are intended to be encompassed by the following claims.
-lZl-
Claims (17)
1. A double stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the s are selected from the oligonucleotides described as TLR2_25 as set forth in SEQ ID NOS:20607 and 20614, 8 as set forth in SEQ ID NOS:20608 and 20615, TLR2_42 as set forth in SEQ ID NOS:20609 and 20616, TLR2_43 as set forth in SEQ ID NOS:20610 and 20617, 7 as set forth in SEQ ID NOS:20611 and 20618, TLR2_31 as set forth in SEQ ID 612 and 20619, and TLR2_34 as set forth in SEQ ID NOS:20613 and 20620.
2. The double stranded nucleic acid le of claim 1 having the following structure: (A1) 5’ (N)x – Z 3’ (antisense strand) 3’ Z’-(N’)y –z” 5’ (sense strand) wherein each N and N’ is a nucleotide which may be unmodified or modified, or an unconventional moiety; wherein each of (N)x and (N’)y is an oligonucleotide in which each consecutive N or N’ is joined to the next N or N’ by a covalent bond; wherein each of Z and Z’ is independently present or absent, but if present independently comprises 1-5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3’ us of the strand in which it is present; wherein z” may be present or absent, but if present is a capping moiety covalently attached at the 5’ terminus of (N’)y; wherein each of x and y is independently an integer between 18 and 25; wherein the sequence of (N’)y is complementary to the sequence of (N)x; wherein (N)x comprises an antisense sequence to a target RNA set forth in SEQ ID NO:1 (TLR2 mRNA); and n (N)x and (N’)y are selected from the oligonucleotides described as TLR2_25 as set forth in SEQ ID NOS:20607 and 20614, the oligonucleotides described as TLR2_28 as set forth in SEQ ID NOS:20608 and 20615, the oligonucleotides described as TLR2_42 as set forth in SEQ ID NOS:20609 and 20616, the oligonucleotides described as TLR2_43 as set forth in SEQ ID NOS:20610 and 20617, and the ucleotides bed as TLR2_47 as set forth in SEQ ID NOS:20611 and 20618.
3. The double stranded nucleic acid molecule of claim 1 having the following structure: (A2) 5’ N1-(N)x - Z 3’ (antisense strand) 3’ (N’)y –z” 5’ (sense strand) wherein each N2, N and N’ is an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of (N)x and (N’)y is an ucleotide in which each consecutive N or N’ is joined to the nt N or N’ by a nt bond; wherein each of x and y is independently an integer between 17 and 24; wherein the sequence of (N’)y is complementary to the sequence of (N)x and (N)x is complementary to a consecutive sequence in a target RNA set forth in SEQ ID NO:1 (TLR2 mRNA); wherein N1 is covalently bound to (N)x and is mismatched to the target RNA or is a complementary DNA moiety to the target RNA; wherein N1 is a moiety selected from the group consisting of unmodified or modified nucleotides selected from uridine (rU), ibouridine (dU), ribothymidine (rT), deoxyribothymidine (dT), adenosine (rA) and deoxyadenosine (dA); wherein z” may be present or absent, but if present is a capping moiety covalently attached at the 5’ terminus of N2- (N’)y; wherein each of Z and Z’ is independently present or absent, but if t is ndently 1-5 consecutive nucleotides, consecutive non-nucleotide moieties or a combination thereof covalently attached at the 3’ terminus of the strand in which it is t; and wherein N1 -(N)x and N2- (N’)y are selected from the oligonucleotides described as TLR2_31 as set forth in SEQ ID NOS:20612 and 20619, and the oligonucleotides described as TLR2_34 as set forth in SEQ ID NOS:20613 and 20620.
4. The double stranded nucleic acid molecule of claim 2 or claim 3 wherein in (N)x or N1- (N)x, N in positions 1, 3, 5, 9, 11, 13, 15, 17 and 19 (5’>3’) comprises 2’-OMe sugar modified cleotides and N in positions 2, 4, 6, 8, 10, 12, 14, 16, and 18 (5’>3’) comprises unmodified ribonucleotides.
5. The double stranded c acid le of claim 2 or claim 3 wherein in (N)x or N1- (N)x, N in positions 2, 4, 6, 8, 11, 13, 15, 17 and 19 (5’>3’) comprises 2’-OMe sugar modified ribonucleotides.
6. The double stranded nucleic acid molecule of any one of claims 2 to 5 wherein Z is covalently attached to the 3’ terminus of (N)x or N1-(N)x and comprises a non-nucleotide moiety selected from the group consisting of C3OH, C3Pi, C3Pi-C3OH and C3Pi-C3Pi.
7. The double stranded nucleic acid molecule of any one of claims 2 to 5 wherein Z is covalently ed to the 3’ terminus of (N)x or N1-(N)x and comprises a dinucleotide dTdT.
8. The double stranded nucleic acid le of any one of claims 2 to 7 wherein N’ in at least one of positions 7, 8, 9 or 10 from the 5’ terminus of (N’)y or N2-(N’)y is selected from a e nucleic acid moiety, a 2’5’ nucleotide and pseudoUridine.
9. The double stranded nucleic acid molecule of any one of claims 2 to 8 n N’ comprises a threose nucleic acid (TNA) moiety or a 2’5’ nucleotide in 4, 5, or 6 utive positions starting at the 3’ terminal or 3’ penultimate positions in (N’)y or N2-(N’)y.
10. The double ed nucleic acid molecule of any one of claims 2 to 9 wherein z” is covalently attached to the 5’ terminus of (N’)y or N2-(N’)y and is selected from the group consisting of an inverted abasic deoxyribose moiety, an inverted abasic ribose , an abasic deoxyribose moiety, an abasic ribose moiety, a C3 moiety, L-DNA or L-RNA.
11. The double stranded nucleic acid molecule of any one of claims 2 to 10 wherein Z’ comprises a C3 moiety or a 3’ terminal phosphate (Pi).
12. The double stranded nucleic acid molecule of any one of claims 2 to 11 wherein x=y=19; N in at least one of positions 5, 6, 7, 8, or 9 from the 5’ terminus of the antisense strand is selected from a threose nucleic acid moiety, a 2’5’ nucleotide or a mirror nucleotide; and N’ in 4, 5, or 6 consecutive positions starting at the 3’ terminal or penultimate position of the sense strand ses a 2’5’ nucleotide.
13. The double stranded nucleic acid molecule of claim 2 or claim 3 wherein at least one of N’ comprises a mirror nucleotide.
14. A pharmaceutical composition comprising a double stranded nucleic acid molecule of any one of claims 1 to 13 in an amount effective to t gene expression, and a pharmaceutically acceptable carrier wherein the gene encodes a RNA having a cleotide sequence set forth in SEQ ID NO:1.
15. Use of the double stranded nucleic acid molecule of any one of claims 1 to 13 or the composition according to claim 14 in the manufacture of a medicament for use in therapy; wherein said therapy is treatment of a disease or injury selected from the group consisting of chronic or acute aseptic mation, athic pain, primary graft failure, ischemiareperfusion injury, reperfusion injury, usion edema, allograft dysfunction, pulmonary antation se and primary graft dysfunction (PGD) in organ transplantation.
16. Use of the double stranded nucleic acid molecule of any one of claims 1 to 13 or the composition according to claim 14 in the manufacture of a medicament for treating a disease or disorder or symptom or condition associated with the expression of a target gene, wherein the gene encodes an RNA having a polynucleotide sequence set forth in SEQ ID NO:1; wherein the disease or disorder or symptom or condition is selected from the group consisting of chronic or acute c inflammation, neuropathic pain, primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft ction, ary reimplantation response and primary graft dysfunction (PGD) in organ transplantation.
17. The use of claim 15 or claim 16, wherein said organ transplantation comprises lung transplantation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ712025A NZ712025B2 (en) | 2011-03-03 | 2012-03-01 | Oligonucleotide modulators of the toll-like receptor pathway |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161448707P | 2011-03-03 | 2011-03-03 | |
US61/448,707 | 2011-03-03 | ||
PCT/US2012/027174 WO2012118911A1 (en) | 2011-03-03 | 2012-03-01 | Oligonucleotide modulators of the toll-like receptor pathway |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614712A NZ614712A (en) | 2015-09-25 |
NZ614712B2 true NZ614712B2 (en) | 2016-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6407347B2 (en) | Oligonucleotide modifiers of the Toll-like receptor pathway | |
US9249414B2 (en) | Oligonucleotide compounds comprising non-nucleotide overhangs | |
WO2011057171A1 (en) | METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM | |
US9738896B2 (en) | Methods and compositions for neuroprotection | |
US9796979B2 (en) | Oligonucleotide modulators of the toll-like receptor pathway | |
NZ614712B2 (en) | Oligonucleotide modulators of the toll-like receptor pathway | |
NZ712025B2 (en) | Oligonucleotide modulators of the toll-like receptor pathway | |
DK2521783T3 (en) | OLIGONUCLEOTIDE COMPOUNDS INCLUDING NON-NUCLEOTIDE COVERAGE | |
EP3696270A1 (en) | Regulation of nucleic acid molecule expression |